WO2014107535A1 - Boronic acid derivatives and therapeutic uses thereof - Google Patents

Boronic acid derivatives and therapeutic uses thereof Download PDF

Info

Publication number
WO2014107535A1
WO2014107535A1 PCT/US2014/010106 US2014010106W WO2014107535A1 WO 2014107535 A1 WO2014107535 A1 WO 2014107535A1 US 2014010106 W US2014010106 W US 2014010106W WO 2014107535 A1 WO2014107535 A1 WO 2014107535A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
composition
group
compound
Prior art date
Application number
PCT/US2014/010106
Other languages
French (fr)
Inventor
Raja Reddy
Tomasz Glinka
Maxim Totrov
Scott Hecker
Original Assignee
Rempex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rempex Pharmaceuticals, Inc. filed Critical Rempex Pharmaceuticals, Inc.
Priority to CN201480003981.3A priority Critical patent/CN104994844A/en
Priority to MX2015008628A priority patent/MX2015008628A/en
Priority to AU2014204045A priority patent/AU2014204045B2/en
Priority to CA2894891A priority patent/CA2894891A1/en
Priority to KR1020157021053A priority patent/KR20150103269A/en
Priority to BR112015016001A priority patent/BR112015016001A2/en
Priority to JP2015551761A priority patent/JP2016509594A/en
Priority to EP14735173.8A priority patent/EP2941246A4/en
Priority to EA201591003A priority patent/EA201591003A1/en
Publication of WO2014107535A1 publication Critical patent/WO2014107535A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the fields of chemistry and medicine. More particularly, the present invention relates to boronic acid antimicrobial compounds, compositions, their preparation, and their use as therapeutic agents.
  • Antibiotics have been effective tools in the treatment of infectious diseases during the last half-century. From the development of antibiotic therapy to the late 1980s there was almost complete control over bacterial infections in developed countries. However, in response to the pressure of antibiotic usage, multiple resistance mechanisms have become widespread and are threatening the clinical utility of anti-bacterial therapy.
  • the increase in antibiotic resistant strains has been particularly common in major hospitals and care centers. The consequences of the increase in resistant strains include higher morbidity and mortality, longer patient hospitalization, and an increase in treatment costs.
  • ⁇ -lactamases can be grouped into 4 classes based on their amino acid sequences, namely, Ambler classes A, B, C, and D. Enzymes in classes A, C, and D include active-site serine ⁇ -lactamases, and class B enzymes, which are encountered less frequently, are Zn-dependent, These enzymes catalyze the chemical degradation of ⁇ -lactam antibiotics, rendering them inactive. Some ⁇ -lactamases can be transferred within and between various bacterial strains and species. The rapid spread of bacterial resistance and the evolution of multi-resistant strains severely limits ⁇ -lactam treatment options available.
  • class D ⁇ -lactamase-expressing bacterium strains such as Acinetobacter baumannu has become an emerging iiiultidrug-resistant threat, A. ba mannii strains express A, C, and D class ⁇ -lactamases.
  • the class D ⁇ -lactamases such as the O.XA families are particularly effective at destroying carbapenem type ⁇ -lactam antibiotics, e.g., imipenem, the active carbapenems component of Merck's Primaxin® (Montefour, K.; et al. Crit, Care Nurse 2008, 28, 15; Perez, F. et al. Expert Rev. Anti Infect. Ther.
  • New ⁇ -lactamases have recently evolved that hydrolyze the carbapenem class of antimicrobials, including imipenem, biapenem, doripenem, meropenem, and ertapenem, as well as other ⁇ -lactam antibiotics.
  • carbapenemases belong to molecular classes A, B, and D, Class A carbapenemases of the PC-type predominantly in Klebsiella pneumoniae but now also reported in other Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii.
  • the PC carbapenemase was first described in 1996 in North Carolina, but since then has disseminated widely in the US.
  • [ ⁇ 6] Another mechanism of ⁇ -lactamase mediated resistance to carbapenems involves combination of permeability or efflux mechanisms combined with hyper production of beta-lactamases.
  • One example is the loss of a porin combined in hy erproduction of ampC beta- lactamase results in resistance to imipenem in Pseudomonas aeruginosa.
  • Efflux pump over expression combined with hyperproduction of the ampC ⁇ -lactamase can also result in resistance to a carbapenem such as meropenem,
  • G is selected from the group consisting of -H, -N R R ⁇ -CH 2 N 3 , -C(0)NR 1 R 2 , - CH 2 C(0) N R R ⁇ -CH 2 S(0) 2 N R R ⁇ -CH 2 -Y-Z, -C ' H-Y-X . and -SR 3 ;
  • Y is selected from a group consisting of -S-, -S(O)-, -S(0) 2 -, -0-, and -NR. 1 -;
  • R is selected from a group consisting of -H, -CR 1 R 2 OC(0)Ci- 9 alkyl, -
  • R 1 and R are each independently selected from the group consisting of -H and - Ci- 4 alkyl;
  • R 3 is -Ci- 4 alkyl
  • R 4 is present 1 to 3 times and each R 4 is independently selected from the group consisting of -H, -Ci- 4 alkyl, -OH, -O Ci- 4 alkyl , S-Ci- 4 alkyl, -CF 3 and halogen;
  • Z is selected from the group consisting of aryl optionally substituted with Ci- 4 alkyl, amino, hydroxy, or halogen; and heteroaiyl optionally substituted with Ci- 4 alkyl, amino, hydroxy, or halogen;
  • X is selected from the group consisting of -CH 2 R 5 , -CH(R 5 ) 2 , and -C(R 5 ) 3 ;
  • R 5 is selected from the group consisting of a halogen, cyano, and azido group.
  • Some embodiments disclosed herein include a compound having the structure of formula II or formul
  • G is selected from the group consisting of
  • phaniiaceutical composition comprising a therapeutically effective amount of a compound disclosed herein and a pharmaceutically acceptable excipient
  • compositions comprising a therapeutically effective amount of a compound disclosed herein and a pharmaceutically acceptable excipient
  • Some embodiments disclosed herein include a pharmaceutical composition comprising a therapeutically effective amount of a compound disclosed herein, a pharmaceutically acceptable excipient and one or more ⁇ -lactam antibacterial agents.
  • inventions disclosed herein include a method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof a compound disclosed herein.
  • compositions comprising:
  • A is selected from the group consisting of C 5-1 o carbocyclyl, Ce- ⁇ aryl, 5- 10 membered heteroaryl, and 5- 10 membered heterocyclyl;
  • X a is -C(R g R h )-, -0-, -S-. -S(O)-, -S(0) 2 -, or -NR. 1 -;
  • K ' is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R optionally substituted -S-C 1-6 alkyl, -C(0)NR 1 R 2 ,
  • R b is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R optionally substituted -S-C 1-6 alkyl, -C(0)NR 1 R 2 , -S(0) 2 NR 1 R 2 , -CN, optionally substituted -S(0)-C 1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster, and
  • R c is selected from the group consisting of -OH, optionally substituted - O-Ci-6 alkyl -NR'R 2 , and or R b and R c together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1- 3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen(N);
  • R d is selected from the group consisting of hydrogen, -OH, optionally substituted -O-G-e alkyl or
  • R b and R c do not together form a 5-8 membered boron ester ring, then optionally R c and R d together with intervening atoms form a 5- 15 membered boron ester or amide ring, optionally comprising additional 1-3 heteroatoms selected from O, S, and N;
  • R e is independently selected from the group consisting of hydrogen, optionally substituted G-ealkyl, optionally substituted C3 -7 cycloalkyl, optionally substituted Ce-ioatyl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl, or R d and R e together with the nitrogen to which they are attached form a 5-8 membered heterocyclic ring, optionally comprising additional 1-3 heteroatoms selected from O, S or N;
  • R s and R h are each independently selected from the group consisitng of - H, Ci-6 alkyl, -OH, -OCi-ealkyl, -SCi-ealkyl, Cs-iocycloalkyl, C2-ioalkenyl, C 2 - l oalkynyl, -NR 1 C(0)R 5 , - R' SCO ⁇ R 3 , -C(0)R 5 , -C(0)OR 3 -alkylaryl, optionally substituted Ce- ⁇ aryl, optionally substituted -O-Ce-ioaryl, -CN, optionally substituted 5-10 membered heteroaryl, optionally substituted -0-heteroaryl, optionally substituted 3 0 membered heterocyclyl, -S(0)(R 3 )R 4 ' -S(0) 2 R 3 , R -
  • R is selected from the group consisting of -H, halogen, -Q ⁇ alkyl,
  • X is hydrogen or optionally substituted
  • Y is selected from a group consisting of -S-, -S(O)-, -S(0) 2 -, -CH 2 -, -0-, - 0-CH 2 -, -C(O)-, and -NR. 1 -;
  • Z is selected from optionally substituted C3-8 cycloalkyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Ce- ⁇ aryl, optionally substituted 5- 10 membered heteroaryl;
  • each R 1 , R 2 , R la and R 2a are independently selected from the group consisting of -H, optionally substituted -Ci-ioalkyl, optionally substituted C 2 -ioalkenyl, optionally substituted C 2 _ioalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
  • R 3 is hydrogen, optionally substituted Ci-ioalkyl, -optionally substituted Ci-ioalkyl-COOH, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl; each R 5 and R 6 are independently selected from the group consisting of - H, -OH, -optionally substituted alkoxyl, optionally substituted -Ci-ioalkyl, optionally substituted C 2-1 oalkenyl, optionally substituted C 2-1 oalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
  • R 4 is present 1 to 5 times and each R 4 is independently selected from the group consisting of -H, -OH, halogen, -CF 3 , Q-Ce alkenyl, Ci-Ce alkynyl, Ci-Ce heteroalkyl, C3-C7 carbocyclyl, 5-10 membered heterocyclyl, aryl, 5-10 membered heteroaryl, cyano, Ci-Ce alkoxy(Ci-C6)alkyl, aryloxy, sulfhydryl (mercapto), and -(CH 2 ) M -Y' -(CH 2 ) P M' ;
  • n and p are independently 0 to 3;
  • Y' is selected from the group consisting of -S-, -S(O)-, -S(0)2-, -0-, CR 5 R 6 -, and -NR. 1 -;
  • CM alky] optionally substituted with 0-2 substituents selected from the group consisting, -OR 3 , -N R R ⁇ halogen, -C(0)NR 1 R 2 , and - NR. 1 C(0)R 5 ; C3-10 cycloalkyl optionally substituted with 0-2 substituents selected from the group consisting of CM alkyl, -OR 3 , -N R R ⁇ halogen, -C(0)NR. 1 R 2 , and -NR. 1 C(0)R 5 ; Cs-10 aryl optionally substituted with 0-2 substituents selected from the group consisting of C alkyl, -OR 3 , -NR R ⁇ halogen, -C(0)NR.
  • each 11 is independently 0-3.
  • Some embodiments include a chemical complex, comprising a complex between a monosaccharide or monosaccharide derivative and a compound having the structure of formula (III) described herein.
  • Other embodiments disclosed herein include a method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof a composition disclosed herein.
  • compounds that contain a boronic acid moiety that act as antimicrobial agents and/or as potentiators of antimicrobial agents.
  • Various embodiments of these compounds include compounds having the structures of Formulas I and II as described above or pharmaceutically acceptable salts thereof.
  • each R 4 can be independently selected from the group consisting of -H, -OH, -0-C l-4alkyl, and halogen; and Z can be selected from the group consisting of aryl optionally substituted with Ci- 4 alkyl, amino, hydroxy, or halogen and heteroaryl optionally substituted with Ci- 4 alkyl, amino, hydroxy, or halogen.
  • R in any of the preceding compounds is H
  • R can be -CR 1 R 2 OC(0)Ci- 9 alkyl or -CR 1 R 2 OC(0)OCi_ 9 alkyl.
  • R can be -CR ! R 2 OC(0)Ci-jalkyl or -CR 1 R 2 0C(0)0Ci- 5 alkyl.
  • R in R can be H and R in R can be H or C ' H ;.
  • R 4 can be selected from H, F, CI, -C ' H ;, -CF 3 , -OCH 3 , and -SCH 3 .
  • R 4 may be either ortho, para, or meta to the carboxylic acid moiety of the phenyl ring.
  • R 4 in any of the preceding compounds is H,
  • G in any of the preceding compounds is H
  • G can be -N R- .
  • G in any of the preceding compounds is NH 2 .
  • G can be -CH2N 3 .
  • G in any of the preceding compounds is -C(0)NR 1 R 2 and R and R are each independently selected from -H and In some such embodiments, R is CH 3 and R is CH 3 ,
  • G is -CH 2 C(0)NR 1 R 2 and R 1 and R 2 are each independently selected from -H and Ci- 4 alkyl.
  • R is CH 3 and R is CH 3 .
  • G can be -CH 2 S(0) 2 NR R ⁇ and R 1 and R are each independently selected from -H and Ci- 4 alkyl.
  • R 3 in any of the preceding compounds is CH 3 ,
  • G is -i l l: Y-Z; Y is -S-; and Z is selected from the group consisting of imidazole, N-methyl imidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine and pyrazine, azitidine, and piperdiiie.
  • Z is N-methyltetrazole.
  • Z is thiadiazole.
  • Z is aminothiadiazole.
  • Z is azitidine.
  • G is -CH 2 -Y-X and Y is -S-.
  • X is -CH 3
  • X is -CH 2 CN
  • X is -CH 2 N 3 .
  • X is— CH 2 F
  • X is -CHF 2
  • X is -CF 3 .
  • G can be -SR . In some embodiments, G can be
  • Some embodiments include compounds having the structure of formula II as described above.
  • G is selected from the group consisting of
  • Some boronic acid derivatives according to Formula (III) as described above have a tendency to form an oligomer such as a dimer, trimer or tetramer.
  • the formation of oligomers is prevented or the amount of oligomers in a composition is reduced by including a monosaccharide or monosaccharide derivative in a composition comprising a compound according to Formula (I), (II), or (III).
  • some embodiments include a pharmaceutical composition comprising meglumine and a compound according to Formula (III) as described above.
  • A can be selected from the group consisting of phenyl, biphenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, indanyl, pyridyl, pyrrolyl, oxazolyl, indolyl and thienyl.
  • R b is attached to ring A at a position that is vicinal to the point of attachment of X a to ring A,
  • R ' is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-6 alkyl, N ' R R ' , and -CN, optionally substituted -S(0)-Ci_6 alkyl, and optionally substituted -S(0) 2 -Ci-6 alkyl.
  • R a is a carboxylic acid isoster
  • R b is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N ' R R ' , and -N(OR 3 )R 1 , optionally substituted -S-C 1-6 alkyl, -C(0)NR 1 R 2 , -8(0) 2 ⁇ 3 ⁇ 4 2 , CN, optionally substituted -S(0)-Ci_6 alkyl, and optionally substituted -S(0) 2 -Ci-6 alkyl.
  • R b is a carboxylic acid isoster
  • J, L, and M are independently selected from the group consisting of CR 4 and N.
  • R b can be -OH or optionally substituted -OCi-ealkyl, In some embodiments, R' can be -OH or optionally substituted -OCi-ealkyl, In some embodiments, R b can be -OH, In some embodiments, R c can be -OH, In some embodiments, R b can be -OH and R' can be -OH, [0053] In some embodiments, K and R c together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1-3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen (N).
  • J, L, and M are independently selected from the group consisting of CR 4 and N.
  • R a can be C(0)OR and R can be -CR 5 R 6 OC(0)Ci_ 9 alkyl or -CR3 ⁇ 4 6 OC(0)OCi_ 9 alkyl. In some embodiments, R a can be C(0)OH.
  • R can be -OCH 2 OC(0)-C(CH 3 ) 3 , -OCH 2 OC(0)-CH(CH 3 ) 2 , or -OCH 2 OC(0)-(CH 2 ) n CH 3 .
  • R can be -CH 2 OC(0)OCH(CH 3 ) 2 .
  • R can be -CH 2 OC(0)OC(CH 3 ) 3 .
  • R can be -CH 2 OC(0)OC(CH 2 ) 2 CH 3 .
  • R can be -CH 2 OC(0)OCH(CH 2 C e embodiments, R can be -CH 2 C(0)OCH 2 CH 3 .
  • R can be [0058] In some embodiments, R can be selected from hydrogen, -OH, halogen, COOK, optionally substituted -0-C 1-6 alkyl, N R R ⁇ and -NCOR ⁇ R 1 . In some embodiments, R d can be -OH or optionally substituted -O-Q-6 alkyl. In some embodiments, R can be -OH,
  • I can be independently selected from the group consisting of hydrogen, optionally substituted Ci-ealkyl, optionally substituted Cs ⁇ cycloalkyl, optionally substituted Ce-ioatyl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3-10 membered heterocyclyl.
  • R can be independently selected from the group consisting of -C(0)G, -C(0)OG, and -S(0) 2 G. In some embodiments, R can be independently selected from-C(0)G or -C(0)OG.
  • G can be selected from the group consisting of embodiments, G is -N H ⁇ In some embodiments, G can be -NH-Ci- 4 alkyl . In some embodiments, G is -C(0)NR 1 R 2 and R and R in G can be each independently selected from - H and Ci-4alkyl, In some embodiments, G can be -CH 2 C(0)NR 1 R 2 and R 1 and R in G are each independently selected from -H and Ci- 4 alkyl,
  • G is -0-(CH 2 ) n -C(0) RiR 2 ; n in G is 0-3; and R and R in G are each independently selected from -H and Ci- 4 alkyl, In some embodiments, G is - 0-CH 2 -C(0)NH 2 .
  • G is - ( €3 ⁇ 4) ⁇ - ⁇ - ⁇ ; n in G is 0-3, Y is -S-; and Z is selected from the group consisting of imidazole, N-methylimidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, azetidine and piperdine, each optionally substituted with one or more d- 4 alkyl, N R R ⁇ hydroxy, or halogen.
  • n in G is 0, In some embodiments, 11 in G is 1.
  • Z can be thiadiazole optionally substituted with one or more C h alky], N R R ⁇ hydroxy, or halogen,
  • Z can be aminothiadiazole optionally substituted with one or more C h alky], NR R ⁇ hydroxy, or halogen,
  • Z can be azitidine optionally substituted with one or more Ci- 4 alkyl, N R R ⁇ hydroxy, or halogen.
  • G is -(CH 2 ) n -Y-X; n in G is 0-3; Y is -S-; and X is hydrogen or optionally d ⁇ alkyl.
  • n in G is 0, In some embodiments, n in G is 1.
  • X is -C3 ⁇ 4, In some embodiments, X is -C3 ⁇ 4CN. In some embodiments, X is -CH 2 N 3 . In some embodiments, X is -C3 ⁇ 4F. In some embodiments, X is - CHFo. In some embodiments, X is -CF 3 .
  • G can be -(CH 2 ) n- Y-Z; 11 in G can be 0-3, Y can be - CH2-, -0-, -O-CH2-, -C(O)-; and Z can be selected from the group consisting of phenyl, napthal, indole, pyrrolidine, thiophene, cyclopropyl, or cyclohexyl, each optionally substituted with one or more Ci- 4 alkyl, N R R ⁇ hydroxy, or halogen.
  • n in G is 1. In some is selected from
  • G is -(CH 2 ) n -Y-X; n in G is 0-3; Y is -O- or -CH 2 -; and X is Ci- 4 alkyl optionally substituted with one or more halogen, cyano, or azido.
  • 11 in G is 0 and Y is -0-, In some embodiments, 11 in G is 1. In some embodiments, 11 in G is 2, In some embodiments, X is optionally substituted
  • X a can be -CH2-, In some emboidments, X a can be - 0-, In some emboidments, X a can be -S-. In some emboidments, X a can be -NH-,
  • R 8 can be H and R h can be H
  • prodrugs e.g., prodiug esters
  • metabolites e.g., stereoisomers
  • hydrates e.g., benzyl alcohol
  • solvates e.g., benzyl ether
  • polymorphs e.g., benzyl ether
  • pharmaceutically acceptable salts of those compounds e.g., benzyl ether
  • the compounds disclosed herein may exist as individual enaiitiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein. Furthermore, compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms. In addition, some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
  • the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen- 1 (protium) and hydrogen-2 (deuterium).
  • hydrogen- 1 protium
  • hydrogen-2 deuterium
  • the compounds described herein may convert to or exist in equilibrium with alternate forms. Accordingly, in some embodiments, the compounds described herein may exist in combination with one or more of these forms. For example, as shown below, the compounds disclosed herein may exist in cyclic form as cyclic boronate monoesters as formula I (or II) or in acyclic form as boronic acids as formula 1.1 (or II.1 ) ⁇ Biochemistry, 2000, 39, 5312- 21), or may exist as a mixture of the TWO forms depending on the medium.
  • the compounds descrived herein may exist in cyclic dimeric form as Formula (C) or trimeric form as Formula (D), tetramenc form as Formula (E) as shown below, or acylic dimeric, trimeric or tetrameric forms and the like.
  • X' can be NR' R in Formula C, D and E.
  • X' can be - NHC(0)-G in Formula C, D and E.
  • prodrug refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drag.
  • prodrug a compound which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial
  • prodrug a compound which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, (ed. H, Bundgaard, Elsevier, 1985), which is hereby incorporated herein by
  • pro-drug ester refers to derivatives of the compounds disclosed herein formed by the addition of any of several ester-forming groups that are hydrolyzed under physiological conditions.
  • pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-l ,3-dioxolen-4-yl)methyl group.
  • Other examples of pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in "Pro-drugs as Novel Delivery Systems", Vol. 14, A.C.S.
  • Methodabolites of the compounds disclosed herein include active species that are produced upon introduction of the compounds into the biological milieu.
  • Solvate refers to the compound formed by the interaction of a solvent and a compound described herein, a metabolite, or salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.
  • pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of a compound, which are not biologically or otherwise undesirable for use in a pharmaceutical.
  • the compounds herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87/05297, Johnston et al, published September 1 1 , 1987 (incorporated by reference herein in its entirety),
  • C a to Q or "C a- b" in which "a” and “b” are integers refer to the number of carbon atoms in the specified group. That is, the group can contain from “a” to "b", inclusive, carbon atoms.
  • a “Ci to C4 alkyl” or “C 1-4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH2-, CH 3 CH2CH2-, (CH 3 ) 2 CH-, CH3CH2CH2CH2-, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-.
  • halogen or "halo,” as used herein, means any one of the radio- stable atoms of column 7 of the Periodic Table of the Elements, e.g. , fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
  • alkyl refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds).
  • the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g. , "1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
  • the alkyl group may also be a medium size alkyl having 1 to 9 carbon atoms.
  • the alkyl group could also be a lower alkyl having 1 to 4 carbon atoms.
  • the alkyl group of the compounds may be designated as "C alkyl” or similar designations.
  • C alkyl indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
  • alkoxy refers to the formula OR wherein R is an alkyl as is defined above, such as "Q.g alkoxy”, including but not limited to methoxy, ethoxy, n- propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy, and the like.
  • alkylthio refers to the formula SR wherein R is an alkyl as is defined above, such as “C1-9 alkylthio” and the like, including but not limited to methy Imercapto , ethylmercapto, n-propylmercapto, 1 -methylethylmercapto
  • alkenyl refers to a straight or branched hydrocarbon chain containing one or more double bonds.
  • the alkenyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl” where no numerical range is designated.
  • the alkenyl group may also be a medium size alkenyl having 2 to 9 carbon atoms.
  • the alkenyl group could also be a lower alkenyl having 2 to 4 carbon atoms.
  • the alkenyl group of the compounds may be designated as "C2-4 alkenyl" or similar designations.
  • C2-4 alkenyl indicates that there are two to four carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen- l -yl, propen-2-yl, propen-3-yl, buten-l-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1 -methyl-propen- 1 -yl, 2-methyl-propen- 1 -yl, 1 -ethyl-ethen- 1 -yl, 2-methyl-propen-3-yl, buta- 1 ,3-dienyl, buta-l,2,-dienyl, and buta- 1 ,2-dien-4-yl.
  • Typical alkenyl groups include, but are in no way limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl, and
  • alkynyl refers to a straight or branched hydrocarbon chain containing one or more triple bonds.
  • the alkynyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl” where no numerical range is designated.
  • the alkynyl group may also be a medium size alkynyl having 2 to 9 carbon atoms.
  • the alkynyl group could also be a lower alkynyl having 2 to 4 carbon atoms.
  • the alkynyl group of the compounds may be designated as "C2-4 alkynyl" or similar designations.
  • C2-4 alkynyl indicates that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn- 1 -yl, propyn-2-yl, butyn-l-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl.
  • Typical alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl, and the like.
  • heteroalkyl refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the chain backbone.
  • the heteroalkyl group may have 1 to 20 carbon atoms although the present definition also covers the occurrence of the term "heteroalkyl” where no numerical range is designated.
  • the heteroalkyl group may also be a medium size heteroalkyl having 1 to 9 carbon atoms.
  • the heteroalkyl group could also be a lower heteroalkyl having 1 to 4 carbon atoms.
  • the heteroalkyl group of the compounds may be designated as "C heteroalkyl” or similar designations.
  • the heteroalkyl group may contain one or more heteroatoms. By way of example only, "C heteroalkyl” indicates that there are one to four carbon atoms in the heteroalkyl chain and additionally one or more heteroatoms in the backbone of the chain.
  • aromatic refers to a ring or ring system having a conjugated pi electron system and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine).
  • carbocyclic aromatic e.g., phenyl
  • heterocyclic aromatic groups e.g., pyridine
  • the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups provided that the entire ring system is aromatic.
  • aryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) containing only carbon in the ring backbone. When the aryl is a ring system, every ring in the system is aromatic.
  • the aryl group may have 6 to 18 carbon atoms, although the present definition also covers the occurrence of the term “aryl” where no numerical range is designated. In some embodiments, the aiyl group has 6 to 10 carbon atoms.
  • the aryl group may be designated as "Ce-io aryl,” “Ce or Cio aryl,” or similar designations. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl,
  • aryloxy and arylthio refers to KO- and K S-, in which R is an aiyl as is defined above, , such as “Ce-io aryloxy” or “Ce-io arylthio” and the like, includingbut not limited to phenyloxy.
  • an "aralkyl” or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group, such "C 7- 1 4 aralkyl” and the like, including but not limited to benzyl, 2- phenylethyl, 3-phenylpropyl, and naphthylalkyl.
  • the alkylene group is a lower alkylene group (i.e., a C alkylene group).
  • heteroaryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent atoms) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the ring backbone.
  • heteroaryl is a ring system, every ring in the system is aromatic.
  • the heteroaryl group may have 5-18 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heteroaryl" where no numerical range is designated.
  • the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members.
  • the heteroaryl group may be designated as "5-7 membered heteroaryl,” "5-10 membered heteroaryl,” or similar designations.
  • heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinlinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl,
  • a “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group. Examples include but are not limited to 2-thienylmethyl, 3- thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl.
  • the alkylene group is a lower alkylene group (i.e., a C 1 -4 alkylene group).
  • carbocyclyl means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone. When the carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro-connected fashion. Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic. Thus, carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls.
  • the carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term "carbocyclyl” where no numerical range is designated.
  • the carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms.
  • the carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms.
  • the carbocyclyl group may be designated as "C 3- 6 carbocyclyl" or similar designations.
  • carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicycle[2,2,2]octanyl, adamantyl, and spiro[4.4]nonanyl.
  • a "(carbocyclyl)alkyl” is a carbocyclyl group connected, as a substituent, via an alkylene group, such as "C 4 -10 (carbocyclyl)alkyl” and the like, including but not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
  • the alkylene group is a lower alkylene group.
  • cycloalkyl means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • cycloalkenyl means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic.
  • An example is cyclohexenyl
  • heterocyclyl means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. The heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system.
  • the heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heterocyclyl” where no numerical range is designated.
  • the heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members.
  • the heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members.
  • the heterocyclyl group may be designated as "3-6 membered heterocyclyl" or similar designations.
  • the heteroatom(s) are selected from one up to three of O, N or S, and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O, N, or S.
  • heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1 ,3-dioxanyl, 1 ,4-dioxinyl, 1 ,4-dioxanyl, 1,3-oxathianyl, 1.4- oxathiinyl, 1 ,4-oxathianyl, 2H-l,2-oxazinyl,
  • heterocyclylalkyl is a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
  • R is hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • Non-limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
  • R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • a "cyano” group refers to a "-CN” group.
  • a "cyanato” group refers to an "-OCN” group.
  • An "isocyanato” group refers to a "-NCO” group.
  • a "thiocyanato” group refers to a "-SCN” group.
  • a “sulfonyl” group refers to an "-SO2R” group in which R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce- ⁇ aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • An “S-sulfonamido” group refers to a "-S0 2 NRARB” group in which R A and R.
  • B are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
  • N-sulfonamido refers to a "-N(RA)SC>2RB” group in which R A and R b are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
  • R A and R B are each independently selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
  • An “amino” group refers to a "-NRARB” group in which R A and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 3-7 carbo
  • Ce-io aryl 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • aminoalkyl refers to an amino group connected via an alkylene group.
  • alkoxyalkyl refers to an alkoxy group connected via an alkylene group, such as a “C2-8 alkoxyalkyl” and the like.
  • a substituted group is derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group. Unless otherwise indicated, when a group is deemed to be "substituted,” it is meant that the group is substituted with one or more subsitutents independently selected from Ci-Ce alkyl, Ci-Ce alkenyl, Ci-Ce alkynyl, d-Ce heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, Ci-Ce alkyl, d- alkoxy, d- haloalkyl, and d-d haloalkoxy), C 3 -C 7 -carbocyclyl-Ci- Ce-alkyl (optionally substituted with halo, d-d alkyl, d-d alkoxy, d-d haloalkyl, and Q- d haloal
  • substituted group(s) is (are) substituted with one or more substituent(s) individually and independently selected from C1-C4 alkyl, amino, hydroxy, and halogen,
  • radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
  • a substituent identified as alkyl that requires two points of attachment includes di-radicals such as -CH 2 - -CH 2 CH 2 - -CH 2 CH(CH 3 )CH 2 -, and the like.
  • Other radical naming conventions clearly indicate that the radical is a di-radical such as "alkylene” or "alkenylene.”
  • alkylene means a branched, or straight chain fully saturated di-radical chemical group containing only carbon and hydrogenthat is attached to the rest of the molecule via two points of attachment (i.e., an alkanediyl).
  • the alkylene group may have 1 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkylene where no numerical range is designated.
  • the alkylene group may also be a medium size alkylene having 1 to 9 carbon atoms.
  • the alkylene group could also be a low r er alkylene having 1 to 4 carbon atoms.
  • the alkylene group may be designated as "C alkylene" or similar designations.
  • C alkylene indicates that there are one to four carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of methylene, ethylene, ethan-l , l-diyl, propylene, propan-l , l-diyl, propan-2,2-diyl, 1-methyl- ethylene, butylene, butan-l , l-diyl, butan-2,2-diyl, 2-methyl-propan- 1 , 1 -diyl, 1 -methyl - propylene, 2-methyl-propylene, 1 , 1 -dimethyl-ethylene, 1 ,2-dimethyl-ethylene, and 1-ethyl- ethylene.
  • alkenylene means a straight or branched chain di-radical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond that is attached to the rest of the molecule via two points of attachment.
  • the alkenylene group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkenylene w r here no numerical range is designated.
  • the alkenylene group may also be a medium size alkenylene having 2 to 9 carbon atoms.
  • the alkenylene group could also be a low r er alkenylene having 2 to 4 carbon atoms.
  • the alkenylene group may be designated as "C2-4 alkenylene" or similar designations.
  • C2-4 alkenylene indicates that there are two to four carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of ethenylene, ethen- 1 , 1 -diyl, propenylene, propen- 1 , 1 -diyl, prop-2-en- 1 ,1 -diyl, 1-methyl-ethenylene, but-l-enylene, but-2- enylene, but-l ,3-dienylene, buten- 1 , 1 -diyl, but- 1 ,3-dien- 1 , 1 -diyl, but-2-en- 1 , 1 -diyl, but-3-en- 1 ,1 -diyl, 1 -methyl -prop-2-en- 1, 1 -diyl, 2-methyl-prop-2-en- 1 ,1 -
  • agent includes any substance, molecule, element, compound, entity, or a combination thereof. It includes, but is not limited to, e.g., protein, polypeptide, peptide or mimetic, small organic molecule, polysaccharide, polynucleotide, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms “agent”, “substance”, and “compound” are used interchangeably herein,
  • analog is used herein to refer to a molecule that structurally resembles a reference molecule but which has been modified in a targeted and controlled manner, by replacing a specific substituent of the reference molecule with an alternate substituent. Compared to the reference molecule, an analog would be expected, by one skilled in the art, to exhibit the same, similar, or improved utility. Synthesis and screening of analogs, to identify variants of known compounds having improved characteristics (such as higher binding affinity for a target molecule) is an approach that is well known in pharmaceutical chemistry,
  • mammal is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, , sheep, goats, swine, rabbits, dogs, cats, rats and mice but also includes many other species.
  • primates including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, , sheep, goats, swine, rabbits, dogs, cats, rats and mice but also includes many other species.
  • microbial infection refers to the invasion of the host organism, whether the organism is a vertebrate, invertebrate, fish, plant, bird, or mammal, by pathogenic microbes. This includes the excessive growth of microbes that are normally present in or on the body of a mammal or other organism. More generally, a microbial infection can be any situation in which the presence of a microbial population(s) is damaging to a host mammal.
  • a mammal is "suffering" from a microbial infection when excessive numbers of a microbial population are present in or on a mammal's body, or when the effects of the presence of a microbial population(s) is damaging the cells or other tissue of a mammal.
  • this description applies to a bacterial infection.
  • the compounds of preferred embodiments are also useful in treating microbial growth or contamination of cell cultures or other media, or inanimate surfaces or objects, and nothing herein should limit the preferred embodiments only to treatment of higher organisms, except when explicitly so specified in the claims.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.
  • various adjuvants such as are commonly used in the art may be included.
  • the pharmaceutically acceptable excipient can be a monosaccharide or monosaccharide derivative.
  • Subject as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
  • an "effective amount” or a “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent that is effective to relieve, to some extent, or to reduce the likelihood of onset of, one or more of the symptoms of a disease or condition, and includes curing a disease or condition. “Curing” means that the symptoms of a disease or condition are eliminated; however, certain long-term or permanent effects may exist even after a cure is obtained (such as extensive tissue damage).
  • Treatment refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
  • prophylactic treatment refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition.
  • therapeutic treatment refers to administering treatment to a subject already suffering from a disease or condition,
  • “Monosaccharide” as used herein refers to a chemical compound of general formula C x (H 2 0) x , where x is 3 to 10, Examples of monosaccharide include but are not limited to glucose (dextrose), arabinose, maiinitol, fructose (levulose) and galactose.
  • “Monosaccharide derivative” as used herein refers to a monosaccharide wherein one or more -OH groups can be replaced by the substituents described above in the definition of "substituted.” In some monosaccharide derivatives, one or more -OH groups on the monosaccharide can be replaced by one or more -NH 2 or -NH-CH3 groups.
  • One example of a monosaccharide derivative includes meglumine.
  • Other examples of a monosaccharide derivative can include an amino alcohol.
  • isosteres are different compounds that have different molecular formulas but exhibit the same or similar properties.
  • tetrazole is an isostere of carboxylic acid because it mimics the properties of carboxylic acid even though they both have very different molecular formulae. Tetrazole is one of many possible isosteric replacements for carboxylic acid.
  • Other carboxylic acid isosteres contemplated include -COOH, -SO3H, -SO2HNR 9 , -P0 2 (R 9 ) 2 , -P0 3 (R 9 ) 2 , -CONHNHSO2R 9 , -COHNSO2R 9 , and -CONR 9 CN.
  • carboxylic acid isosteres can include 5-7 membered carbocycles or heterocycles containing any combination of C3 ⁇ 4, O, S, or N in any chemically stable oxidation state, where any of the atoms of said ring structure are optionally substituted in one or more positions.
  • the following structures are non-limiting examples of carbocyclic and heterocyclic isosteres contemplated.
  • the atoms of said ring structure may be optionally substituted at one or more positions with R 9 .
  • R 9 substituents upon a carbocyclic or heterocyclic carboxylic acid isostere shall not be peniiitted at one or more atom(s) which maintain(s) or is/are integral to the carboxylic acid isosteric properties of the compound, if such substituent(s) would destroy the carboxylic acid isosteric properties of the compound.
  • Other carboxylic acid isosteres not specifically exemplified or described in this specification are also contemplated.
  • the compounds disclosed herein may be synthesized by methods described below, or by modification of these methods. Ways of modifying the methodology include, among others, temperature, solvent, reagents etc., known to those skilled in the art. In general, during any of the processes for preparation of the compounds disclosed herein, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum Press, 1973); and P.G.M. Green, T.W.
  • protecting groups for oxygen atoms are selected for their compatibility with the requisite synthetic steps as well as compatibility of the introduction and deprotection steps with the overall synthetic schemes (P.G.M, Green, T.W. Wutts, Protecting Groups in Organic Synthesis (3rd ed.) Wiley, New York (1999)). Handling of protecting and/or sterodirectiiig groups specific to boronic acid derivatives is described in a recent review of chemistry of boronic acids: D.G. Hall (Ed.), Boronic Acids. Preparation and Application in Organic Synthesis and Medicine, Wiley VCH (2005) and in earlier reviews: Mattesoii, D, S.
  • Matteson reaction precursors of formula Ia-3 may be made by palladium mediated coupling of pinanediol diboronate from corresponding appropriately protected benzyl alcohols (J. Am, Chem, Soc. 2011, 133, 409-41 1 , which is incorporated herein by reference in its entirety) or benzyl bromides Ia-4 (Xetrahedron Letters 2003, 44, 233-235; J. Am. Chem. Soc, 2010, 132, 1 1825-1 1827, which is incorporated herein by reference in its entirety).
  • Compounds of formula Ia-3 may also be prepared by homologation of the corresponding arylboronate ester by reaction with chloromethyl anion (PCX Publication No. WO09064414, which is incorporated herein by reference in its entirety).
  • the compounds of formula Ia-4 may be achieved by means of several earlier known methods (PCX Publication No. WO0458679, which is incorporated herein by reference in its entirety) with conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum, 1973); and Protecting Groups in Organic Synthesis, P.G.M. Wutts, T.W.
  • Bi s-trimethyl silylamides of formula Ia-2 may be reacted in situ with an acid chloride to result directly in analogs of formula Ia-1,
  • Such analogs of f - 1 can also be made via coupling of the bis-TMS amine with commercially available carboxylic acids under typical amide coupling conditions (e.g., carbodiimide or HATU coupling) (Tetrahedron, 2005, 61 , 10827- 10852, which is incorporated herein by reference in its entirety).
  • Varieties of substituted thioacetic acid or glycolate or glycinate precursors are commercially available. Such precursors may be also obtained by several well-known methods in the literature (J. Org, Chem, (2012), DOI: 10, 1021/jo302088t, which is incorporated herein by reference in its entirety),
  • compounds of formula Ia-2 where X is M KHCl can be made via asymmetric addition of boron to a carbon heteroatom double bond, enabling production of enantiomerically pure N-sulfinyl-a-amino boronate ester derivatives.
  • Such transformation is achieved form appropriately protected N-sulfinyl inline (Ia-5) using a Cu/ligand catalyst system (J. Am. Chem. Soc. (2008), 130, 6910-691 1 , which is incorporated herein by reference in its entirety) followed by treatment with mild acid.
  • Enantiomerically pure N-sulfinyl imines of foniiula Ia-5 may be made by condensation of appropriately protected phenylacetaldehyde intermediates (Ia-6) and enantiomerically pure t-butylsulfonylamine (Chem. Rev. 2010, 110, 3600-3740, which is incorporated herein by reference in its entirety),
  • Phenylacetaldehyde derivatives of formula Ia-6 can be made from Claisen rearrangement of allyl ethers of commercially available salicylates followed by oxidative cleavage of the allyl group (J. Med. Chem. 1995, 38, 3094-3105, which is incorporated herein by reference in its entirety). Such intermediates of formula Ia-6 can also be made by Wacker oxidation of vinyl substituted salicylates (Org. Lett. 2012, 14, 3237-3239, which is incorporated herein by reference in its entirety). Protective groups may be used separately for phenol and acid or together from a variety of available options as described above.
  • Y can be -OH, halogen, -CMO alkyl, -CMO alkyl-OH, -CMO alkyl-halogen
  • R 1A can be hydrogen or CMO alkyl
  • R 2A can be hydrogen or C MO alkyl.
  • the compound of Foniiula 1-1 can be treated first with TFA and TFAA and then with Bis(pinacolato)diboron to form a pinacol boronic ester compound of Foniiula 1-3.
  • the compound of Formula 1-3 is then reacted with pinaiiediol to yield a Pinanediol Methylboronic Ester Compound of Formula 1-4,
  • the compound of Formula 1-4 undergoes homologation to yield a compound of Foniiula 1-5, which then undergoes another homologation reaction to provide a chloroethlene product of Foniiula 1-6.
  • the compound of Foniiula 1-6 reacts with the bis-TMS amine to form a bis-triiiiethyl silyamine of Formula 1-7.
  • Different types of thioacetic acid, glycolate or glycinate precursors can then react with the compound of Foniiula 1-7 to form an amide of Formula 1-8.
  • the compound of Foniiula 1-8 then undergoes the deprotection of the pinane ester and salicylic acid protective groups to afford the compound of Formula la.
  • compounds of Formula la can also be prepared by using the general synthetic Scheme lb illustrated below.
  • the starting compound of Formula 1-2 can be prepared by adding protective groups to a salicylate derivative compound following procedures described above in Scheme la.
  • the compound of Formula 1-2 can be treated with vinyl trifluoroborate to form a vinyl phenyl compound of Formula 1-9.
  • the compound of Formula 1-9 then undergoes reaction to form a phneylacetaldehyde derivative of Formula 1- 10.
  • the compound of Formula I- 10 then reacts with (R)-t-butylsulfmic amide to provide a N-sulfinyl imine compound of Formula 1- 1 1.
  • the compound of Formula 1-11 undergoes boron addition to form a pinacol boronic ester compound of Formula 1-12,
  • the compound of Formula 1-12 can react with the acid to remove the t-butylsulfinic group.
  • Different types of thioacetic acid, glycolate or glycinate precursors can then react with the compound of Formula 1-13 to form an amide of Formula 1-14,
  • the amide of Formula 1-14 can react with pinanediol to yield a Pinanediol Methylboronic Ester Compound of Formula 1-8.
  • the compound of Formula 1-8 can then undergo the deprotection of the pinane ester and salicylic acid protective groups to afford the compound of Formula la.
  • Compounds of Formula I where the K is a prodrug moiety may be synthesized by a variety of known methods of different carboxylic acid prodrugs (Prodrugs: Challenges and Rewards, V. J. Stella, et al,, ed., Springer, New York, 2007, which is incorporated herein by reference in its entirety).
  • These prodrugs include but are not limited to substituted or non-substituted alkyl esters, (acyloxy)alkyl esters (Synthesis 2012, 44, 207, which is incorporated herein by reference in its entirety), [(alkoxycarbonyl)oxy]methyl esters (PCT Publication No.
  • compounds of Formula I may be also utilized for introduction of prodrugs (Scheme 2b).
  • Such carboxylic acids (VIII) can be made from compounds of Formula la- 1 by selective deprotection of OR'.
  • the prodrug group may also be introduced earlier in the sequence in compounds of Formula Ia-4 or Ia-6 where R' is R. Such a sequence where the prodrug is introduced in earlier intermediates is only feasible when the ester is stable under the final deprotection conditions to remove the phenol protective group and the boronate ester.
  • a daily dose may be from about 0,25 mg/kg to about 120 mg/kg or more of body weight, from about 0.5 mg/kg or less to about 70 mg/kg, from about 1.0 mg/kg to about 50 mg/kg of body weight, or from about 1.5 mg/kg to about 10 mg/kg of body weight.
  • the dosage range would be from about 17 mg per day to about 8000 mg per day, from about 35 mg per day or less to about 7000 mg per day or more, from about 70 mg per day to about 6000 mg per day, from about 100 mg per day to about 5000 mg per day, or from about 200 mg to about 3000 mg per day.
  • the amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician,
  • Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, or intraocularly. Oral and parenteral administrations are customary in treating the indications that are the subject of the preferred embodiments.
  • compositions comprising: (a) a safe and therapeutically effective amount of a compound described herein (including enaiitiomers, diastereoisomers, tautomers, polymorphs, and solvates thereof), or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
  • compositions containing a pharmaceutically-acceptable carrier include compositions containing a pharmaceutically-acceptable carrier.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. In addition, various adjuvants such as are commonly used in the art may be included.
  • substances which can serve as pharmaceutically- acceptable carriers or components thereof, are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, com oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the TWEENS; wetting agents, such sodium lauiyl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservative
  • compositions described herein are preferably provided in unit dosage form.
  • a "unit dosage form" is a composition containing an amount of a compound that is suitable for administration to an animal, preferably mammal subject, in a single dose, according to good medical practice.
  • the preparation of a single or unit dosage form does not imply that the dosage form is administered once per day or once per course of therapy.
  • Such dosage forms are contemplated to be administered once, twice, thrice or more per day and may be administered as infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours), or administered as a continuous infusion, and may be given more than once during a course of therapy, though a single administration is not specifically excluded.
  • the skilled artisan will recognize that the formulation does not specifically contemplate the entire course of therapy and such decisions are left for those skilled in the art of treatment rather than formulation,
  • compositions useful as described above may be in any of a variety of suitable forms for a variety of routes for administration, for example, for oral, nasal, rectal, topical (including transdermal), ocular, intracerebral, intracranial, intrathecal, intra-arterial, intravenous, intramuscular, or other parental routes of administration.
  • routes for administration for example, for oral, nasal, rectal, topical (including transdermal), ocular, intracerebral, intracranial, intrathecal, intra-arterial, intravenous, intramuscular, or other parental routes of administration.
  • oral and nasal compositions comprise compositions that are administered by inhalation, and made using available methodologies.
  • a variety of pharmaceutically-acceptable carriers well-known in the art may be used.
  • Pharmaceutically-acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropies, surface-active agents, and encapsulating substances.
  • Optional pharmaceutically-active materials may be included, which do not substantially interfere with the inhibitory activity of the compound.
  • the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
  • Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet triturates, enteric- coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
  • Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.
  • the pharmaceutically-acceptable carrier suitable for the preparation of unit dosage forms for peroral administration is well-known in the art.
  • Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc.
  • Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture.
  • Coloring agents such as the FD&C dyes, can be added for appearance.
  • Sweeteners and flavoring agents such as aspartame, saccharin, menthol, pepperm int, and fruit flavors, are useful adjuvants for chewable tablets.
  • Capsules typically comprise one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations like taste, cost, and shelf stability, which are not critical, and can be readily made by a person skilled in the art,
  • Peroral compositions also include liquid solutions, emulsions, suspensions, and the like.
  • the pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art.
  • Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water.
  • typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RC-591 , tragacanth and sodium alginate;
  • typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
  • Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants disclosed above.
  • Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action.
  • dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
  • compositions described herein may optionally include other drug actives.
  • compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms.
  • Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
  • a liquid composition which is formulated for topical ophthalmic use, is formulated such that it can be administered topically to the eye.
  • the comfort should be maximized as much as possible, although sometimes formulation considerations (e.g. drug stability) may necessitate less than optimal comfort.
  • the liquid should be formulated such that the liquid is tolerable to the patient for topical ophthalmic use.
  • an ophthalmically acceptable liquid should either be packaged for single use, or contain a preservative to prevent contamination over multiple uses.
  • solutions or medicaments are often prepared using a physiological saline solution as a major vehicle.
  • Ophthalmic solutions should preferably be maintained at a comfortable pH with an appropriate buffer system.
  • the formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
  • Preservatives that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric, acetate and phenylmer curie nitrate.
  • a useful surfactant is, for example, Tween 80.
  • various useful vehicles may be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol , povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.
  • Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
  • Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. For many compositions, the pH will be between 4 and 9. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
  • an ophthalmically acceptable antioxidant includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
  • excipient components which may be included in the ophthalmic preparations, are chelating agents.
  • a useful chelating agent is edetate disodium, although other chelating agents may also be used in place or in conjunction with it,
  • Topical formulations may generally be comprised of a pharmaceutical carrier, co-solvent, emulsifier, penetration enhancer, preservative system, and emollient,
  • the compounds and compositions described herein may be dissolved or dispersed in a pharmaceutically acceptable diluent, such as a saline or dextrose solution. Suitable excipients may be included to achieve the desired pH, including but not limited to NaOH, sodium carbonate, sodium acetate, HC1, and citric acid. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably from 4 to 7.
  • Antioxidant excipients may include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA, Other non-limiting examples of suitable excipients found in the final intravenous composition may include sodium or potassium phosphates, citric acid, tartaric acid, gelatin, and carbohydrates such as dextrose, mannitol, and dextran.
  • Antimicrobial agents may also be included to achieve a bacteriostatic or fungistatic solution, including but not limited to phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.
  • compositions for intravenous administration may be provided to caregivers in the form of one more solids that are reconstituted with a suitable diluent such as sterile water, saline or dextrose in water shortly prior to administration.
  • a suitable diluent such as sterile water, saline or dextrose in water shortly prior to administration.
  • the compositions are provided in solution ready to administer parenterally.
  • the compositions are provided in a solution that is further diluted prior to administration.
  • the combination may be provided to caregivers as a mixture, or the caregivers may mix the two agents prior to administration, or the TWO agents may be administered separately.
  • Some boronic acid derivatives described herein can form an oligomer such as a dimer, t rimer or tetramer.
  • some embodiments include pharmaceutical composition in which an excipient is included that prevents or limits the formation of oligomers.
  • the excipient can be a monosaccharide or monosaccharide derivative.
  • the monosaccharide or monosaccharide derivative is meglumine.
  • Other excipients include but are not limited to ethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane (Tris), L-lysine, and Pyridine- 2-methanol.
  • Some embodiments described herein relate to a chemical complex formed between the monosaccharide or monosaccharide derivative and the compound of Formula (III) described herein.
  • the interaction between the two components help increase the stability and/or solubility of the compound of Formula (III).
  • the monosaccharide or monosaccharide derivative can form a chemical complex with any compound containing a boronate moiety .
  • the compound containing a boronate moiety can be a boronic acid derivative described herein such as a compound of Formula (III) described herein.
  • the compound containing a boronate moiety can be any other boronate containing compounds, for example, known boron ate-contain ing pharmaceutical agents.
  • the monosaccharide or monosaccharide derivative used in forming the stable complex can be meglumine.
  • the pH of the composition can be in the range of about 5 to about 9, about 6 to 8, about 6 to about 7.5, about 7.1 to about 7.3, or about 7.1 to about 7.2. In some embodiments, the pH of the composition can be in the range of about 7.0-7.3. In some embodiments, the pH of the composition can be about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1 , 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, and 7.8. In some embodiments, the pH of the composition can be about 7.1. In some embodiments, the pH of the composition can be about 7.2,
  • the amount of the boronic acid derivatives that are present in a monomer form can vary depending on the pH of the solution, the oligomer-preventing excipient included, and the amount of the excipient in the composition.
  • the percentage of the monomer form can be more than 85%, more than 88%, more than 90%, more than 92%, more than 95%, more than 97% by weight, based on the total amount of the boronic acid derivative in the composition.
  • the percentage of the monomer form can be more than 96% by weight based on the total amount of the boronic acid derivative in the composition.
  • the percentage of the monomer form can be more than 97% by weight based on the total amount of the boronic acid derivative in the composition.
  • Some embodiments of the present invention include methods of treating bacterial infections with the compounds and compositions comprising the compounds described herein. Some methods include administering a compound, composition, pharmaceutical composition described herein to a subject in need thereof.
  • a subject can be an animal, e.g., a mammal (including a human).
  • the bacterial infection comprises a bacteria described herein.
  • methods of treating a bacterial infection include methods for preventing bacterial infection in a subject at risk thereof.
  • the subject is a human
  • a combination can include a compound, composition, pharmaceutical composition described herein with an additional medicament,
  • Some embodiments include co-administering a compound, composition, and/or pharmaceutical composition described herein, with an additional medicament.
  • coadministration it is meant that the two or more agents may be found in the patient's bloodstream at the same time, regardless of when or how they are actually administered.
  • the agents are administered simultaneously.
  • administration in combination is accomplished by combining the agents in a single dosage form.
  • the agents are administered sequentially.
  • the agents are administered through the same route, such as orally.
  • the agents are administered through different routes, such as one being administered orally and another being administered i.v.
  • additional medicaments include an antibacterial agent, antifungal agent, an antiviral agent, an anti-inflammatory agent and an anti-allergic agent,
  • Preferred embodiments include combinations of a compound, composition or pharmaceutical composition described herein with an antibacterial agent such as a ⁇ -lactam.
  • ⁇ -lactams include Amoxicillin, Ampicillin (e.g., Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicillin (G), Clometocilliii, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Plienoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (e.g., Dicloxacillin, Flucloxacilli
  • Preferred embodiments include ⁇ -lactams such as Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem and Panipenem,
  • Additional preferred embodiments include ⁇ -lactams such as Aztreonam, Tigemonam, BAL30072, SYN 241.6 and Carumonam.
  • ⁇ -lactams include penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof, wherein the penicillin is benzathine penicillin, benzylpenicillin, phenoxymethylpenicillin, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacilliii, temocillin, amoxicillin, ampicillin, co- amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacilliii, talapicilliii, aspoxicilliii, cloxacillin, nafcillin, pivampicillin, or a combination thereof.
  • the cephalosporin can be cephalothin, cephaloridin, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetfil, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefinenoxime, cefinetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpirami.de, cef uperazone, cefozopran, cefepim, cefoselis, cefluprenam, cefuzonam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil
  • the cephalosporin can be an anti-MRSA cephalosporin
  • the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
  • the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, panipenem, or a combination thereof.
  • the carbapenem is an anti-MRSA carbapenem
  • the anti-MRSA carbapenem is PZ601 or ME 1036.
  • Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises a monobactam.
  • additional agent comprises a monobactam.
  • monobactams include aztreonam, tigemonam, nocardicin A, carumonam, and tabtoxin.
  • the compound, composition and/or pharmaceutical composition comprises a class A, C, or D beta- lactamase inhibitor.
  • Some embodiments include co-administering the compound, composition or pharmaceutical composition described herein with one or more additional agents.
  • Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises a class B beta lactamase inhibitor.
  • a class B beta lactamase inhibitor includes ME 1071 (Yoshikazu Ishii et al, "In Vitro Potentiation of Carbapenems with ME1071 , a Novel Metallo-B-Lactamase Inhibitor, against Metallo-B- lactamase Producing Pseudomonas aeruginosa Clinical Isolates.” Antimicrob. Agents Chemother, doi: 10.1128/AAC.01397-09 (July 2010)).
  • Some embodiments include coadministering the compound, composition or pharmaceutical composition described herein with one or more additional agents.
  • Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises one or more agents that include a class A, B, C, or D beta lactamase inhibitor. Some embodiments include co-administering the compound, composition or pharmaceutical composition described herein with the one or more additional agents.
  • Bacterial infections that can be treated with the compounds, compositions and methods described herein can comprise a wide spectrum of bacteria.
  • Example organisms include gram-positive bacteria, gram-negative bacteria, aerobic and anaerobic bacteria, such as Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus, Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella and other organisms.
  • More examples of bacterial infections include Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenoirophomonas maltophilia, Burkholderia cepacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus
  • the aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were dried over aoS0 4 .
  • the concentrated material was chromatographed (100% hexane ⁇ 20% EtOAc-hexane) to obtain the titled compound IF (2,07 g, 95% yield) as slightly yellow oil.
  • the reaction mixture was quenched with a saturated solution of ammonium chloride and the phases were separated.
  • the aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were dried over filtered and concentrated under reduced pressure.
  • the concentrated material was then chromatographed (100% hexane ⁇ 20% EtOAc-hexane) to obtain the titled compound 1G (1 ,48 g, 63% yield) as slightly yellow oil.
  • Step 9 Synthesis of (R)-2-hydroxy-3-(2-(trifluoromethylthio)acetamido)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (1)
  • Step 2 Synthesis of (R)-2-hydroxy-3-(2-(l -methyl- lH-tetrazol-5-ylthio)acetamido)-3, 4- dihydro-2H-benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (2)
  • Step 8 Synthesis of (R)-3-(2-(difluoromethylthio)acetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (3)
  • Step 2 Synthesis of (R)-3-formamido-2-hydroxy-3,4-dihydro-2H-benzo[e][l,2]oxaborinine-8- carboxylic acid (4)
  • Step 2 Synthesis of (R)-3-(2-(5-amino-l ,3,4-thiadiazol-2-ylthio)acetamido)-2-hydroxy-3,4- dihydro-2H-benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (5)
  • Step 3 Synthesis of compound 7D [0239] The mixture of compound 7C (47.5 g, 123 mmol), bis(pinanediolato)diboron (39.9 g, 112 mmol), KOAc (32.9 g, 336 mmol) and PdCl 2 (dppf) (4.5 g, 5.6 mmol) in dioxane (500 iiiL) was degassed for three times and flushed with nitrogen. The mixture was stirred at 95 °C for 8 hours. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/200-1/100) to give the titled compound 7D (40 g, 59% yield) as slightly yellow oil.
  • Step 7 Synthesis of (R)-3-(2-(l ,3,4-thiadiazol-2-ylthio)acetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e] [l ,2]oxaborinine-8-carboxylic acid (7)
  • Step 2 Synthesis of (R)-3-(2-azidoacetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (8)
  • Step 2 Synthesis of (R)-3-(2-(dimethylamino)-2-oxoacetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (9)
  • Step 1 Synthesis of 10B [0251] Bis(trimethylsilyl)amine compound 7F (300 mg, 0,5 mmol) was stirred in
  • Step 2 Synthesis of (R)-3-(3-(dimethylamino)-3-oxopropanamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (10)
  • Step 2 Synthesis of (R)-2-hydroxy-3-(methylthiocarbonylamino)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (11)
  • Compound 22 was prepared following the same procedure described in example 7 (steps 1-7) except replacing the ([ 1 ,3 ,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 2-( ⁇ l-[(tert-butoxy)carbonyl]azetidin-3-yl ⁇ sulfanyl)acetic acid.
  • ⁇ -lactamase inhibitors were determined by assessing their aztreonam potentiation activity in a dose titration potentiation assay using strains of various bacteria that are resistant to aztreonam due to expression of various ⁇ - lactamases.
  • Aztreonam is a monobactam antibiotic and is hydrolyzed by the majority of beta- lactamases that belong to class A or C (but not class B or D),
  • the potentiation effect was observed as the ability of BLI compounds to inhibit growth in the presence of sub-inhibitory concentration of aztreonam, MICs of test strains varied from 64 ⁇ g/mL to > 128 ⁇ g/mL, Aztreonam was present in the test medium at 4 ⁇ g/mL, Compounds were tested at concentrations up to 40 ⁇ g/mL.
  • potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 4 ⁇ g/mL of aztreonam (MPC@4).
  • Table 1 summarizes the BLI potency of aztreonam potentiation (MPC @4 ) for various strains overexpressing class A (ESBL and KPC), and class C beta- lactamases. Aztreonam MIC for each strain is also shown. The results were compared to comparative compounds A and B:
  • Selected ⁇ -lactamase inhibitors were also tested for their ability to potentiate the monobactam tigemonam.
  • the potentiation effect is observed as the ability of BLI compounds to inhibit growth in the presence of sub-inhibitory concentration of tigemonam, MICs of test strains varied from 16 ⁇ g/mL to > 64 ⁇ g/l ⁇ L, Tigemonam was present in the test medium at 4 ⁇ g/mL, Compounds were tested at concentrations up to 40 ⁇ g/mL, In this assay potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 4 ⁇ g/mL of aztreonam (MPC@4).
  • Table 2 summarizes the BLI potency of tigemonani potentiation (MPC @4 ) for various strains overexpressing class A (ESBL) and class C beta-lactamases. Tigemonani MIC for each strain is also shown. The results w r ere compared to comparative compounds A and B:
  • ⁇ -lactamase inhibitors were also tested for their ability to potentiate the carbapenem biapenem against strains producing class A ( PC) and class D (OXA-48) carbapenemases.
  • the potentiation effect is observed as the ability of BLI compounds to inhibit growth in the presence of a sub- inhibitory concentration of biapenem, Biapenem MIC of test strains were 16-32 ⁇ g/mL, Biapenem was present in the test medium at 1 ⁇ g/mL, Compounds were tested at concentrations up to 40 ⁇ g/mL, In this assay potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 1 ⁇ g/mL of biapenem (MPC@i).
  • Table 3 summarizes the BLI potency of biapenem potentiation (MPC@i) for two strains overexpressing class A (KPC) and class D (OXA-48) carbapenemases. Biapenem MIC for each strain is also shown. The results were compared to comparative compounds A and B:
  • Efflux of BLIs from Pseudomonas aeruginosa by the MexAB-OprM efflux pump was also evaluated.
  • the plasmid expressing the gene encoding KPC-2 was introduced into two strains of P. aeruginosa, PAMl 032 and PAMl 154 that overexpressed or lacked MexAB- OprM, respectively. Due to expression of KPC-2 both strains became resistant to biapenem, Biapenem is not affected by efflux in P. aeruginosa and both strains had the same biapenem MIC of 32 ⁇ g/ml, Potency of BLIs to potentiate biapenem in these strains was determined.
  • Potency was defined as the ability of BLI to decrease MIC of biapenem 64-fold, from 32 ⁇ g/ml to 0.5 ⁇ g/ml, or MPC 64 .
  • the ratio of MPC 64 values for each BLI in PAM1032/KPC-2 (efflux proficient) and PAMl 154/KPC-2 (efflux deficient) was determined to generate the Efflux Index (EI). The results were compared to comparative compound A:
  • Table 5 shows MPCe4 and Els values for selected BLIs.
  • Prodrug strategy is one of the ways to achieve or increase oral bioavailability of therapeutic drags.
  • Compound 13 was used as template a for various ester prodrugs. After a prodrug molecule is absorbed into systemic circulation, the prodrug molecule can be hydrolyzed in the blood to release the active form. The hydrolysis of several prodrugs by rat and human serum were evaluated.
  • the test compounds are treated with rat or human serum in Eppendorf tubes.
  • One example of the testing procedures includes: 992 ⁇ of serum was prewarmed at 37 °C for 2 minutes and then 8 ⁇ of a compound (at 5 mg/ml, 125x) was added to get a final concentration of 40 ⁇ g/ml and immediately mixed.
  • serum stability can be tested at 1 mg/ml.
  • the tube was placed back in a 37 degree water bath and 100 ⁇ -samples were taken at designated times and transferred directly into Eppendorf tubes containing 400 ⁇ of precipitant solution (a 4,00 ⁇ g/mL solution of a standard compound (2-((3R,6S)-3- benzamido-2-hydroxy- 1 ,2-oxaborinan-6-yl)acetic acid) - in 10% water, 45% methanol and 45% acetonitrile). After vortexing for 30 seconds, the tube was centrifuged in a microcentrifuge for 10 minutes at 15 rpm.
  • NDT signifies below the quantifiable limit for this assay.
  • Example 35 Formation of Salts/Complexes of Boron ic Acid Derivatives to Maintain the Monomelic Form
  • the compounds described herein were observed to form oligomers (such as dimers and trimers) in aqueous solution.
  • the effect of additives that would form a salt or complex with the boronic acid derivatives was evaluated in order to identify those that would strongly favor the monomeric form at an acceptable pH for IV infusion (pH 4-8),
  • a base or complexing agent was added to a dispersion of Compound 13 in water at the given concentration (Table 10), and the formed mixture was sonicated to provide a homogeneous solution.
  • the pH of the resulting homogeneous solution was measured with a pH meter and the purity was monitored by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.

Description

BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
BACKGROUND
Field of the Invention
[0001] The present invention relates to the fields of chemistry and medicine. More particularly, the present invention relates to boronic acid antimicrobial compounds, compositions, their preparation, and their use as therapeutic agents.
Description of the Related. Art
[00021 Antibiotics have been effective tools in the treatment of infectious diseases during the last half-century. From the development of antibiotic therapy to the late 1980s there was almost complete control over bacterial infections in developed countries. However, in response to the pressure of antibiotic usage, multiple resistance mechanisms have become widespread and are threatening the clinical utility of anti-bacterial therapy. The increase in antibiotic resistant strains has been particularly common in major hospitals and care centers. The consequences of the increase in resistant strains include higher morbidity and mortality, longer patient hospitalization, and an increase in treatment costs.
[0003] Various bacteria have evolved β-lactam deactivating enzymes, namely, β- lactamases, that counter the efficacy of the various β-lactam antibiotics, β-lactamases can be grouped into 4 classes based on their amino acid sequences, namely, Ambler classes A, B, C, and D. Enzymes in classes A, C, and D include active-site serine β-lactamases, and class B enzymes, which are encountered less frequently, are Zn-dependent, These enzymes catalyze the chemical degradation of β-lactam antibiotics, rendering them inactive. Some β-lactamases can be transferred within and between various bacterial strains and species. The rapid spread of bacterial resistance and the evolution of multi-resistant strains severely limits β-lactam treatment options available.
[0004] The increase of class D β-lactamase-expressing bacterium strains such as Acinetobacter baumannu has become an emerging iiiultidrug-resistant threat, A. ba mannii strains express A, C, and D class β-lactamases. The class D β-lactamases such as the O.XA families are particularly effective at destroying carbapenem type β-lactam antibiotics, e.g., imipenem, the active carbapenems component of Merck's Primaxin® (Montefour, K.; et al. Crit, Care Nurse 2008, 28, 15; Perez, F. et al. Expert Rev. Anti Infect. Ther. 2008, 6, 269; Bou, G.; Martinez-Beltran, J. Aiitimicrob. Agents Chemother. 2000, 40, 428. 2006, 50, 2280; Bou, G. et al, J. Aiitimicrob. Agents Chemother. 2000, 44, 1556), This has imposed a pressing threat to the
- I - effective use of drugs in that category to treat and prevent bacterial infections. Indeed the number of catalogued serine -based β-lactamases has exploded from less than ten in the 1970s to over 300 variants. These issues fostered the development of five "generations" of cephalosporins. When initially released into clinical practice, extended-spectrum cephalosporins resisted hydrolysis by the prevalent class A β-lactamases, TEM-1 and SHV-1. However, the development of resistant strains by the evolution of single amino acid substitutions in TEM-1 and SHV-1 resulted in the emergence of the extended-spectrum β-lactamase (ESBL) phenotype.
[0005] New β-lactamases have recently evolved that hydrolyze the carbapenem class of antimicrobials, including imipenem, biapenem, doripenem, meropenem, and ertapenem, as well as other β-lactam antibiotics. These carbapenemases belong to molecular classes A, B, and D, Class A carbapenemases of the PC-type predominantly in Klebsiella pneumoniae but now also reported in other Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. The PC carbapenemase was first described in 1996 in North Carolina, but since then has disseminated widely in the US. It has been particularly problematic in the New York City area, where several reports of spread within major hospitals and patient morbidity have been reported. These enzymes have also been recently reported in France, Greece, Sweden, United Kingdom, and an outbreak in Germany has recently been reported. Treatment of resistant strains with carbapenems can be associated with poor outcomes.
[§§§6] Another mechanism of β-lactamase mediated resistance to carbapenems involves combination of permeability or efflux mechanisms combined with hyper production of beta-lactamases. One example is the loss of a porin combined in hy erproduction of ampC beta- lactamase results in resistance to imipenem in Pseudomonas aeruginosa. Efflux pump over expression combined with hyperproduction of the ampC β-lactamase can also result in resistance to a carbapenem such as meropenem,
[0007] Thus, there is a need for improved β-lactamase inhibitors.
SUMMARY
[§§§8] Some embodiments disclosed herein include a compound having the structure of formula (I) or formu
Figure imgf000003_0001
or pharmaceutically acceptable salt thereof, wherein:
G is selected from the group consisting of -H, -N R R\ -CH2N3, -C(0)NR1R2, - CH2C(0) N R R\ -CH2S(0)2 N R R\ -CH2-Y-Z, -C 'H-Y-X . and -SR3;
Y is selected from a group consisting of -S-, -S(O)-, -S(0)2-, -0-, and -NR.1-;
R is selected from a group consisting of -H,
Figure imgf000004_0001
-CR1R2OC(0)Ci-9alkyl, -
CR1R2OC(0)OCi-9alkyl, and
Figure imgf000004_0002
R1 and R are each independently selected from the group consisting of -H and - Ci-4alkyl;
R3 is -Ci-4alkyl;
R4 is present 1 to 3 times and each R4 is independently selected from the group consisting of -H, -Ci-4alkyl, -OH, -O Ci-4alkyl , S-Ci-4alkyl, -CF3 and halogen;
Z is selected from the group consisting of aryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen; and heteroaiyl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen;
X is selected from the group consisting of
Figure imgf000004_0003
-CH2R5, -CH(R5)2, and -C(R5)3; and
R5 is selected from the group consisting of a halogen, cyano, and azido group.
[0009] Some embodiments disclosed herein include a compound having the structure of formula II or formul
or pharmaceutically acc ereof, wherein G is selected from the group consisting of
Figure imgf000004_0004
Figure imgf000005_0001
[OO lOj Other embodiments disclosed herein include a phaniiaceutical composition comprising a therapeutically effective amount of a compound disclosed herein and a pharmaceutically acceptable excipient,
[§§11] Other embodiments disclosed herein include a phaniiaceutical composition comprising a therapeutically effective amount of a compound disclosed herein and a pharmaceutically acceptable excipient,
[0012] Some embodiments disclosed herein include a pharmaceutical composition comprising a therapeutically effective amount of a compound disclosed herein, a pharmaceutically acceptable excipient and one or more β-lactam antibacterial agents.
[0013] Other embodiments disclosed herein include a method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof a compound disclosed herein.
[0014] Some embodiments described herein include a pharmaceutical composition, comprising:
a monosaccharide or monosaccharide derivative; and
a compound of Formula III):
Figure imgf000005_0002
R1
(III)
or pharmaceutically acceptable salts thereof, wherein:
A is selected from the group consisting of C5-1o carbocyclyl, Ce-ιο aryl, 5- 10 membered heteroaryl, and 5- 10 membered heterocyclyl;
Xa is -C(RgRh)-, -0-, -S-. -S(O)-, -S(0)2-, or -NR.1-;
K ' is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R
Figure imgf000006_0001
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2,
-S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster;
Rb is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R
Figure imgf000006_0002
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2, -S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster, and
Rc is selected from the group consisting of -OH, optionally substituted - O-Ci-6 alkyl -NR'R2, and
Figure imgf000006_0003
or Rb and Rc together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1- 3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen(N);
Rd is selected from the group consisting of hydrogen, -OH, optionally substituted -O-G-e alkyl
Figure imgf000006_0004
or
when Rb and Rc do not together form a 5-8 membered boron ester ring, then optionally Rc and Rd together with intervening atoms form a 5- 15 membered boron ester or amide ring, optionally comprising additional 1-3 heteroatoms selected from O, S, and N;
Re is independently selected from the group consisting of hydrogen, optionally substituted G-ealkyl, optionally substituted C3-7cycloalkyl, optionally substituted Ce-ioatyl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl, or Rd and Re together with the nitrogen to which they are attached form a 5-8 membered heterocyclic ring, optionally comprising additional 1-3 heteroatoms selected from O, S or N;
R is independently selected from the group consisting of -H, -OH, -C(0)G, -C(0)OG, -S(0)2G, -C(=NR1R2)G, -C(=NOR3)G, optionally substituted Q-6 alkyl, optionally substituted -O-Ci-ealkyl, optionally substituted C3-8 cycloalkyl, optionally substituted Ce-ιο aryl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl;
Rs and Rh are each independently selected from the group consisitng of - H, Ci-6 alkyl, -OH, -OCi-ealkyl, -SCi-ealkyl, Cs-iocycloalkyl, C2-ioalkenyl, C2- loalkynyl, -NR1C(0)R5, - R' SCO^R3, -C(0)R5, -C(0)OR3-alkylaryl, optionally substituted Ce-ιο aryl, optionally substituted -O-Ce-ioaryl, -CN, optionally substituted 5-10 membered heteroaryl, optionally substituted -0-heteroaryl, optionally substituted 3 0 membered heterocyclyl, -S(0)(R3)R4' -S(0)2R3, R -
O-COOR3, or Rg and Rh together with the carbon to which they are attached form a C3-8 cycloalkyl or a 4-8 membered heterocyclyl;
R is selected from the group consisting of -H, halogen, -Q^alkyl,
-CR5R6OC(0)Ci_9alkyl, -CR5R6OC(0)OCi_9alkyl, and
Figure imgf000007_0001
G is selected from the group consisting of hydrogen, N R R\ -CH2N3, - C(0)NR1R2, -CH2C(0)NR1R2, -CH2S(0)2NR1R2, -(CH2)n-Y-Z, -(CH2)n-Y-X, - 0-(CH2)n-C(0)NR1R2, SR \ -CH2NR1C(0)R5, -C(=NOR3)-X, -C(=NOR3)-Z, - C(0)OR3, -C(0)-X, -C(0)-Z, -S(0)2R3, -C(0)NR1OR3, -NR^OR3), -NR1C(0)R3, -NR1C(0)NR2Rla, -NR1C(0)OR3, -NR1S(0)2R3, -NR1S(0)2NR2Rla, - N R N R R ; , -C(0)NR1NR2Rla, -S(0)2NR1NR2Rla, -C(=NR1)R5, C(=NR1)NR2Rla, -NR1CR3(=NR2), and -NR1C(=NR2)NRlaR2a, optionally substituted C MO alkyl, optionally substituted C2-ioalkenyl, optionally substituted C2-ioalkynyl, optionally substituted C3-7 carbocyclyl, optionally substituted 5- 10 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
X is hydrogen or optionally substituted
Figure imgf000007_0002
Y is selected from a group consisting of -S-, -S(O)-, -S(0)2-, -CH2-, -0-, - 0-CH2-, -C(O)-, and -NR.1-;
Z is selected from optionally substituted C3-8 cycloalkyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Ce-ιο aryl, optionally substituted 5- 10 membered heteroaryl;
each R1, R2, Rla and R2a are independently selected from the group consisting of -H, optionally substituted -Ci-ioalkyl, optionally substituted C2-ioalkenyl, optionally substituted C2_ioalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
R3 is hydrogen, optionally substituted Ci-ioalkyl, -optionally substituted Ci-ioalkyl-COOH, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl; each R5 and R6 are independently selected from the group consisting of - H, -OH, -optionally substituted alkoxyl, optionally substituted -Ci-ioalkyl, optionally substituted C2-1oalkenyl, optionally substituted C2-1oalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
R4 is present 1 to 5 times and each R4 is independently selected from the group consisting of -H, -OH, halogen, -CF3, Q-Ce alkenyl, Ci-Ce alkynyl, Ci-Ce heteroalkyl, C3-C7 carbocyclyl, 5-10 membered heterocyclyl, aryl, 5-10 membered heteroaryl, cyano, Ci-Ce alkoxy(Ci-C6)alkyl, aryloxy, sulfhydryl (mercapto), and -(CH2)M-Y' -(CH2)PM' ;
m and p are independently 0 to 3;
Y' is selected from the group consisting of -S-, -S(O)-, -S(0)2-, -0-, CR5R6-, and -NR.1-;
M' is selected from the group consisting of -C(0)NR.1R2; -C(0)NR1OR3; -NR.1C(0)R5; -NR1C(0)NR.2Rla; -NR.1C(0)OR3; -NR.1S(0)2R3; NR.1S(0)2NR2Rla; -C(=NR.1)R5; -C(=NR.1)NR.2Rla; -NR.1CR5(=NR.2); - NR.1C(=NR.2)NR.laR.2a; CM alky] optionally substituted with 0-2 substituents selected from the group consisting, -OR3, -N R R\ halogen, -C(0)NR1R2, and - NR.1C(0)R5; C3-10 cycloalkyl optionally substituted with 0-2 substituents selected from the group consisting of CM alkyl, -OR3, -N R R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; Cs-10 aryl optionally substituted with 0-2 substituents selected from the group consisting of C alkyl, -OR3, -NR R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; 5 to 10 membered heteroaryl optionally substituted with 0-2 substituents selected from the group consisting of CM alkyl, -OR3, -N R R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R.5; and 4 to 1.0 membered heterocyclyl optionally substituted with 0-2 substituents selected from the group consisting of CM alkyl, -OR1, -NR R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; and
each 11 is independently 0-3.
[§015] Some embodiments include a chemical complex, comprising a complex between a monosaccharide or monosaccharide derivative and a compound having the structure of formula (III) described herein. [0016] Other embodiments disclosed herein include a method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof a composition disclosed herein.
DETAILED DESCRIPTION
[0017] In some embodiments, compounds that contain a boronic acid moiety are provided that act as antimicrobial agents and/or as potentiators of antimicrobial agents. Various embodiments of these compounds include compounds having the structures of Formulas I and II as described above or pharmaceutically acceptable salts thereof.
Formula I
[0018] In some embodiments, for the compounds of Formula (I), each R4 can be independently selected from the group consisting of -H,
Figure imgf000009_0001
-OH, -0-C l-4alkyl, and halogen; and Z can be selected from the group consisting of aryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen and heteroaryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen.
[0019] Some embodiments of compounds of Formula (I) or their pharmaceutically acceptable salts have the following stereochemistry as shown in the structure of formula (la) or formula (Ia. l):
Figure imgf000009_0002
(la) (Ia.l)
[0020] In some embodiments, R in any of the preceding compounds is H,
[0021] In some embodiments, R can be -CR1R2OC(0)Ci-9alkyl or -CR1R2OC(0)OCi_9alkyl.
[0022] In some embodiments, R can be -CR!R2OC(0)Ci-jalkyl or -CR1R20C(0)0Ci-5alkyl.
[0023] In some embodiments, R in R can be H and R in R can be H or C'H ;.
[0024] In some embodiments, R4 can be selected from H, F, CI, -C'H ;, -CF3, -OCH3, and -SCH3. [0025] In some embodiments, R4 may be either ortho, para, or meta to the carboxylic acid moiety of the phenyl ring. In some embodiments, R4 in any of the preceding compounds is H,
[0026] In some embodiments, G in any of the preceding compounds is H,
[0027] In some embodiments, G can be -N R- . In some embodiments, G in any of the preceding compounds is NH2.
[0028] In some embodiments, G can be -CH2N3.
[0029] In some embodiments, G in any of the preceding compounds is -C(0)NR1R2 and R and R are each independently selected from -H and
Figure imgf000010_0001
In some such embodiments, R is CH3 and R is CH3,
[0030] In some embodiments, G is -CH2C(0)NR1R2 and R1 and R2 are each independently selected from -H and Ci-4alkyl. In some such embodiments, R is CH3 and R is CH3.
[0031] In some embodiments, G can be -CH2S(0)2 NR R\ and R1 and R are each independently selected from -H and Ci-4alkyl.
[0032] In some embodiments, R3 in any of the preceding compounds is CH3,
[0033] In some embodiments, G is -i l l: Y-Z; Y is -S-; and Z is selected from the group consisting of imidazole, N-methyl imidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine and pyrazine, azitidine, and piperdiiie. In some such embodiments, Z is N-methyltetrazole. In other embodiments, Z is thiadiazole. In other embodiments, Z is aminothiadiazole. In some embodiments, Z is azitidine.
[0034] In some embodiments, G is -CH2-Y-X and Y is -S-. In some such embodiments, X is -CH3, In other embodiments, X is -CH2CN, In other embodiments, X is -CH2N3. In other embodiments, X is— CH2F, In other embodiments, X is -CHF2, In some embodiments, X is -CF3.
[0035] In some embodiments, G can be -SR . In some embodiments, G can be
SCH3.
[0036] Some specific embodiments of the compounds described herein have the following structures:
Figure imgf000011_0001
Figure imgf000011_0002
or pharmaceutically acceptable salt thereof.
[§037] Some specific embodiments of the compounds described herein have the
Figure imgf000011_0003
pharmaceutically acceptable salts thereof.
[§§38] Some specific embodiments of the compounds described herein have the following structures:
Figure imgf000011_0004
Figure imgf000012_0001
and , or pharmaceutically acceptable salts thereof.
Formula II
[0039] Some embodiments include compounds having the structure of formula II as described above.
[0040] In some embodiments, selected from the group consisting of
Figure imgf000012_0002
Figure imgf000012_0003
[0041] Some embodiments of compounds of Formula (II) or their pharmaceutically acceptable salts have the following stereochemistry as shown in the structure of formula (Ila) or formula (Ila.1):
Figure imgf000012_0004
(Ha) ( I la. l )
- I I - [0042] Some specific embodiments of the compounds described herein have the
or
Figure imgf000013_0001
or pharmaceutically acceptable salt thereof.
[0043] Some specific embodiments of the compounds described herein can be
selected from the following structures:
Figure imgf000013_0002
or
Figure imgf000013_0003
aceutically acceptable salt thereof
[0044] Some specific embodiments of the compounds described herein can have the
structure of
Figure imgf000013_0004
H or pharmaceutically acceptable salt thereof.
[004 me embodiments, G is selected from the group consisting of
Figure imgf000013_0005
Figure imgf000013_0006
Formula III
[0046] Some boronic acid derivatives according to Formula (III) as described above have a tendency to form an oligomer such as a dimer, trimer or tetramer. In some embodiments, the formation of oligomers is prevented or the amount of oligomers in a composition is reduced by including a monosaccharide or monosaccharide derivative in a composition comprising a compound according to Formula (I), (II), or (III). Accordingly, some embodiments include a pharmaceutical composition comprising meglumine and a compound according to Formula (III) as described above.
[§§47] In some embodiments, A can be selected from the group consisting of phenyl, biphenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, indanyl, pyridyl, pyrrolyl, oxazolyl, indolyl and thienyl.
[§§48] In some embodiments of Formula (III), Rb is attached to ring A at a position that is vicinal to the point of attachment of Xa to ring A,
[0049] In some embodiments, R ' is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-6 alkyl, N'R R' , and
Figure imgf000014_0001
-CN, optionally substituted -S(0)-Ci_6 alkyl, and optionally substituted -S(0)2-Ci-6 alkyl. In some embodiments, Ra is a carboxylic acid isoster,
[§050] In some embodiments, Rb is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N'R R' , and -N(OR3)R1, optionally substituted -S-C1-6 alkyl, -C(0)NR1R2, -8(0)2 Κ¾2, CN, optionally substituted -S(0)-Ci_6 alkyl, and optionally substituted -S(0)2-Ci-6 alkyl. In some embodiments, Rb is a carboxylic acid isoster,
[§051] The compound of of Formula (Ilia):
Figure imgf000014_0002
(Ilia)
or pharmaceutically acceptable salts thereof, wherein J, L, and M are independently selected from the group consisting of CR4 and N.
[0052] In some embodiments, Rb can be -OH or optionally substituted -OCi-ealkyl, In some embodiments, R' can be -OH or optionally substituted -OCi-ealkyl, In some embodiments, Rb can be -OH, In some embodiments, Rc can be -OH, In some embodiments, Rb can be -OH and R' can be -OH, [0053] In some embodiments, K and Rc together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1-3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen (N).
[0054] The compounds of Formula (III) or their pharmaceutically acceptable salts can also have the structure of formula (Illb):
Figure imgf000015_0001
(Illb)
or pharmaceutically acceptable salts thereof, wherein J, L, and M are independently selected from the group consisting of CR4 and N.
[0055] Some embodiments of compounds of Formula (Illb) or their pharmaceutically acceptable salts have the following stereochemistry as shown in the structure of formula ( l i fe ):
Figure imgf000015_0002
or pharmaceutically acceptable salts thereof.
[0056] In some embodiments, Ra can be C(0)OR and R can be -CR5R6OC(0)Ci_9alkyl or -CR¾6OC(0)OCi_9alkyl. In some embodiments, Ra can be C(0)OH.
[0057] In some embodiments, R can be -OCH2OC(0)-C(CH3)3, -OCH2OC(0)-CH(CH3)2, or -OCH2OC(0)-(CH2)nCH3. In some embodiments, R can be -CH2OC(0)OCH(CH3)2. In some embodiments, R can be -CH2OC(0)OC(CH3)3. In some embodiments, R can be -CH2OC(0)OC(CH2)2CH3. In some embodiments, R can be -CH2OC(0)OCH(CH2C e embodiments, R can be -CH2C(0)OCH2CH3. In some
embodiments, R can be
Figure imgf000015_0003
[0058] In some embodiments, R can be selected from hydrogen, -OH, halogen, COOK, optionally substituted -0-C1-6 alkyl, N R R\ and -NCOR^R1. In some embodiments, Rd can be -OH or optionally substituted -O-Q-6 alkyl. In some embodiments, R can be -OH,
[0059] In some embodiments, I can be independently selected from the group consisting of hydrogen, optionally substituted Ci-ealkyl, optionally substituted Cs^cycloalkyl, optionally substituted Ce-ioatyl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3-10 membered heterocyclyl.
[0060] In some embodiments, R can be independently selected from the group consisting of -C(0)G, -C(0)OG, and -S(0)2G. In some embodiments, R can be independently selected from-C(0)G or -C(0)OG.
[0061 ] In some embodiments, G can be selected from the group consisting of
Figure imgf000016_0001
embodiments, G is -N H \ In some embodiments, G can be -NH-Ci-4alkyl. In some embodiments, G is -C(0)NR1R2 and R and R in G can be each independently selected from - H and Ci-4alkyl, In some embodiments, G can be -CH2C(0)NR1R2 and R1 and R in G are each independently selected from -H and Ci-4alkyl,
[0062] In some embodiments, G is -0-(CH2)n-C(0) RiR2; n in G is 0-3; and R and R in G are each independently selected from -H and Ci-4alkyl, In some embodiments, G is - 0-CH2-C(0)NH2.
[0063] In some embodiments, G is - (€¾)η-Υ-Ζ; n in G is 0-3, Y is -S-; and Z is selected from the group consisting of imidazole, N-methylimidazole, aminoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, azetidine and piperdine, each optionally substituted with one or more d- 4alkyl, N R R\ hydroxy, or halogen. In some embodiments, n in G is 0, In some embodiments, 11 in G is 1.
[0064] In some embodiments, Z can be thiadiazole optionally substituted with one or more Chalky], N R R\ hydroxy, or halogen,
[0065] In some embodiments, Z can be aminothiadiazole optionally substituted with one or more Chalky], NR R \ hydroxy, or halogen,
[0066] In some embodiments, Z can be azitidine optionally substituted with one or more Ci-4alkyl, N R R\ hydroxy, or halogen. [0067] In some embodiments, G is -(CH2)n-Y-X; n in G is 0-3; Y is -S-; and X is hydrogen or optionally d^alkyl. In some embodiments, n in G is 0, In some embodiments, n in G is 1. In some embodiments, X is -C¾, In some embodiments, X is -C¾CN. In some embodiments, X is -CH2N3. In some embodiments, X is -C¾F. In some embodiments, X is - CHFo. In some embodiments, X is -CF3.
[0068] In some embodiments, G can be -(CH2)n-Y-Z; 11 in G can be 0-3, Y can be - CH2-, -0-, -O-CH2-, -C(O)-; and Z can be selected from the group consisting of phenyl, napthal, indole, pyrrolidine, thiophene, cyclopropyl, or cyclohexyl, each optionally substituted with one or more Ci-4alkyl, N R R\ hydroxy, or halogen. In some embodiments, n in G is 1. In some is selected from
Figure imgf000017_0001
[0069] In some embodiments, G is -(CH2)n-Y-X; n in G is 0-3; Y is -O- or -CH2-; and X is Ci-4alkyl optionally substituted with one or more halogen, cyano, or azido. In some embodiments, 11 in G is 0 and Y is -0-, In some embodiments, 11 in G is 1. In some embodiments, 11 in G is 2, In some embodiments, X is optionally substituted
Figure imgf000017_0002
[0070] In some embodiments, Xa can be -CH2-, In some emboidments, Xa can be - 0-, In some emboidments, Xa can be -S-. In some emboidments, Xa can be -NH-,
[0071] In some embodiments, R8 can be H and Rh can be H,
[0072] Some specific examples of the compound of formula (III) include
Figure imgf000017_0003
Figure imgf000018_0001
18'
Figure imgf000020_0001
Figure imgf000021_0001
HO COOH
Figure imgf000022_0001
Figure imgf000023_0001
pharmaceutically acceptable salts thereof. [0073] Other specific examples of the compound of formula (III) include
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000025_0001
-24-
Figure imgf000026_0001
Figure imgf000027_0001
[§074] Some embodiments of any of the compounds described above include prodrugs (e.g., prodiug esters), metabolites, stereoisomers, hydrates, solvates, polymorphs, and pharmaceutically acceptable salts of those compounds.
[§075] Where the compounds disclosed herein have at least one chiral center, they may exist as individual enaiitiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein. Furthermore, compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms. In addition, some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
[§§76] The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically; the artisan recognizes that such structures may only represent a very small portion of a sample of such compound(s). Such compounds are considered within the scope of the structures depicted, though such resonance forms or tautomers are not represented herein. [0077] Isotopes may be present in the compounds described. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound structure a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position of the compound that a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen- 1 (protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
[§§78] In some embodiments, due to the facile exchange of boron esters, the compounds described herein may convert to or exist in equilibrium with alternate forms. Accordingly, in some embodiments, the compounds described herein may exist in combination with one or more of these forms. For example, as shown below, the compounds disclosed herein may exist in cyclic form as cyclic boronate monoesters as formula I (or II) or in acyclic form as boronic acids as formula 1.1 (or II.1 ) {Biochemistry, 2000, 39, 5312- 21), or may exist as a mixture of the TWO forms depending on the medium.
Figure imgf000028_0001
Formula I Formula 1.1
[0079] In some embodiments, the compounds descrived herein may exist in cyclic dimeric form as Formula (C) or trimeric form as Formula (D), tetramenc form as Formula (E) as shown below, or acylic dimeric, trimeric or tetrameric forms and the like. In some embodiments, X' can be NR' R in Formula C, D and E. In some embodiments, X' can be - NHC(0)-G in Formula C, D and E.
Figure imgf000028_0002
Figure imgf000029_0001
Definitions
[0080 J A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drag. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial, A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, (ed. H, Bundgaard, Elsevier, 1985), which is hereby incorporated herein by reference in its entirety,
[0081] The term "pro-drug ester" refers to derivatives of the compounds disclosed herein formed by the addition of any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-l ,3-dioxolen-4-yl)methyl group. Other examples of pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in "Pro-drugs as Novel Delivery Systems", Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); and "Bioreversible Carriers in Drug Design: Theoiy and Application", edited by E, B, Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups). Each of the above-mentioned references is herein incorporated by reference in their entirety,
[§§82] "Metabolites" of the compounds disclosed herein include active species that are produced upon introduction of the compounds into the biological milieu.
[0083] "Solvate" refers to the compound formed by the interaction of a solvent and a compound described herein, a metabolite, or salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.
[0084] The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of a compound, which are not biologically or otherwise undesirable for use in a pharmaceutical. In many cases, the compounds herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87/05297, Johnston et al, published September 1 1 , 1987 (incorporated by reference herein in its entirety),
[§085] As used herein, "Ca to Q," or "Ca-b" in which "a" and "b" are integers refer to the number of carbon atoms in the specified group. That is, the group can contain from "a" to "b", inclusive, carbon atoms. Thus, for example, a "Ci to C4 alkyl" or "C1-4 alkyl" group refers to all alkyl groups having from 1 to 4 carbons, that is, CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2-, CH3CH2CH(CH3)- and (CH3)3C-. [0086] The term "halogen" or "halo," as used herein, means any one of the radio- stable atoms of column 7 of the Periodic Table of the Elements, e.g. , fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
[0087] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds). The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as "1 to 20" refers to each integer in the given range; e.g. , "1 to 20 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 9 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds may be designated as "C alkyl" or similar designations. By way of example only, "C alkyl" indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
[0088] As used herein, "alkoxy" refers to the formula OR wherein R is an alkyl as is defined above, such as "Q.g alkoxy", including but not limited to methoxy, ethoxy, n- propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy, and the like.
[0089] As used herein, "alkylthio" refers to the formula SR wherein R is an alkyl as is defined above, such as "C1-9 alkylthio" and the like, including but not limited to methy Imercapto , ethylmercapto, n-propylmercapto, 1 -methylethylmercapto
(isopropylmercapto), n-buty Imercapto, iso-butylmercapto, sec -buty Imercapto, tert- buty Imercapto, and the like.
[0090] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. The alkenyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl" where no numerical range is designated. The alkenyl group may also be a medium size alkenyl having 2 to 9 carbon atoms. The alkenyl group could also be a lower alkenyl having 2 to 4 carbon atoms. The alkenyl group of the compounds may be designated as "C2-4 alkenyl" or similar designations. By way of example only, "C2-4 alkenyl" indicates that there are two to four carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen- l -yl, propen-2-yl, propen-3-yl, buten-l-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1 -methyl-propen- 1 -yl, 2-methyl-propen- 1 -yl, 1 -ethyl-ethen- 1 -yl, 2-methyl-propen-3-yl, buta- 1 ,3-dienyl, buta-l,2,-dienyl, and buta- 1 ,2-dien-4-yl. Typical alkenyl groups include, but are in no way limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl, and the like.
[00 11 As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing one or more triple bonds. The alkynyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl" where no numerical range is designated. The alkynyl group may also be a medium size alkynyl having 2 to 9 carbon atoms. The alkynyl group could also be a lower alkynyl having 2 to 4 carbon atoms. The alkynyl group of the compounds may be designated as "C2-4 alkynyl" or similar designations. By way of example only, "C2-4 alkynyl" indicates that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn- 1 -yl, propyn-2-yl, butyn-l-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl. Typical alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl, and the like.
[0092 J As used herein, "heteroalkyl" refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the chain backbone. The heteroalkyl group may have 1 to 20 carbon atoms although the present definition also covers the occurrence of the term "heteroalkyl" where no numerical range is designated. The heteroalkyl group may also be a medium size heteroalkyl having 1 to 9 carbon atoms. The heteroalkyl group could also be a lower heteroalkyl having 1 to 4 carbon atoms. The heteroalkyl group of the compounds may be designated as "C heteroalkyl" or similar designations. The heteroalkyl group may contain one or more heteroatoms. By way of example only, "C heteroalkyl" indicates that there are one to four carbon atoms in the heteroalkyl chain and additionally one or more heteroatoms in the backbone of the chain.
[0093] The term "aromatic" refers to a ring or ring system having a conjugated pi electron system and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups provided that the entire ring system is aromatic.
[009 1 As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) containing only carbon in the ring backbone. When the aryl is a ring system, every ring in the system is aromatic. The aryl group may have 6 to 18 carbon atoms, although the present definition also covers the occurrence of the term "aryl" where no numerical range is designated. In some embodiments, the aiyl group has 6 to 10 carbon atoms. The aryl group may be designated as "Ce-io aryl," "Ce or Cio aryl," or similar designations. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl,
[§§95] As used herein, "aryloxy" and "arylthio" refers to KO- and K S-, in which R is an aiyl as is defined above, , such as "Ce-io aryloxy" or "Ce-io arylthio" and the like, includingbut not limited to phenyloxy.
[§§96] An "aralkyl" or "arylalkyl" is an aryl group connected, as a substituent, via an alkylene group, such "C7- 14 aralkyl" and the like, including but not limited to benzyl, 2- phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., a C alkylene group).
[§097] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent atoms) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the ring backbone. When the heteroaryl is a ring system, every ring in the system is aromatic. The heteroaryl group may have 5-18 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heteroaryl" where no numerical range is designated. In some embodiments, the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members. The heteroaryl group may be designated as "5-7 membered heteroaryl," "5-10 membered heteroaryl," or similar designations. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinlinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl,
[0098] A "heteroaralkyl" or "heteroarylalkyl" is heteroaryl group connected, as a substituent, via an alkylene group. Examples include but are not limited to 2-thienylmethyl, 3- thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., a C1 -4 alkylene group).
[§§99] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone. When the carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro-connected fashion. Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic. Thus, carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls. The carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term "carbocyclyl" where no numerical range is designated. The carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms. The carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms. The carbocyclyl group may be designated as "C3-6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicycle[2,2,2]octanyl, adamantyl, and spiro[4.4]nonanyl.
[0100 J A "(carbocyclyl)alkyl" is a carbocyclyl group connected, as a substituent, via an alkylene group, such as "C4-10 (carbocyclyl)alkyl" and the like, including but not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like. In some cases, the alkylene group is a lower alkylene group.
[0101] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0102] As used herein, "cycloalkenyl" means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl,
[0103] As used herein, "heterocyclyl" means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. The heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system. The heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heterocyclyl" where no numerical range is designated. The heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members. The heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members. The heterocyclyl group may be designated as "3-6 membered heterocyclyl" or similar designations. In preferred six membered monocyclic heterocyclyls, the heteroatom(s) are selected from one up to three of O, N or S, and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1 ,3-dioxanyl, 1 ,4-dioxinyl, 1 ,4-dioxanyl, 1,3-oxathianyl, 1.4- oxathiinyl, 1 ,4-oxathianyl, 2H-l,2-oxazinyl, trioxanyl, hexahydro- 1 ,3 ,5-triazinyl, 1,3-dioxolyl,
1.3- dioxolanyl, 1,3-dithiolyl, 1 ,3-dithiolanyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinonyl, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuraiiyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydro-
1.4- thiazinyl, thiamorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl, and tetrahydroquinoline.
[0104 J A "(heterocyclyl)alkyl" is a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
[0105] As used herein, "acyl" refers to -C(=0)R, wherein R is hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein. Non-limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
[0106] An "O-carboxy" group refers to a "-OC(=0)R" group in which R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
[0107] A "C-carboxy" group refers to a "-C(=0)OR" group in which R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein. A non -limiting example includes carboxyl (i.e., -C(=0)OH),
[010 1 A "cyano" group refers to a "-CN" group.
[0109] A "cyanato" group refers to an "-OCN" group.
[0110] An "isocyanato" group refers to a "-NCO" group.
[01 1 11 A "thiocyanato" group refers to a "-SCN" group.
[01 12 | An "isothiocyanato" group refers to an "-NCS" group.
[01 13 J A "sulfmyl" group refers to an "-S(=0)R" group in which R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-ιο aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
[01 14 | A "sulfonyl" group refers to an "-SO2R" group in which R is selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-ιο aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein. [0115] An "S-sulfonamido" group refers to a "-S02NRARB" group in which RA and R.B are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0116] An "N-sulfonamido" group refers to a "-N(RA)SC>2RB" group in which RA and Rb are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0117] An "O-carbamyl" group refers to a "-OC(=0)NRARB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0118] An "N-carbamyl" group refers to an "-N(RA)OC(=0)RB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3- 7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0119] An "O-thiocarbamyl" group refers to a "-OC(=S)NRARB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3- 7 carbocyclyl, aCe-io ryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0120] An "N-thiocarbamyl" group refers to an "-N(RA)OC(=S)RB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0121] A "C-amido" group refers to a "-C(=0)NRARB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein.
[0122] An "N-amido" group refers to a "-N(RA)C(=0)RB" group in which RA and RB are each independently selected from hydrogen, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, Ce-io aryl, 5-10 membered heteroaiyl, and 5-10 membered heterocyclyl, as defined herein. [0123] An "amino" group refers to a "-NRARB" group in which RA and RB are each independently selected from hydrogen, Q-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl,
Ce-io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
[0124] An "aminoalkyl" group refers to an amino group connected via an alkylene group.
[0125] An "alkoxyalkyl" group refers to an alkoxy group connected via an alkylene group, such as a "C2-8 alkoxyalkyl" and the like.
[0126] As used herein, a substituted group is derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group. Unless otherwise indicated, when a group is deemed to be "substituted," it is meant that the group is substituted with one or more subsitutents independently selected from Ci-Ce alkyl, Ci-Ce alkenyl, Ci-Ce alkynyl, d-Ce heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, Ci-Ce alkyl, d- alkoxy, d- haloalkyl, and d-d haloalkoxy), C3-C7-carbocyclyl-Ci- Ce-alkyl (optionally substituted with halo, d-d alkyl, d-d alkoxy, d-d haloalkyl, and Q- d haloalkoxy), 5-10 membered heterocyclyl (optionally substituted with halo, d-d alkyl, d- d alkoxy, d-d haloalkyl, and d-d haloalkoxy), 5-10 membered heterocyclyl-Ci-Ce-alkyl (optionally substituted with halo, d-d alkyl, d-d alkoxy, d-d haloalkyl, and d-d haloalkoxy), aryl (optionally substituted with halo, d-d alkyl, d-Ce alkoxy, d-d haloalkyl, and d-d haloalkoxy), aryl(Ci-C6)alkyl (optionally substituted with halo, d-d alkyl, d-d alkoxy, d-d haloalkyl, and d-d haloalkoxy), 5-10 membered heteroaryl (optionally substituted with halo, d-d alkyl, d-d alkoxy, d-d haloalkyl, and Ci-Ce haloalkoxy), 5-10 membered heteroaryl(Ci-C6)alkyl (optionally substituted with halo, Ci-Ce alkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, and Ci-Ce haloalkoxy), halo, cyano, hydroxy, Ci-Ce alkoxy, Ci-Ce alkoxy (C 1- Ce)alkyl (i.e., ether), aryloxy, sulfhydryl (mercapto), halo(Ci-C6)alkyl (e.g., -CF3), halo(Ci- Ce)alkoxy (e.g., -OCF3), Ci-Ce alkylthio, arylthio, amino, amino(Ci-C6)alkyl, nitro, ( )- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N- sulfonamido, C-carboxy, O-carboxy, acyl, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, and oxo (=0). Wherever a group is described as "optionally substituted" that group can be substituted with the above substituents.
[0127] In some embodiments, substituted group(s) is (are) substituted with one or more substituent(s) individually and independently selected from C1-C4 alkyl, amino, hydroxy, and halogen,
[0128] It is to be understood that certain radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical. For example, a substituent identified as alkyl that requires two points of attachment includes di-radicals such as -CH2- -CH2CH2- -CH2CH(CH3)CH2-, and the like. Other radical naming conventions clearly indicate that the radical is a di-radical such as "alkylene" or "alkenylene."
[0129] As used herein, "alkylene" means a branched, or straight chain fully saturated di-radical chemical group containing only carbon and hydrogenthat is attached to the rest of the molecule via two points of attachment (i.e., an alkanediyl). The alkylene group may have 1 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkylene where no numerical range is designated. The alkylene group may also be a medium size alkylene having 1 to 9 carbon atoms. The alkylene group could also be a lowrer alkylene having 1 to 4 carbon atoms. The alkylene group may be designated as "C alkylene" or similar designations. By wray of example only, "C alkylene" indicates that there are one to four carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of methylene, ethylene, ethan-l , l-diyl, propylene, propan-l , l-diyl, propan-2,2-diyl, 1-methyl- ethylene, butylene, butan-l , l-diyl, butan-2,2-diyl, 2-methyl-propan- 1 , 1 -diyl, 1 -methyl - propylene, 2-methyl-propylene, 1 , 1 -dimethyl-ethylene, 1 ,2-dimethyl-ethylene, and 1-ethyl- ethylene.
[0130] As used herein, "alkenylene" means a straight or branched chain di-radical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond that is attached to the rest of the molecule via two points of attachment. The alkenylene group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term alkenylene wrhere no numerical range is designated. The alkenylene group may also be a medium size alkenylene having 2 to 9 carbon atoms. The alkenylene group could also be a lowrer alkenylene having 2 to 4 carbon atoms. The alkenylene group may be designated as "C2-4 alkenylene" or similar designations. By wray of example only, "C2-4 alkenylene" indicates that there are two to four carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of ethenylene, ethen- 1 , 1 -diyl, propenylene, propen- 1 , 1 -diyl, prop-2-en- 1 ,1 -diyl, 1-methyl-ethenylene, but-l-enylene, but-2- enylene, but-l ,3-dienylene, buten- 1 , 1 -diyl, but- 1 ,3-dien- 1 , 1 -diyl, but-2-en- 1 , 1 -diyl, but-3-en- 1 ,1 -diyl, 1 -methyl -prop-2-en- 1, 1 -diyl, 2-methyl-prop-2-en- 1 ,1 -diyl, 1-ethyl-ethenylene, 1 ,2- dimethyl-ethenylene, 1 -methyl-propenylene, 2-methyl-propenylene, 3-methyl-propenylene, 2- methyl -propen- 1 , 1 -diyl, and 2 ,2-dimethyl-ethen- 1 , 1 -diyl. [0131] The term "agent" or "test agent" includes any substance, molecule, element, compound, entity, or a combination thereof. It includes, but is not limited to, e.g., protein, polypeptide, peptide or mimetic, small organic molecule, polysaccharide, polynucleotide, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms "agent", "substance", and "compound" are used interchangeably herein,
[0132] The term "analog" is used herein to refer to a molecule that structurally resembles a reference molecule but which has been modified in a targeted and controlled manner, by replacing a specific substituent of the reference molecule with an alternate substituent. Compared to the reference molecule, an analog would be expected, by one skilled in the art, to exhibit the same, similar, or improved utility. Synthesis and screening of analogs, to identify variants of known compounds having improved characteristics (such as higher binding affinity for a target molecule) is an approach that is well known in pharmaceutical chemistry,
[0133] The term "mammal" is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, , sheep, goats, swine, rabbits, dogs, cats, rats and mice but also includes many other species.
[0134] The term "microbial infection" refers to the invasion of the host organism, whether the organism is a vertebrate, invertebrate, fish, plant, bird, or mammal, by pathogenic microbes. This includes the excessive growth of microbes that are normally present in or on the body of a mammal or other organism. More generally, a microbial infection can be any situation in which the presence of a microbial population(s) is damaging to a host mammal. Thus, a mammal is "suffering" from a microbial infection when excessive numbers of a microbial population are present in or on a mammal's body, or when the effects of the presence of a microbial population(s) is damaging the cells or other tissue of a mammal. Specifically, this description applies to a bacterial infection. Note that the compounds of preferred embodiments are also useful in treating microbial growth or contamination of cell cultures or other media, or inanimate surfaces or objects, and nothing herein should limit the preferred embodiments only to treatment of higher organisms, except when explicitly so specified in the claims.
[0135] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. In addition, various adjuvants such as are commonly used in the art may be included. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Oilman et al, (Eds.) (1990); Goodman and Oilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, which is incorporated herein by reference in its entirety. The pharmaceutically acceptable excipient can be a monosaccharide or monosaccharide derivative.
[0136] "Subject" as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
[0137] An "effective amount" or a "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent that is effective to relieve, to some extent, or to reduce the likelihood of onset of, one or more of the symptoms of a disease or condition, and includes curing a disease or condition. "Curing" means that the symptoms of a disease or condition are eliminated; however, certain long-term or permanent effects may exist even after a cure is obtained (such as extensive tissue damage).
[0138] "Treat," "treatment," or "treating," as used herein refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The term "prophylactic treatment" refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition. The term "therapeutic treatment" refers to administering treatment to a subject already suffering from a disease or condition,
[0139] "Monosaccharide" as used herein refers to a chemical compound of general formula Cx(H20)x, where x is 3 to 10, Examples of monosaccharide include but are not limited to glucose (dextrose), arabinose, maiinitol, fructose (levulose) and galactose. "Monosaccharide derivative" as used herein refers to a monosaccharide wherein one or more -OH groups can be replaced by the substituents described above in the definition of "substituted." In some monosaccharide derivatives, one or more -OH groups on the monosaccharide can be replaced by one or more -NH2 or -NH-CH3 groups. One example of a monosaccharide derivative includes meglumine. Other examples of a monosaccharide derivative can include an amino alcohol.
[0140] As used herein, "isosteres" are different compounds that have different molecular formulas but exhibit the same or similar properties. For example, tetrazole is an isostere of carboxylic acid because it mimics the properties of carboxylic acid even though they both have very different molecular formulae. Tetrazole is one of many possible isosteric replacements for carboxylic acid. Other carboxylic acid isosteres contemplated include -COOH, -SO3H, -SO2HNR9, -P02(R9)2, -P03(R9)2, -CONHNHSO2R9, -COHNSO2R9, and -CONR9CN. In addition, carboxylic acid isosteres can include 5-7 membered carbocycles or heterocycles containing any combination of C¾, O, S, or N in any chemically stable oxidation state, where any of the atoms of said ring structure are optionally substituted in one or more positions. The following structures are non-limiting examples of carbocyclic and heterocyclic isosteres contemplated. The atoms of said ring structure may be optionally substituted at one or more positions with R9.
Figure imgf000041_0001
[0141] It is also contemplated that when chemical substituents are added to a carboxylic isostere, the compound retains the properties of a carboxylic isostere. It is contemplated that when a carboxylic isostere is optionally substituted with one or more moieties selected from R9, then the substitution cannot eliminate the carboxylic acid isosteric properties of the compound. It is also contemplated that the placement of one or more R9 substituents upon a carbocyclic or heterocyclic carboxylic acid isostere shall not be peniiitted at one or more atom(s) which maintain(s) or is/are integral to the carboxylic acid isosteric properties of the compound, if such substituent(s) would destroy the carboxylic acid isosteric properties of the compound. Other carboxylic acid isosteres not specifically exemplified or described in this specification are also contemplated.
Methods of Preparation
[0142] The compounds disclosed herein may be synthesized by methods described below, or by modification of these methods. Ways of modifying the methodology include, among others, temperature, solvent, reagents etc., known to those skilled in the art. In general, during any of the processes for preparation of the compounds disclosed herein, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum Press, 1973); and P.G.M. Green, T.W. Wutts, Protecting Groups in Organic Synthesis (3rd ed.) Wiley, New York (1999), which are both hereby incorporated herein by reference in their entirety. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. Synthetic chemistry transformations useful in synthesizing applicable compounds are known in the art and include e.g. those described in K. Larock, Comprehensive Organic Transformations, VCH Publishers, 1989, or L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons, 1995, which are both hereby incorporated herein by reference in their entirety. The routes shown and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise alternate routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims.
[§143] In the following schemes, protecting groups for oxygen atoms are selected for their compatibility with the requisite synthetic steps as well as compatibility of the introduction and deprotection steps with the overall synthetic schemes (P.G.M, Green, T.W. Wutts, Protecting Groups in Organic Synthesis (3rd ed.) Wiley, New York (1999)). Handling of protecting and/or sterodirectiiig groups specific to boronic acid derivatives is described in a recent review of chemistry of boronic acids: D.G. Hall (Ed.), Boronic Acids. Preparation and Application in Organic Synthesis and Medicine, Wiley VCH (2005) and in earlier reviews: Mattesoii, D, S. (1988), Asymmetric synthesis with boronic esters. Accounts of Chemical Research, 21(8), 294-300, and Mattesoii, D. S. (1989). Tetrahedron, 45(7), 1859-1885), all of which are incorporated herein by reference in their entirety. The latter review articles also describe methodology for stereoselective insertion of halomethine functionality next to the boronate which is employed in the synthetic schemes below.
[§144] In addition to standard acid catalyzed deprotection, special methods for removal of boronic acid protecting and/or sterodirectiiig groups methods using fluorides (Yuen, A. K. L., & Button, C. A. (2005). Tetrahedron Letters, 46(46), 7899-7903 - incorporated herein by reference in its entirety) or periodate oxidation (Courts, S. J., et al, (1994), Tetrahedron Letters, 35(29), 5109-51 12 - incorporated herein by reference in its entirety) can also be employed in preparations of the compounds disclosed herein. [0145] In strategies employing pinanediol or other diol-based chiral auxiliaries for stereospecific introduction of new chiral centers, the early stages of chemistry on boronic intermediates can be performed on chiral boronate esters or alternatively nonchiral borate/boronate intermediates can be used in early stages followed by transesterifi cation with chiral diols prior to the step where stereoselection is required.
Synthesis of Compounds of Formula I
[0146] Compounds of formula I (for example, compounds of formula la) where R is H can be prepared as depicted in scheme 1 from intermediates of formula Ia-2, which may be assembled by several known a-aminoboronate formation reactions (Boronic Acids: Preparations and Applications in Organic Synthesis, Medicine and Materials, D, G. Hall, ed., Wiley-VCH, Weinheim, 2011, which is incorporated herein by reference in its entirety),
Scheme 1
Figure imgf000043_0001
[0147] Such intermediates of formula Ia-2 where X = -N(TMS)2 and R' and R" are alkyl groups may be prepared by earlier described methods (PCX Publication Nos. WO09064414 and WO10130708, which are incorporated herein by reference in their entirety). In an alternate sequence, compounds of formula Ia-2, where X = -N(TMS)2 and R" is Boc and R' is t-Butyl or R' and R" are protected together as isopropylideiie or any other groups protected separately or together in cyclic form, may be made from compounds of formula Ia-3 via homologation to give chloromethylene addition product with good stereocontrol by Matteson reaction conditions, followed by stereospecific substitution with hexamethyldisilazane (PCX Publication No. WO0946098, which is incorporated herein by reference in its entirety), Bromo precursors may be made analogously to the chloro compounds utilizing dibromomethane (J.
Am, Chem. Soc. 1990, 1 12, 3964-969, which is incorporated herein by reference in its entirety), Matteson reaction precursors of formula Ia-3 may be made by palladium mediated coupling of pinanediol diboronate from corresponding appropriately protected benzyl alcohols (J. Am, Chem, Soc. 2011, 133, 409-41 1 , which is incorporated herein by reference in its entirety) or benzyl bromides Ia-4 (Xetrahedron Letters 2003, 44, 233-235; J. Am. Chem. Soc, 2010, 132, 1 1825-1 1827, which is incorporated herein by reference in its entirety). Compounds of formula Ia-3 may also be prepared by homologation of the corresponding arylboronate ester by reaction with chloromethyl anion (PCX Publication No. WO09064414, which is incorporated herein by reference in its entirety). The compounds of formula Ia-4 may be achieved by means of several earlier known methods (PCX Publication No. WO0458679, which is incorporated herein by reference in its entirety) with conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum, 1973); and Protecting Groups in Organic Synthesis, P.G.M. Wutts, T.W. Green, Wiley, New York, 1999) (both incorporated herein by reference in their entirety) from commercially available salicylic acid derivatives. Compounds of formula Ia-4 where Y is methyl can be readily transformed to corresponding benzyl bromides (Bioorg, Med. Chem. Lett, 1999, 9, 34-346, which is incorporated herein by reference in its entirety) for boronation reaction to give Ia-3.
[0148] Bi s-trimethyl silylamides of formula Ia-2 may be reacted in situ with an acid chloride to result directly in analogs of formula Ia-1, Such analogs of f - 1 can also be made via coupling of the bis-TMS amine with commercially available carboxylic acids under typical amide coupling conditions (e.g., carbodiimide or HATU coupling) (Tetrahedron, 2005, 61 , 10827- 10852, which is incorporated herein by reference in its entirety). Varieties of substituted thioacetic acid or glycolate or glycinate precursors are commercially available. Such precursors may be also obtained by several well-known methods in the literature (J. Org, Chem, (2012), DOI: 10, 1021/jo302088t, which is incorporated herein by reference in its entirety),
[0149] Simultaneous deprotection of pinaiie ester and salicylic acid protective groups of compounds of formula Ia-1 can be achieved by heating with dilute HC1, affording the desired compounds of formula la. This transfoniiation may also be achieved by treatment with BCI3 or ΒΒΓ3 (PCT Publication No. WO09064414, which is incorporated herein by reference in its entirety). Alternatively, the deprotection may be attained via trans-esterification with isobutyl boronic acid in presence of dilute acid (PCT Publication No. WO09064413, which is incorporated herein by reference in its entirety) or via other known methods (J. Org. Chem. ( 20 1 0). 75, 468-471 , which is incorporated herein by reference in its entirety),
[§150] In an alternate approach, compounds of formula Ia-2 where X is M KHCl can be made via asymmetric addition of boron to a carbon heteroatom double bond, enabling production of enantiomerically pure N-sulfinyl-a-amino boronate ester derivatives. Such transformation is achieved form appropriately protected N-sulfinyl inline (Ia-5) using a Cu/ligand catalyst system (J. Am. Chem. Soc. (2008), 130, 6910-691 1 , which is incorporated herein by reference in its entirety) followed by treatment with mild acid. Enantiomerically pure N-sulfinyl imines of foniiula Ia-5 may be made by condensation of appropriately protected phenylacetaldehyde intermediates (Ia-6) and enantiomerically pure t-butylsulfonylamine (Chem. Rev. 2010, 110, 3600-3740, which is incorporated herein by reference in its entirety),
[0151] Phenylacetaldehyde derivatives of formula Ia-6 can be made from Claisen rearrangement of allyl ethers of commercially available salicylates followed by oxidative cleavage of the allyl group (J. Med. Chem. 1995, 38, 3094-3105, which is incorporated herein by reference in its entirety). Such intermediates of formula Ia-6 can also be made by Wacker oxidation of vinyl substituted salicylates (Org. Lett. 2012, 14, 3237-3239, which is incorporated herein by reference in its entirety). Protective groups may be used separately for phenol and acid or together from a variety of available options as described above.
[0152] One exemplary but non-limiting general synthetic scheme for preparing compound of Formula la is shown below in Scheme la. For the starting compound of Foniiula 1- 1 , Y can be -OH, halogen, -CMO alkyl, -CMO alkyl-OH, -CMO alkyl-halogen, R1A can be hydrogen or CMO alkyl, and R2A can be hydrogen or C MO alkyl. The compound of Foniiula 1-1 can be treated first with TFA and TFAA and then with Bis(pinacolato)diboron to form a pinacol boronic ester compound of Foniiula 1-3. The compound of Formula 1-3 is then reacted with pinaiiediol to yield a Pinanediol Methylboronic Ester Compound of Formula 1-4, The compound of Formula 1-4 undergoes homologation to yield a compound of Foniiula 1-5, which then undergoes another homologation reaction to provide a chloroethlene product of Foniiula 1-6. The compound of Foniiula 1-6 reacts with the bis-TMS amine to form a bis-triiiiethyl silyamine of Formula 1-7. Different types of thioacetic acid, glycolate or glycinate precursors can then react with the compound of Foniiula 1-7 to form an amide of Formula 1-8. The compound of Foniiula 1-8 then undergoes the deprotection of the pinane ester and salicylic acid protective groups to afford the compound of Formula la. Scheme la
Figure imgf000046_0001
la
[§153] Alternatively, compounds of Formula la can also be prepared by using the general synthetic Scheme lb illustrated below. The starting compound of Formula 1-2 can be prepared by adding protective groups to a salicylate derivative compound following procedures described above in Scheme la. The compound of Formula 1-2 can be treated with vinyl trifluoroborate to form a vinyl phenyl compound of Formula 1-9. The compound of Formula 1-9 then undergoes reaction to form a phneylacetaldehyde derivative of Formula 1- 10. The compound of Formula I- 10 then reacts with (R)-t-butylsulfmic amide to provide a N-sulfinyl imine compound of Formula 1- 1 1. The compound of Formula 1-11 undergoes boron addition to form a pinacol boronic ester compound of Formula 1-12, The compound of Formula 1-12 can react with the acid to remove the t-butylsulfinic group. Different types of thioacetic acid, glycolate or glycinate precursors can then react with the compound of Formula 1-13 to form an amide of Formula 1-14, The amide of Formula 1-14 can react with pinanediol to yield a Pinanediol Methylboronic Ester Compound of Formula 1-8. The compound of Formula 1-8 can then undergo the deprotection of the pinane ester and salicylic acid protective groups to afford the compound of Formula la. Scheme lb
Figure imgf000047_0001
Synthesis of Prodrugs
[§154] Compounds of Formula I where the K is a prodrug moiety may be synthesized by a variety of known methods of different carboxylic acid prodrugs (Prodrugs: Challenges and Rewards, V. J. Stella, et al,, ed., Springer, New York, 2007, which is incorporated herein by reference in its entirety). These prodrugs include but are not limited to substituted or non-substituted alkyl esters, (acyloxy)alkyl esters (Synthesis 2012, 44, 207, which is incorporated herein by reference in its entirety), [(alkoxycarbonyl)oxy]methyl esters (PCT Publication No. WO 10097675, which is incorporated herein by reference in its entirety), or (oxodioxolyl)methyl esters (J. Med. Chem. 1996, 39, 323-338, which is incorporated herein by reference in its entirety). Such prodrugs can be made from compounds of Formula I where K = H by treatment with acid or in neutral conditions (e.g., carbodiimide coupling) in the presence of alcohols (ROH) or via base promoted esterifi cation with RX where X is a leaving group in the presence of an appropriate base.
[§155] One exemplary but non-limiting general synthetic scheme for preparing the prodrug is shown in Scheme 2a below. The boronic acid of Formula la where R is hydrogen can react with a chloro/bromo-substituted prodrug moiety to form a prodrug of Formula lb. Examples of the prodrug moiety RIb can be
Figure imgf000048_0001
-CR1R2OC(0)Ci-9alkyl, -
CR1R2OC(0)OCi_9alkyl, and
Figure imgf000048_0002
Scheme 2a
Figure imgf000048_0003
[§156] Alternatively, compounds of Formula I may be also utilized for introduction of prodrugs (Scheme 2b). Such carboxylic acids (VIII) can be made from compounds of Formula la- 1 by selective deprotection of OR'. The prodrug group may also be introduced earlier in the sequence in compounds of Formula Ia-4 or Ia-6 where R' is R. Such a sequence where the prodrug is introduced in earlier intermediates is only feasible when the ester is stable under the final deprotection conditions to remove the phenol protective group and the boronate ester.
Scheme 2b
Figure imgf000048_0004
VIII ormu a a
Administration and Pharmaceutical Compositions
[0157] The compounds are administered at a therapeutically effective dosage. While human dosage levels have yet to be optimized for the compounds described herein, generally, a daily dose may be from about 0,25 mg/kg to about 120 mg/kg or more of body weight, from about 0.5 mg/kg or less to about 70 mg/kg, from about 1.0 mg/kg to about 50 mg/kg of body weight, or from about 1.5 mg/kg to about 10 mg/kg of body weight. Thus, for administration to a 70 kg person, the dosage range would be from about 17 mg per day to about 8000 mg per day, from about 35 mg per day or less to about 7000 mg per day or more, from about 70 mg per day to about 6000 mg per day, from about 100 mg per day to about 5000 mg per day, or from about 200 mg to about 3000 mg per day. The amount of active compound administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician,
[§158] Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, or intraocularly. Oral and parenteral administrations are customary in treating the indications that are the subject of the preferred embodiments.
[§159] The compounds useful as described above can be formulated into pharmaceutical compositions for use in treatment of these conditions. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Ed., Lippiiicott Williams & Wilkins (2005), incorporated by reference in its entirety. Accordingly, some embodiments include pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of a compound described herein (including enaiitiomers, diastereoisomers, tautomers, polymorphs, and solvates thereof), or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
[§160] In addition to the selected compound useful as described above, come embodiments include compositions containing a pharmaceutically-acceptable carrier. The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. In addition, various adjuvants such as are commonly used in the art may be included. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Oilman et al, (Eds.) (1990); Goodman and Oilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, which is incorporated herein by reference in its entirety,
[§161] Some examples of substances, which can serve as pharmaceutically- acceptable carriers or components thereof, are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, com oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the TWEENS; wetting agents, such sodium lauiyl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.
[0162] The choice of a pharmaceutically-acceptable earner to be used in conjunction with the subject compound is basically determined by the way the compound is to be administered.
[0163] The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition containing an amount of a compound that is suitable for administration to an animal, preferably mammal subject, in a single dose, according to good medical practice. The preparation of a single or unit dosage form however, does not imply that the dosage form is administered once per day or once per course of therapy. Such dosage forms are contemplated to be administered once, twice, thrice or more per day and may be administered as infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours), or administered as a continuous infusion, and may be given more than once during a course of therapy, though a single administration is not specifically excluded. The skilled artisan will recognize that the formulation does not specifically contemplate the entire course of therapy and such decisions are left for those skilled in the art of treatment rather than formulation,
[0164] The compositions useful as described above may be in any of a variety of suitable forms for a variety of routes for administration, for example, for oral, nasal, rectal, topical (including transdermal), ocular, intracerebral, intracranial, intrathecal, intra-arterial, intravenous, intramuscular, or other parental routes of administration. The skilled artisan will appreciate that oral and nasal compositions comprise compositions that are administered by inhalation, and made using available methodologies. Depending upon the particular route of administration desired, a variety of pharmaceutically-acceptable carriers well-known in the art may be used. Pharmaceutically-acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropies, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with the inhibitory activity of the compound. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods described herein are described in the following references, all incorporated by reference herein: Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (Banker & Rhodes, editors, 2002); Lieberman et ah, Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms 8th Edition (2004),
[§165] Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet triturates, enteric- coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.
[§166] The pharmaceutically-acceptable carrier suitable for the preparation of unit dosage forms for peroral administration is well-known in the art. Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, pepperm int, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically comprise one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations like taste, cost, and shelf stability, which are not critical, and can be readily made by a person skilled in the art,
[§167] Peroral compositions also include liquid solutions, emulsions, suspensions, and the like. The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. For a suspension, typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RC-591 , tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants disclosed above. [0168] Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
[0169] Compositions described herein may optionally include other drug actives.
[0170] Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
[0171 J A liquid composition, which is formulated for topical ophthalmic use, is formulated such that it can be administered topically to the eye. The comfort should be maximized as much as possible, although sometimes formulation considerations (e.g. drug stability) may necessitate less than optimal comfort. In the case that comfort cannot be maximized, the liquid should be formulated such that the liquid is tolerable to the patient for topical ophthalmic use. Additionally, an ophthalmically acceptable liquid should either be packaged for single use, or contain a preservative to prevent contamination over multiple uses.
[0172] For ophthalmic application, solutions or medicaments are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions should preferably be maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
[0173] Preservatives that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric, acetate and phenylmer curie nitrate. A useful surfactant is, for example, Tween 80. Likewise, various useful vehicles may be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol , povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.
[ 174 J Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor. [0175] Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. For many compositions, the pH will be between 4 and 9. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
[0176] In a similar vein, an ophthalmically acceptable antioxidant includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
[0177] Other excipient components, which may be included in the ophthalmic preparations, are chelating agents. A useful chelating agent is edetate disodium, although other chelating agents may also be used in place or in conjunction with it,
[0178] For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound disclosed herein are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, co-solvent, emulsifier, penetration enhancer, preservative system, and emollient,
[0179] For intravenous administration, the compounds and compositions described herein may be dissolved or dispersed in a pharmaceutically acceptable diluent, such as a saline or dextrose solution. Suitable excipients may be included to achieve the desired pH, including but not limited to NaOH, sodium carbonate, sodium acetate, HC1, and citric acid. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably from 4 to 7. Antioxidant excipients may include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA, Other non-limiting examples of suitable excipients found in the final intravenous composition may include sodium or potassium phosphates, citric acid, tartaric acid, gelatin, and carbohydrates such as dextrose, mannitol, and dextran. Further acceptable excipients are described in Powell, et al, Compendium of Excipients for Parenteral Formulations, PDA J P harm Sci and Tech 1998, 52 238-311 and Nema et al,, Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, PDA J P harm Sci and Tech 2011, 65 287-332, both of which are incorporated herein by reference in their entirety. Antimicrobial agents may also be included to achieve a bacteriostatic or fungistatic solution, including but not limited to phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.
[0180] The compositions for intravenous administration may be provided to caregivers in the form of one more solids that are reconstituted with a suitable diluent such as sterile water, saline or dextrose in water shortly prior to administration. In other embodiments, the compositions are provided in solution ready to administer parenterally. In still other embodiments, the compositions are provided in a solution that is further diluted prior to administration. In embodiments that include administering a combination of a compound described herein and another agent, the combination may be provided to caregivers as a mixture, or the caregivers may mix the two agents prior to administration, or the TWO agents may be administered separately.
[0181] The actual dose of the active compounds described herein depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan,
[0182] Some boronic acid derivatives described herein can form an oligomer such as a dimer, t rimer or tetramer. To prevent the boronic acid derivatives from forming such oligomers, some embodiments include pharmaceutical composition in which an excipient is included that prevents or limits the formation of oligomers. The excipient can be a monosaccharide or monosaccharide derivative. In one embodiment, the monosaccharide or monosaccharide derivative is meglumine. Other excipients include but are not limited to ethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane (Tris), L-lysine, and Pyridine- 2-methanol.
[0183 J Some embodiments described herein relate to a chemical complex formed between the monosaccharide or monosaccharide derivative and the compound of Formula (III) described herein. In some embodiments, the interaction between the two components help increase the stability and/or solubility of the compound of Formula (III).
[0184] More generally, in some embodiments the monosaccharide or monosaccharide derivative can form a chemical complex with any compound containing a boronate moiety . In some embodiments, the compound containing a boronate moiety can be a boronic acid derivative described herein such as a compound of Formula (III) described herein. In other embodiments, the compound containing a boronate moiety can be any other boronate containing compounds, for example, known boron ate-contain ing pharmaceutical agents. In some other embodiments, the monosaccharide or monosaccharide derivative used in forming the stable complex can be meglumine.
[0185] In some embodiments, of the inclusion of meglumine in a pharmaceutical composition prevents or reduces the formation of oligomers at a pH range desirable for pharmaceutical administration. In some embodiments, the pH of the composition can be in the range of about 5 to about 9, about 6 to 8, about 6 to about 7.5, about 7.1 to about 7.3, or about 7.1 to about 7.2. In some embodiments, the pH of the composition can be in the range of about 7.0-7.3. In some embodiments, the pH of the composition can be about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1 , 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, and 7.8. In some embodiments, the pH of the composition can be about 7.1. In some embodiments, the pH of the composition can be about 7.2,
[§186] The amount of the boronic acid derivatives that are present in a monomer form can vary depending on the pH of the solution, the oligomer-preventing excipient included, and the amount of the excipient in the composition. In some embodiments, the percentage of the monomer form can be more than 85%, more than 88%, more than 90%, more than 92%, more than 95%, more than 97% by weight, based on the total amount of the boronic acid derivative in the composition. In some embodiments, the percentage of the monomer form can be more than 96% by weight based on the total amount of the boronic acid derivative in the composition. In some embodiments, the percentage of the monomer form can be more than 97% by weight based on the total amount of the boronic acid derivative in the composition.
Methods of Treatment
[§187] Some embodiments of the present invention include methods of treating bacterial infections with the compounds and compositions comprising the compounds described herein. Some methods include administering a compound, composition, pharmaceutical composition described herein to a subject in need thereof. In some embodiments, a subject can be an animal, e.g., a mammal (including a human). In some embodiments, the bacterial infection comprises a bacteria described herein. As will be appreciated from the foregoing, methods of treating a bacterial infection include methods for preventing bacterial infection in a subject at risk thereof.
[0188] In some embodiments, the subject is a human,
[§189] Further embodiments include administering a combination of compounds to a subject in need thereof. A combination can include a compound, composition, pharmaceutical composition described herein with an additional medicament,
[0190] Some embodiments include co-administering a compound, composition, and/or pharmaceutical composition described herein, with an additional medicament. By "coadministration," it is meant that the two or more agents may be found in the patient's bloodstream at the same time, regardless of when or how they are actually administered. In one embodiment, the agents are administered simultaneously. In one such embodiment, administration in combination is accomplished by combining the agents in a single dosage form. In another embodiment, the agents are administered sequentially. In one embodiment the agents are administered through the same route, such as orally. In another embodiment, the agents are administered through different routes, such as one being administered orally and another being administered i.v. [0191] Examples of additional medicaments include an antibacterial agent, antifungal agent, an antiviral agent, an anti-inflammatory agent and an anti-allergic agent,
[0192] Preferred embodiments include combinations of a compound, composition or pharmaceutical composition described herein with an antibacterial agent such as a β-lactam. Examples of such β-lactams include Amoxicillin, Ampicillin (e.g., Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicillin (G), Clometocilliii, Benzathine benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Plienoxymethylpenicillin (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (e.g., Dicloxacillin, Flucloxacilliii), Oxacillin, Methicillin, Nafcillin, Faropeiiem, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforani.de, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftazidime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, Ceftiofur, Cefquinome, Cefovecin, Aztreonam, Tigemonam and Carumonam, CXA-101, R.WJ-54428, MC-04,546, ME 1036, R.WJ-442831, R.WJ-333441 , or R.WJ-333442.
[0193] Preferred embodiments include β-lactams such as Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem and Panipenem,
[0194] Additional preferred embodiments include β -lactams such as Aztreonam, Tigemonam, BAL30072, SYN 241.6 and Carumonam.
[0195] Additional Examples of such β -lactams include penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof, wherein the penicillin is benzathine penicillin, benzylpenicillin, phenoxymethylpenicillin, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacilliii, temocillin, amoxicillin, ampicillin, co- amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacilliii, talapicilliii, aspoxicilliii, cloxacillin, nafcillin, pivampicillin, or a combination thereof. [0196] In some embodiments, the cephalosporin can be cephalothin, cephaloridin, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetfil, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefinenoxime, cefinetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpirami.de, cef uperazone, cefozopran, cefepim, cefoselis, cefluprenam, cefuzonam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil, cefditoren pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, latamoxef, or a combination thereof
[0197] In some embodiments, the cephalosporin can be an anti-MRSA cephalosporin,
[0198] In some embodiments, the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
[0199] In some embodiments, the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, panipenem, or a combination thereof.
[0200] In some embodiments, the carbapenem is an anti-MRSA carbapenem,
[0201] In some embodiments, the anti-MRSA carbapenem is PZ601 or ME 1036.
[0202] Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises a monobactam. Examples of monobactams include aztreonam, tigemonam, nocardicin A, carumonam, and tabtoxin. In some such embodiments, the compound, composition and/or pharmaceutical composition comprises a class A, C, or D beta- lactamase inhibitor. Some embodiments include co-administering the compound, composition or pharmaceutical composition described herein with one or more additional agents.
[0203] Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises a class B beta lactamase inhibitor. An example of a class B beta lactamase inhibitor includes ME 1071 (Yoshikazu Ishii et al, "In Vitro Potentiation of Carbapenems with ME1071 , a Novel Metallo-B-Lactamase Inhibitor, against Metallo-B- lactamase Producing Pseudomonas aeruginosa Clinical Isolates." Antimicrob. Agents Chemother, doi: 10.1128/AAC.01397-09 (July 2010)). Some embodiments include coadministering the compound, composition or pharmaceutical composition described herein with one or more additional agents.
[0204] Some embodiments include a combination of the compounds, compositions and/or pharmaceutical compositions described herein with an additional agent, wherein the additional agent comprises one or more agents that include a class A, B, C, or D beta lactamase inhibitor. Some embodiments include co-administering the compound, composition or pharmaceutical composition described herein with the one or more additional agents.
Indications
[0205] The compounds and compositions comprising the compounds described herein can be used to treat bacterial infections. Bacterial infections that can be treated with the compounds, compositions and methods described herein can comprise a wide spectrum of bacteria. Example organisms include gram-positive bacteria, gram-negative bacteria, aerobic and anaerobic bacteria, such as Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus, Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella and other organisms.
[0206] More examples of bacterial infections include Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenoirophomonas maltophilia, Burkholderia cepacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchisepiica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemofytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Kingella, Moraxella, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellular e, Mycobacterium leprae, Coryne bacterium diphtheriae, Coryne bacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.
[0207] The following examples will further describe the present invention, and are used for the purposes of illustration only, and should not be considered as limiting,
EXAMPLES
Example V. (R)-2-hvdroxv-3-(2-(trifluoromethvlthio)acetamido>-3,4-dihydro-2H- benzo[el[l ,21oxaborinine-8-carboxylic acid (1)
Scheme 3:
Figure imgf000059_0001
Step 1 : Synthesis of compound IB
[0208] To the mixture of TFAA (225 mL) and TFA (370 mL) was added compound 1A (45 g, 292 mmol) slowly at -10 °C, followed by the addition of acetone (60 g, 1.03 mmol) in TFA(77 mL) over 1 h. After being stirred at -4 °C for 3 h, the solution was warmed up to room temperature and stirred for 2 days before it was concentrated in vacuo to dryness. The residue was dissolved in EtOAc, washed with NaHCO solution, dried over Na2SC>4. Column chromatography (hexanes/ethyl acetate/DCM, v/v/v, 20/1/20) gave the titled compound IB (28 g, 49.4% yield) as slightly yellow oil. Step 2: Synthesis of compound 1C
[§209] To the solution of compound IB (28 g, 144,2 mmol) and triethylamine (73 g,
721 mmol) in dichloromethane (300 iiiL) at -78 °C was added Tf»0 (81.3 g, 288.4 mmol, 2 eq). The resulting mixture was warmed up to 0 °C slowly and stirred at 0 °C for 1 hour before it was quenched with water. The mixture was extracted with DCM and dried over Na2S04. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/40) to give the titled compound 1C (44 g, 93.6%) as a slightly yellow oil.
Step 3: Synthesis of compound ID
[0210] The mixture of compound 1C (21 g, 64,4 mmol), bis(pinacolato)diboron (21.3 g, 83.7 mmol), KOAc (18.9 g, 193 mmol) and PdCl2(dppf) (2.6 g, 3.22 mmol) in dioxane (200 niL) was degassed for three times and flushed with nitrogen. The mixture was stirred at 95 °C for 15 hours. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/100-1/20) to give the titled compound ID (8.9 g, 45%) as slightly yellow oil.
Step 4: Synthesis of Compound IE
[0211] Compound ID (8.9 g, 29.3 mmol) was dissolved in THF (100 mL) and (+)- pinanediol (4,98 g, 29.3 mmol) was added. The resulting reaction mixture was stirred at room temperature for 15 hours. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/200-1/50) to give the titled compound IE (3.2 g, 31% yield) as slightly yellow oil.
MS calcd for (C20H25BO5): 356
MS (ESI, positive) found: (M+l): 357
Step 5: Synthesis of Compound IF
[0212] To a solution of CH2IC1 (1.34 g, 7.67 mmol) in THF (15 mL) at -78 °C was added 2,5 M n-butyl lithium in hexane (3.07 mL, 7.67 mmol) slowly under nitrogen and down the inside wall of the flask. The resulting solution was stirred for 30 minutes before the addition of Compound IE from step 4 (2, 1 g, 5.90 mmol) in THF (5 mL) at -78 °C. The reaction was allowed to warm to room temperature and stirred for 16 h before it was quenched with a saturated solution of ammonium chloride. The phases were separated. The aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were dried over aoS04. The concentrated material was chromatographed (100% hexane~20% EtOAc-hexane) to obtain the titled compound IF (2,07 g, 95% yield) as slightly yellow oil.
MS calcd for (C21H27BO5): 370
MS (ESI, positive) found: (M+l): 371
Step 6: Synthesis of Compound 1G
[§213] To a solution of CH2C12 (0.72 ml., 1 1.2 mmol) in THF (20 mL) at -100 °C was added 2,5 M n-butyl lithium in hexane (2,9 mL, 7.28 mmol) slowly under nitrogen and down the inside wall of the flask, maintaining the temperature below -90 °C. The reaction mixture was stirred for 30 minutes before the addition of Compound IF from step 5 (2,07 g, 5.6 mmol) in THF (5 mL) at -90°C. The reaction was allowed to warm to room temperature slowly and stirred at room temperature for 16 h. The reaction mixture was quenched with a saturated solution of ammonium chloride and the phases were separated. The aqueous phase was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were dried over
Figure imgf000061_0001
filtered and concentrated under reduced pressure. The concentrated material was then chromatographed (100% hexane~20% EtOAc-hexane) to obtain the titled compound 1G (1 ,48 g, 63% yield) as slightly yellow oil.
Step 7: Synthesis of Compound 1H
[0214] Compound 1G (1.48 g, 3.53 mmol) in THF (15 mL) was cooled to -78 °C under nitrogen. A solution of 1 M LiHMDS solution in THF (3.6 mL, 3.6 mmol) was added slowly at -78 °C. Upon completion of the addition, the reaction flask was allowed to warm to room temperature. After stirring at room temperature for 16 h, the reaction mixture was concentrated under vacuum and hexane (20 mL) was added. The precipitated lithium salts were filtered off through a C elite pad, rinsed with additional hexane and the combined filtrates were concentrated under vacuum to give crude bis(trimethylsilyl)amine product 1 II (3.5 mmol). MS calcd for
Figure imgf000061_0002
543
MS (ESI, positive) found: (M-2*TMS+3): 400
Step 8: Synthesis of Compound II
[0215] Bis(trimethylsilyl)amine compound 1H (260 nig, 0,48 mmol) was stirred in MeOH/THF (1 iiiL/10 mL) for 30 min at room temperature before it was concentrated to dryness in vacuo to afford the free amine as yellow oil. Trifluoroniethylsulfanyl-acetic acid (91 nig, 0,57 mmol) and CDI(115 nig, 0,71 mmol) were dissolved in DMF (2 mL) at stirred at 45 °C for 1 h. After cooling down, the free amine obtained above in 1 ml. DMF was added and was stirred at room temperature for 15 hours. The mixture was diluted with DCM and washed with water and brine, dried over
Figure imgf000062_0001
The concentrated material was then chromatograph ed (EtOAc-hexane: 1/20-1/2) to obtain the titled compound II (110 mg, 42.5% yield) as slightly yellow oil.
MS calcd for (C25H3iBF3N06S): 541
MS (ESI, negative) found: (M-l): 540
Step 9: Synthesis of (R)-2-hydroxy-3-(2-(trifluoromethylthio)acetamido)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (1)
[§216] To the solution of compound I (1 10 mg, 0,2 mmol) in MeOH/hexane (2 niL/2 niL) was added isobutyl boronic acid (41 mg, 0,4 mmol) and concentrated HCl (0,2 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The two layers were separated and the MeOH layer was washed with hexanes twice before it was concentrated in vacuo. The residue was stirred in dioxane (2 mL) and 3 N aqueous HCl (3 mL) at 80 °C for 2 h. After concentration, the residue was purified by reverse-phase prep-HPLC to afford 1 (8 mg) as a white solid after lyophilization,
H NMR (400 MHz, CD3OD) δ 7.83 (dd, 1 H, J = 6.0, 6.0 Hz), 7.32 (d, 1 H, J = 6.8 Hz), 6.96
(dd, 1 H, J = 8.0, 8.0 Hz), 3.86 (d, 2 H. J 5.6 Hz), 3.34 (s, 1 H), 2.97 (s, 2H).
MS calcd for (C^HnBFsNOsS): 349
MS (ESI, positive) found: (M+l): 350
MS (ESI, negative) found: (M-l): 348
Example 2 : (R)-2-hydroxy-3-(2-( 1 -methyl- 1 H-tetrazol.-5-yl.thio)acetamido)-3 ,4-dihydro-2H- benzo[e1P. ,21oxaborini.ne-8-carboxyli.e acid (2)
Scheme 5:
Figure imgf000063_0001
2
Step 1 : Synthesis of Compound 2A
[§217] Bis(trimethylsilyl)amine compound 1H (260 nig, 0,48 mmol) was stirred in MeOH/THF (1 iiiL/10 iiiL) for 1 h at room temperature before it was concentrated to dryness in vacuo to afford the free amine as yellow oil. (1 -Methyl- lH-tetrazol-5-ylsulfanyl)-acetic acid (99 nig, 0,57 mmol) and GDI (1 15 nig, 0,71 mmol) were dissolved in DMF (2 niL) at stirred at 50 °C for 2 h. After cooling down, the free amine obtained above in 1 ml. DMF was added and was stirred at room temperature for 15 hours. The mixture was diluted with DCM and washed with water and brine, dried over Na2SC>4. After concentration, the crude compound 2A was used directly for next step (205 nig, crude).
MS calcd for
Figure imgf000063_0002
555
MS (ESI, negative) found: (M-l): 554
Step 2: Synthesis of (R)-2-hydroxy-3-(2-(l -methyl- lH-tetrazol-5-ylthio)acetamido)-3, 4- dihydro-2H-benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (2)
[§218] To the solution of compound 2A (200 nig, crude) in MeOH/hexane (1.5 niL/1 ,5 niL) was added isobutyl boronic acid (82 nig, 0,8 mmol) and concentrated HC1 (0, 15 niL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The TWO layers were separated and the MeOH layer was diluted with 10 nil. MeOH, washed with hexanes twice before it was concentrated in vacuo. The residue was stirred in dioxane (1.5 niL) and 3 N aqueous HC1 (1.5 niL) at 80 °C for 2 h. After concentration, the residue was purified by reverse- phase prep- HP I. C to afford 2 (17 nig) as a white solid after lyophilization. H NMR (400 MHz, CD3OD) δ 7.74 (dd, 1 H, J = 2.0, 8.4 Hz), 7.09 (d, 1 H, J = 6.4 Hz), 6.81 (t, 1 H, J= 7.6 Hz), 4.12 - 4.24 (111, 2 H), 3.80 (s, 3H), 3.34 (s, 1 H), 2.89 (d, 2H, J = 3.6 Hz). MS calcd for (C13H14BN5O5S): 363
MS (ESI, positive) found: (M+l): 364
MS (ESI, negative) found: (M- l): 362
Example 1: iJ j diJlu^
benzofel [ 1 ,21oxaborinine-8-carboxylic acid (3)
Figure imgf000064_0001
[§219] IC was prepared as described in example 1.
Step 1 : Synthesis of compound 3A
[02201 The mixture of compound IC (10.8 g, 33.1 mmol), potassium vinyl trifluoroborate (5.3 g, 39.8 mmol), triethylamine (6.7 g, 9.3 ml., 66.2 mmol) and PdCl2(dppf) (1.35 g, 1.65 mmol) in i-PrOH (200 mL) was degassed for three times and flushed with nitrogen. The mixture was stirred at 85 °C for 1 hour. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/100-1/40) to give the titled compound 3A (6.6 g, 98%yield) as a slightly yellow oil. Step 2: Synthesis of Compound 3B
[§221] Benzoquinone (3.85 g, 35.6 mmol) and PdCl2(CH3CN)2 ( 201 mg, 0.78 mmol) were added into t-BuOH (150 mL) at 85 °C, followed by water (0.56 ml., 31 mmol) and compound 3A (6.3 g, 31 mmol). The resulting solution was stirred at 85 °C for 30 minutes until TLC indicating the disappearance of compound 3A, After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/5-1/2) to give the titled compound 3B (4.1 g, 60% yield) as slightly yellow solid.
Step 3: Synthesis of Compound 3C
[§222] To a solution of compound 3B (2,0 g, 9.1 mmol) and (R)-tert-butylsulfmic amide (1.32 g, 10.9 mmol) in THF (40 mL) was added titanium(IV) ethoxide (3.8 mL, 18 mmol). The resulting solution was stirred at room temperature for 20 hours before it was quenched with brine. The mixture was filtered through Celite and washed with EtOAc. The filtrate was concentrated and chromatographed (ethyl acetate/hexanes, v/v, 1/2-1/1) to afford the titled compound 3C (2.04 g, 70% yield) as slightly yellow solid.
Step 4: Synthesis of Compound 3E
[0223] The solution of compound 3C (1.9 g, 5.9 mmol), bis(pinacolato)diboron (1.7 g, 6.5 mmol) and NHC-Cu complex 3D (220 mg, 0,60 mmol) (For the synthesis of compound 3D, see: J. Am. Chem. Soc. 2006. 128, 1 1036) in anhydrous benzene (20 mL) was stirred at room temperature under nitrogen atmosphere for 3 days. The reaction solution was diluted with EtOAc and washed with saturated aqueous NaHC(¾ and brine, dried over Na2SC>4. After concentration, the residue was quickly chromatographed (20% EtOAc-dichloromethane, silica gel was de-activated with 35 wt% water) to afford the titled compound 3E (2.6 g, quantitative yield) as yellow solid.
Step 5: Synthesis of Compound 3F
[§224] To the solution of compound 3E (2,6 g, 5.9 mmol) in dioxane (30 mL) was added methanol (2,4 mL, 59 mmol) and HC1 (1.6 mL, 6.5 mmol, 4M in dioxane). The reaction mixture was concentrated to dryness in vacuo and washed with ether/hexanes (v/v, 1/2), The residue (about 2,5 g) was used for next step without further purification. Step 6: Synthesis of Compound 3H
[§225] Difluoromethylsulfanyl-acetic acid 3G (850 mg, 6.0 mmol) and GDI (1.01 g,
6.3 mmol) were dissolved in DMF (15 iiiL) at stirred at 50 °C for 1 h. After cooling down, compound 3F in 12 m l. DMF was added and the solution was stirred at room temperature for 4 hours. The mixture was diluted with hexanes/EtOAc (1/4, v/v) and washed with water (2x) and brine, dried over Na2SC>4. After concentration, the crude compound 3H (1.8 g) was obtained as brown greasy solid, which was used directly for the next step.
Step 7: Synthesis of Compound 31
[§226] The crude compound 3H (1.8 g, 3.8 mmol) and (+)-pinanediol (976 mg, 5.7 mmol) were stirred in THF (20 mL) at room temperature for 16 hours before it was concentrated to dryness. The residue was chromatographed (ethyl acetate/hexanes, v/v, 1/2-1/1) to afford the titled compound 31 (1.02 g) as orange oil.
MS calcd for (C25H32BF2 06S): 523
MS (ESI, negative) found: (M- l): 522
Step 8: Synthesis of (R)-3-(2-(difluoromethylthio)acetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (3)
[0227] To the solution of compound 31 (1 ,02 g, 1 ,95 mmol) in dioxane (50 mL) was added isobutyl boronic acid (800 mg, 7.8 mmol) and 3N aqueous HC1 (20 mL). The resulting solution was stirred at 85 °C for 1.5 hours. The mixture was concentrated to about 20 mL and washed with hexanes and then ether. The organic layers were extracted with MeCN/water (v/v, 1/2). The combined water layer was purified by reverse-phase prep- H P I. (' to afford 3, (283 mg) as a white solid after lyophilization.
H N. R. (300 MHz, DMSO-t 6) δ 10.58 (s, 1H), 10.39 (s, 1H), 7.64 (d, 1 H), 7.34 (d, 1 H), 7.01
(t, 1H), 6.80 - 6.96 (m, 1H), 3.60 - 3.82 (m, 2H), 2.72 - 3.05 (m, 3H).
MS calcd for (Ci2H12BF2 05S): 331
MS (ESI, positive) found: (M+l): 332
MS (ESI, negative) found: (M- l): 330 Example 4: (^)-3-formamid.o-2-hvdroxy-3,4-dihvdro-2H-beiizo[e1[l ,21oxaboriDine-8-cai¾oxylic acid ( 4)
Scheme 7:
Figure imgf000067_0001
[§228] 3F was prepared as described in example 3.
Step 1 : Synthesis of Compound 4A
[§229] To the solution of compound 3F (150 mg, 0,39 mmol) and formic acid (15 mg, 0.32 mmol) in DCM/DMF (3 iiiL/l iiiL) was added TEA (58 mg, 0.58 mmol) and diethyl cyanophosphonate (52 mg, 0,32 mmol). The resulting solution was stirred for 15 hours at room temperature before it was concentrated to dryness in vacuo. The residue was dissolved in THF and (+)-pinanediol (66 mg, 0,39 mmol) was added. After stirring at room temperature for 3 hours, the reaction mixture was concentrated and chromatographed (ethyl acetate/hexanes, v/v, 1/2-1/1) to afford the titled compound 4A (95 mg) as a yellow oil.
MS calcd for (C23H3oBN06): 427
MS (ESI, negative) found: (M-l): 426
Step 2: Synthesis of (R)-3-formamido-2-hydroxy-3,4-dihydro-2H-benzo[e][l,2]oxaborinine-8- carboxylic acid (4)
[0230] To the mixture of TFA (6 niL) and triethylsilane (1 iiiL) was added compound 4A (95 mg, 0,22 mmol). The resulting solution was stirred at 50 °C for 1 hour before it was concentrated to diyness. The residue was washed with EtoO (20 niL), and purified by prep-HPLC to afford 4, 13.4 mg) as a white solid.
H NMR (400 MHz, CD3OD) δ 8.09 (s, 1H), 7.83 (d, 1 H, J = 8.0 Hz), 7.32 (d, 1 H, J = 6.8 Hz), 6.97 (dd, 1 H, J = 12, 7.2 Hz), 3.22 (s, 1 H), 2.97 (s, 2H).
MS calcd for (Ci0H10BNO5): 235
MS (ESI, positive) found: (M+l): 236
MS (ESI, negative) found: (M-l): 234 Example 5 : (R)-3-(2-(5-amino-13 hiadiazol-2-ylthio)acetamido)-2 dimv-3^-dihvdro-2H- benzo[el[l ,21oxaborinine-8-carboxylic acid ( 5)
Sche
Figure imgf000068_0001
5
[0231] 3F was prepared as described in example 3.
Step 1 : Synthesis of Compound 5A
[0232] To the solution of compound 3F (140 mg, 0,36 mmol) and (5-Amino- [ 1 ,3 ,4]thiadiazol-2-ylsulfanyl)-acetic acid (84 mg, 0,44 mmol) in DCM/DMF (3 iiiL/1 iiiL) was added TEA (81 mg, 0,80 mmol) and diethyl cyanophosphoiiate (71 mg, 0,44 mmol). The resulting solution was stirred for 3 hours at room temperature before it was concentrated to dryness in vacuo. The residue was dissolved in THF and (+)-pinanediol (93 mg, 0.55 mmol) was added. After stirring at room temperature for 15 hours, the reaction mixture was concentrated and the residue was used directly for next step.
MS calcd for (C26H33BN4O6S2): 572
MS (ESI, negative) found: (M-l): 571
Step 2: Synthesis of (R)-3-(2-(5-amino-l ,3,4-thiadiazol-2-ylthio)acetamido)-2-hydroxy-3,4- dihydro-2H-benzo[e] [ 1 ,2]oxaborinine-8-carboxylic acid (5)
[0233] To the mixture of TFA (6 iiiL) and triethylsilane (1 iiiL) was added crude compound 5A, The resulting solution was stirred at 50 °C for 1 hour before it was concentrated to dryness. The residue was washed with Et20 (20 iiiL), and purified by prep-HPLC to afford 5 (35 mg) as white solid.
H NMR (400 MHz, CD3OD) δ 7.79 (dd, 1 H, J = 1.6, 8.0 Hz), 7.25 (d, 1 H, J = 7.2 Hz), 6.94 (dd, 1 H, J = 8.0, 8.0 Hz), 3.90 - 4.06 (111, 2H), 3.31 (s, 1 H), 2.93 (s, 2H). MS calcd for (C13HBBN4O5S2): 380
MS (ESI, positive) found: (M+l): 381
MS (ESI, negative) found: (M-l): 379
Example 6: (R)-2-hvdroxv-3-ureido-3,4-dihydro-2H-benzo[el[l ,21oxaborinine-8-carboxvlic acid (6)
Scheme 9:
Figure imgf000069_0001
[0234] 3F was prepared as described in example 3.
Step 1 : Synthesis of Compound 6A
[0235] To the solution of compound 3F (120 mg, 0,32 mmol) in DCM (3 mL) was added TMSNCO (43 mg, 0.38 mmol) and DIPEA (48 mg, 0.38 mmol). The resulting solution was stirred for 2 hours at room temperature before it was concentrated to dryness in vacuo. The residue was dissolved in THF and (+)-pinanediol (80 mg, 0.47 mmol) was added. After stirring at room temperature for 15 hours, the reaction mixture was concentrated and the residue was used directly for next step.
MS calcd for (C2iH3iBN206): 442
MS (ESI, negative) found: (M-l): 441
Step 2: Synthesis of (R)-2-hydroxy-3-ureido-3,4-dihydro-2H-benzo[e][l,2]oxaborinine-8- carboxylic acid (6)
[0236] To the mixture of TFA (6 mL) and triethylsilane (1.5 mL) was added crude compound 6A, The resulting solution was stirred at 50 °C for 1 hour before it was concentrated to dryness. The residue was washed with Et20 (20 mL), and purified by prep-HPLC to afford 6 (5.2 mg) as white solid.
H NMR (400 MHz, CD3OD) δ 7.81 (dd, 1 H, J = 2.0, 8.0 Hz), 7.30 (d, 1 H, J = 7.2Hz), 6.94
(dd, 1 H, J = 7.6, 7.6 Hz), 3.18 (s, 1 H), 2.84 (s, 2H).
MS calcd for (QoHnB^Os): 250
MS (ESI, positive) found: (M+l): 251 MS (ESI, negative) found: (M-l): 249
Example 7: (R)-3-(2-(1.3.4-thiadiazol-2-vlthio)acetamido)-2-hvdroxv-3,4-dihvdro-2H- benzoiein .21oxaborinine-8-carboxvlic acid (7)
Figure imgf000070_0001
Step 1 : Synthesis of compound 7B
[0237] To the solution of compound 7A (100 g, 0.657 mol) in THF (400 iiiL) was added Boc20 (573 g, 2.63 mol), DMAP (24 g, 0.197 mol) and t-BuOH (800 mL). The resulting solution was stirred at 60 °C for 6 hours before it was concentrated in vacuo. The residue was purified by flash column chromatography (ethyl acetate/hexanes, v/v, 1/200-1/100) to give the titled compound 7B (85.9 g, 42.5% yield) as colorless oil.
Step 2: Synthesis of compound 7C
[0238] To the solution of compound 7B (44.3 g, 144 mmol) and NBS (28.1 g, 158 mmol) in CCLj (400 mL) was added BPO (3.5 g, 14,4 mmol). The resulting mixture was refluxed at 80 °C for 15 hours. The solid was filtered off and the filtrate was concentrated in vacuo. The residue was reciystallized with hexanes to afford the titled compound 7C (32.0 g, 57.6% yield) as white solid.
Step 3: Synthesis of compound 7D [0239] The mixture of compound 7C (47.5 g, 123 mmol), bis(pinanediolato)diboron (39.9 g, 112 mmol), KOAc (32.9 g, 336 mmol) and PdCl2(dppf) (4.5 g, 5.6 mmol) in dioxane (500 iiiL) was degassed for three times and flushed with nitrogen. The mixture was stirred at 95 °C for 8 hours. After concentrated to dryness, the residue was purified by column chromatography (ethyl acetate/hexanes, v/v, 1/200-1/100) to give the titled compound 7D (40 g, 59% yield) as slightly yellow oil.
Step 4: Synthesis of Compound 7E
[0240] To a solution of CH2C12 (4.2 iiiL, 65.8 mmol) in THF (160 iiiL) at -100 °C was added 2,5 M n -butyl lithium in hexane (18.4 ml., 46,0 mmol) slowly under nitrogen and down the inside wall of the flask, maintaining the temperature below -90 °C. The reaction mixture was stirred at -100 °C for another 30 minutes before the addition of Compound 7D from step 3 (16.0 g, 32,9 mmol) in THF (30 mL) at -90 °C and then the reaction was allowed to warm to room temperature where it was stirred for 16 h. The reaction was concentrated in vacuo directly to dryness and then chromatographed (100% hexane~20% EtOAc-hexane) to obtain the titled compound 7E (15.0 g, 85% yield) as slightly yellow oil.
Step 5: Synthesis of Compound 7F
[0241] Compound 7E (14.1 g, 26.4 mmol) in THF (100 mL) was cooled to -78 °C under nitrogen, A solution of I. i HMDS (27 mL, 1.0M in THF, 27.0 mmol) was added slowly at - 78 °C. Upon completion of the addition, the reaction flask was allowed to warm to room temperature. After stirring at room temperature for 2 h, the reaction mixture was concentrated under vacuum and hexane (100 mL) was added. The precipitated lithium salts were filtered off through a C elite pad, rinsed with additional hexane, and the combined filtrates were concentrated under vacuum to give crude bis(trimethylsilyl)amine product 7F (26.4 mmol), which was stored as a stock solution for future use.
MS calcd for (C34H58BNO7S-2): 659
MS (ESI, positive) found: (M-2*TMS+3): 516
Step 6: Synthesis of Compound 7G
[0242] To the solution of ([l,3,4]Thiadiazol-2-ylsulfanyl)-acetic acid (655 nig, 3.72 mmol) in DCM/DMF (10 mL/5 mL) was added HATU (1.40 g, 3.72 mmol) at 0 °C. After stirring at 0 °C for 15 minutes, a solution of bis(trimethylsilyl)amine compound 7F (3.4 mmol) in DCM (5 mL) was added, followed by DIPEA (0,71 mL, 4,08 mmol). The resulting mixture was warmed up and stirred at room temperature for 1 hour, extracted with DCM (50 mL*3), washed with water and bri ne, dried over Na2S04. The concentrated material was then chromatographed (EtOAc-hexane: v/v: 10/1-1/1) to obtain the titled compound 7G (1 ,35 g, 59% yield) as a slightly yellow greasy solid.
MS calcd for (C32H44BN3O8S2): 673
MS (ESI, negative) found: (M+Na): 672
Step 7: Synthesis of (R)-3-(2-(l ,3,4-thiadiazol-2-ylthio)acetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e] [l ,2]oxaborinine-8-carboxylic acid (7)
[0243] To the mixture of TFA (40 111L) and triethylsilane (6 111L) was added compound 7G (1.35 g, 2,01 mmol). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue was washed with Et20 (3 x 20 111L), and dissolved in CH3CN/H20 (20 mL/20 mL), dried by lyophilization to afford 7 (380 mg, 52% yield) as a white solid.
H NMR (400 MHz, CD3OD) δ 9.28 (s, 1 H), 7.73 (d, 1 H, J = 7.6 Hz), 7.15 (d, 1 H, J = 1.2 Hz), 6.84 (dd, 1 H, J = 1.6, 7.6 Hz), 4.13 - 4.29 (111, 211), 3.30 (s, 1 H), 2.91 (d, 2H, J = 3.2
Hz).
MS calcd for (CoHoBNsOjSz): 365
MS (ESI, positive) found: (M+l): 366
MS (ESI, negative) found: (M- l): 364
Example 8: (R)-3-(2-azidoacetamido)-2-hvdroxv-3,4-dihvdro-2H-benzo[el i l ,21oxaborinine-8- carboxyl ic acid ( 8)
Scheme 1 1 :
Figure imgf000072_0001
[0244] 7F was prepared as described in exam;
Step 1 : Synthesis of Compound 8B
[0245] To the solution of 2-azidoacetic acid (8A) (J. Med Chem., 2011, 54, 7375) (544 mg, 5.4 mmol) in DCM/DMF (20 iiiL/10 mL) was added HATU (2.05 g, 5.4 mmol) at 0 °C. After stirring at 0 °C for 15 minutes, a solution of bis(trimethylsilyl)amine compound F (3.59 mmol) in DCM (10 iiiL) was added, followed by DIPEA (0.94 ml., 5.4 mmol). The resulting mixture was warmed up and stirred at room temperature overnight, extracted with DCM (50 mL*3), washed with water and brine, dried over Na2S04. The concentrated material was then chromatographed (EtOAc-hexane: v/v: 10/1-1/1) to obtain the titled compound 8B (582 mg, 27% yield) as a slightly yellow greasy solid.
MS calcd for (C30H43BN4O8): 598
MS (ESI, negative) found: (M-l): 597
Step 2: Synthesis of (R)-3-(2-azidoacetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (8)
[0246] To the mixture of TFA (46 niL) and triethylsilane (8 mL) was added compound 8B (582 mg, 0,97 mmol). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue was partitioned in 20 mL water and 20 mL ether. The aqueous layer was washed with ether (2 x 20 mL) and dried by lyophilization to afford (8, 120 mg, 43% yield) as white solid.
H NMR (400 MHz, CD3OD) δ 7.83 (dd, 1 H, J = 2.0, 8.4 Hz), 7.31 (d, 1 H, J = 5.4 Hz), 6.97 (dd, 1 H, J = 7.6, 7.6 Hz), 4.25 (d, 2 H, J = 5.2 Hz), 3.31 (s, 1 H), 2.97 (d, 2H, J = 3.2 Hz). MS calcd for (CnHnBN-jOs): 290
MS (ESI, positive) found: (M+l): 291
MS (ESI, negative) found: (M-l): 289
Example 9l ( R )-3 iethvlamino)-2-oxoacetamido)-2-hvdroxv-3,4-dihvdro-2H- benzoiel Γ 1.21oxaborinine-8-carboxvlic acid ( 9)
Scheme 12:
Figure imgf000073_0001
[0247] 7F was prepared as described in example 7. Step 1 : Synthesis of 9B
[§248] To the solution of NN-Dimethyl-oxalamic acid 9A (Heterocycles, 1993, 36,
2687) (125 mg, 1 ,07 mmol) in DCM (3 iiiL) was added Ghosez reagent (157 mg, 1.18 mmol) at 0 °C. After stirring at 0 °C for 30 minutes, a solution of compound 7F in pyridine (1 mL) was added into the reaction mixture. The resulting mixture was stirred at room temperature for 3 hours before it was concentrated to dryness. The residue was dissolved in EtOAc, washed with water and brine, dried over Na2S04. After concentration, the crude 9B (157 mg) was obtained as yellow oil, which was used for next step without further purification.
MS calcd for (C32H47BN2O9): 614
MS (ESI, negative) found: (M-l): 613
Step 2: Synthesis of (R)-3-(2-(dimethylamino)-2-oxoacetamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (9)
[0249] To the mixture of 90% TFA (2 mL) and triethylsilane (0.5 mL) was added compound 9B (157 mg, crude). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue purified by reverse-phase prep-HPLC to afford 9, (5.4 mg) as white solid.
H NYI R (400 MHz, CD3OD) δ 7.82 (d, 1 H, J = 7.6 Hz), 7.34 (d, 1 H, J = 6.8 Hz), 6.98 (dd, 1 H, J = 7.6, 7.6 Hz), 3.37 (s, 1H), 2.85 - 3.05 (111, 2 H), 2.88 (s, 3 H), 2.55 (s, 3H).
MS calcd for (Ci3H15BN206): 306
MS (ESI, positive) found: (M+l): 307
MS (ESI, negative) found: (M-l): 305
Example 10: (R)-3-(3-(dimethvlamino)-3-oxopropanamido)-2-hvdroxv-3,4-dihydro-2H- benzo[e1[l ,21oxaborinine-8-carboxytie acid (10)
Figure imgf000074_0001
[§250] 7F was prepared as described in exam;
Step 1 : Synthesis of 10B [0251] Bis(trimethylsilyl)amine compound 7F (300 mg, 0,5 mmol) was stirred in
MeOH/THF (1 mL/5 iiiL) for 30 min at room temperature before it was concentrated to dryness in vacuo to afford the free amine as a yellow oil. Compound 1 OA (WO 091 17540 ) (76 mg, 0,58 mmol) and CDI (94 mg, 0,58 mmol) were dissolved in DMF (2 mL) at stirred at 45 °C for 1 h. After cooling down, the free amine obtained above in 1 mL DMF was added and was stirred at room temperature for 15 hours. The mixture was diluted with DCM and washed with water and brine, dried over Na2S04. After concentration, the crude titled compound 10B (345 mg) was obtained as slightly yellow oil, which was used for next step without further purification, MS calcd for (C33H49BN2O9): 628
MS (ESI, negative) found: (M-l): 627
Step 2: Synthesis of (R)-3-(3-(dimethylamino)-3-oxopropanamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (10)
[0252] To the mixture of 90% TFA (7 mL) and triethylsilane (2 mL) was added compound 10B (325 mg, crude). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue purified by reverse-phase prep- HP I. C to afford 10 (40 mg) as white solid.
H NMR (400 MHz, CD3OD) δ 7.83 (d, 1 H, J = 6.4 Hz), 7.32 (d, 1 H, J = 7.6 Hz), 6.96 (dd, 1 H, J = 7.6, 7.6 Hz), 3.54 - 3.56 (m, 2H), 3.31 (s, 1H), 2.96 (d, 2H, J = 3.2 Hz), 2.82 (d, 6H, J = 2.0 Hz).
MS calcd for (Ci4H17BN206): 320
MS (ESI, positive) found: (M+l): 321
MS (ESI, negative) found: (M-l): 319
Example 11 : (R)-2-hvdroxv-3-(methvlthiocarbonvlamino)-3,4-dihvdro-2H- benzoic! P. ,21oxaborini.ne-8-carboxyli.e acid (11)
Figure imgf000075_0001
[0253] 7F was prepared as described in example 7. Step 1 : Synthesis of 11 A
[§254] Bis(trimethylsilyl)amine compound 7F ( 0,4 mmol) was stirred in MeOH/THF (0,5 mL/2 iiiL) for 30 min at room temperature before it was concentrated to dryness in vacuo to afford the free amine as a yellow oil. The free amine was dissolved in DCM (2 niL) and pyridine (38 mg, 0,48 mmol) was added, followed by methyl chlorothiolformate (53 mg, 0,4 mmol). After stirring at room temperature for 12 hours, the reaction mixture was diluted with DCM, washed with water and brine, dried over
Figure imgf000076_0001
After concentration, the crude titled compound 11A (280 mg) was obtained as yellow oil, which was used for next step without further purification.
MS calcd for (C3oH44BNOgS): 589
MS (ESI, negative) found: (M-l): 588
Step 2: Synthesis of (R)-2-hydroxy-3-(methylthiocarbonylamino)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (11)
[§255] To the mixture of TFA (2 mL) and triethylsilane (0,5 niL) was added compound CI (280 mg, crude). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue purified by reverse-phase prep- HP I. (' to afford 11 ( 30 mg) as white solid.
H NMR (400 MHz, CD3OD) δ 7.85 (dd, 1H, J = 1.2, 8.0 Hz), 7.31 (d, 1H, J = 1.6 Hz), 6.97 (dd, 1 H, J = 1.2, 8.0 Hz), 3.30 (s, 1H), 2.91 (s, 2H), 2.39 (s, 3H).
MS calcd for (CnH12BN05S): 281
MS (ESI, positive) found: (M+l): 282
MS (ESI, negative) found: (M-l): 280
Example 12: (R)-2-hvdroxy-3-(nicotinamido)-3.4-dihvdro-2H-benzo[el Γ 1 ,21oxaborinine-8- carboxvlic acid (12)
Scheme 15:
Figure imgf000076_0002
[§256] Intermediate 7F was made as described in example 7. Step 1 : Synthesis of 12A
[0257] To the solution of compound 7F (4 mmol, crude) and 3-pyridinecarboxylic acid (492 mg, 4 mmol) in DMF (40 mL) was added (EtO)2POCN (652 mg, 4 mmol). The resulting reaction mixture was stirred at room temperature overnight before it was concentrated. The residue was dissolved in DCM and washed with water, brine and dried over Na2SC>4. Column chromatography gave titled compound 12A (1.31 1 g) as slightly yellow oil.
MS calcd for (C34H45BN2O8): 620
MS (ESI, negative) found: (M-l): 619
Step 2: Synthesis of (R)-2-hydroxy-3-(nicotinamido)-3,4-dihydro-2H-benzo[e][l,2]oxaborinine- 8-carboxylic acid (12)
[0258] To the mixture of TFA (56 mL) and triethylsilane (16 mL) was added compound 12A (1.311 g). The resulting solution was stirred at room temperature for 1 hour before it was concentrated to dryness. The residue was washed with ether to afford 12 (450 mg) as white solid.
H NMR (400 MHz, CD3OD) δ 9.18 (m, 1H), 8.98 (111, 1H), 8.42 (111, IH), 7.98 (111, 1H), 7.76 (111, 1 H,), 7.52 (m, 1 H), 7.12 (111, 1 H), 3.69 (s, IH), 3.26 (s, 2H).
MS calcd for (C15H13BN205): 312
MS (ESI, positive) found: (M+l): 313
MS (ESI, negative) found: (M-l): 31 1
Example 13: (R)-2-hvdroxv-3-(2-(methvlthio)acetamido)-3,4-dihydro-2H- benzo[ein ,21oxaborinine-8-carboxylic acid (13)
Figure imgf000077_0001
13
[0259] (R)-2-hydroxy-3-(2-(methylthio)acetamido)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (13) was prepared following the procedure described in example 7 (steps 1-7) replacing the ([l ,3,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 2-(methylthio)acetic acid. H NMR (400 MHz, CD3OD) δ 7.84 (d, 1 H, J = 8.0 Hz), 7.33 (d, 1 H, J = 7.2 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 3.33 (S, 1H), 3.20 (s, 2H), 2.97 (s, 2H), 1.70 (s, 3H).
MS calcd for (C12H14BNO5S): 295
MS (ESI, positive) found: (M+l): 296
MS (ESI, negative) found: (M 4): 294
Example 14: (R)-3-(5-fluoronicotinamido)-2-hvdroxv-3,4-dihvdro-2H- benzo[el[l ,21oxaborinine-8-carboxylic acid (14)
Figure imgf000078_0001
14
[0260] (R)-3-(5-fluoronicotinamido)-2-hydroxy-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (14) was prepared following the procedure described in example 7 (steps 1-7) replacing the ([l ,3,4]Tfaiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 5-fluoronicotinic acid.
H NMR (400 MHz, CD3OD) δ 11.10 (s, 1H), 8.84 (d, 2H, J = 15.6 Hz), 8.10 (d, 1 H, J = 8.8 Hz), 7.63 (d, 1 H, J = 7.2 Hz), 7.29 (d, 1 H, J = 6.8 Hz), 6.87 (t, 1 H, J = 7.6 Hz), 3.25 (s, 1H), 2.95 (s, 2H).
MS calcd for (CuHoBFNzOj): 330
MS (ESI, positive) found: (M+l): 331
MS (ESI, negative) found: (M -1): 329
Example 15: (R)-2-hvdroxv-3-(thiazole-5-carboxamido)-3,4-dihydro-2H- benzofel [ 1 ,21oxaborinine-8-carboxylic acid (15)
Figure imgf000078_0002
15
[0261] (R)-2-hydroxy-3-(thiazole-5-carboxamido)-3,4-dihydro-2H- benzo[e][l ,2]oxaborinine-8-carboxylic acid (15) was prepared following the procedure described in example 7 (steps 1-7) replacing the ([l ,3,4]Tfaiadiazol-2-ylsulfanyl)-acetic acid in step 6 with thiazole-5-carboxylic acid. H NMR (400 MHz, CD3OD) δ 9.31 (s, 1H), 8.57 (s, 1H), 7.81 (d, 1 H, J
H, J = 7.6 Hz), 6.94 (t, 1 H, J = 8.0 Hz), 3.48 (s, 1H), 3.05 (s, 2H).
MS calcd for (C15H12BFN2O5): 318
MS (ESI, positive) found: (M+l): 319
MS (ESI, negative) found: (M 4): 317
Example 16: (R)-3-(3-amino-3-oxopropanamido)-2-hvdroxy-3,4-dihvdro-2H- benzofel [ 1 ,21oxaborinine-8-carboxylic acid (16)
Figure imgf000079_0001
16
[0262] Compound 16 above was prepared following the procedure described in Example 8 except replacing the 2-azidoacetic acid in step 1 with 3 -amin o-3 -oxopropan oic acid. H NMR (400 MHz, CD3OD) δ 7.82 (dd, 1 H, J = 1.2, 8.0 Hz), 7.31 (d, 1 H, J = 6.4 Hz), 6.94 (dd, 1 H, J = 12, 12 Viz), 321 - 3.32 (m, 3H), 2.95 (d, 2H, J = 3.6 Hz).
MS calcd for (Ci2Hi3BN206): 292
MS (ESI, positive) found: (M+l): 293
MS (ESI, negative) found: (M -1): 291
Example 17: (R)-3-(2-amino-2-oxoacetamido)-2-hvdroxv-3,4-dihydro-2H- benzo[ein ,21oxaborinine-8-carboxylic acid ( 17)
Figure imgf000079_0002
[0263] Compound (17) was prepared following the procedure described in example 8 except replacing the 2-azidoacetic acid in step 1 with 2-amino-2-oxoacetic acid.
H NMR (400 MHz, CD3OD) δ 7.82 (d, 1 H, J = 8.0 Hz), 7.31 (d, 1 H, J = 12 Hz), 6.96 (dd, 1 H, J = 7.6, 7.6 Hz), 3.39 (t, 1H, J = 4.0 Hz), 2.98 (d, 2H, J = 3.6 Hz).
MS calcd for (CnHnB^Oe): 278 MS (ESI, positive) found: (M-H20+1): 261
MS (ESI, negative) found: (M-l): 277
Example 18: (R)-2-hvdroxv-3-(pvrimidine-5-carboxamido)-3,4-dihydro-2H- benzo[el[l ,21oxaborinine-8-carboxylic acid (18)
Figure imgf000080_0001
18
[0264] Compound (18) was prepared following the procedure described in Example 8 except replacing the 2-azidoacetic acid in step 1 with pyrimidine-5-carboxylic acid.
H NMR (400 MHz, CD3OD) δ 9.34 (s, 1H), 9.16 (s, 2H), 7.80 (d, 1 H, J = 6.8 Hz), 7.34 (d, 1 H, J = 6.4 Hz), 6.94 (dd, 1 H, J = 7.6, 7.6 Hz), 3.51 (t, 1H, J = 3.6 Hz), 3.09 (s, 2H).
MS calcd for (CMHOB SOJ): 313
MS (ESI, positive) found: (M +1): 314
MS (ESI, negative) found: (M-l): 312
Example 19: (R)-3-(5-amino-l,3,4-thiadiazole-2-carboxamido)-2-hvdroxv-3,4-dihvdro-2H- benzo[e1[l ,21oxaborinine-8-carboxylie acid (19)
Figure imgf000080_0002
19
[0265] Compound (19) was prepared following the procedure described in example 7 (steps 1-7) except replacing the ([l ,3,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 5- (tert-butoxycarbonylamino)- 1 ,3 ,4-thiadiazole-2-carboxylic acid.
[0266] 5-(tert-butoxycarbonylamino)-l,3,4-thiadiazole-2-carboxylic acid was prepared in accordance with the method described for preparing 5-(tert-butoxycarbonylamino)- 1 ,3 ,4-oxadiazole-2-carboxylic acid in PCX publication WO 2010/144338, which is incorporated by reference in its entirety.
H NMR (400 MHz, CD3OD) δ 7.78 (dd, 1 H, J = 0.8, 8.0 Hz), 7.32 (d, 1 H, J
(dd, 1 H, J = 8.0, 8.0 Hz), 3.43 (t, 1H, J = 3.6 Hz), 3.01 - 3.04 (m, 2H). MS calcd for (CnHnB AS): 334
MS (ESI, positive) found: (M +1): 335
MS (ESI, negative) found: (M-l): 333
Example 20: (R)-3-(5-amino-1.3,4-oxadiazole-2-carboxamido)-2-hvdroxv-3,4-dihvdro-2H- benzoiein .21oxaborinine-8-carboxvlic acid (20)
Figure imgf000081_0001
H
20
[§267] Compound (20) was prepared following the same procedure described in example 7 (steps 1-7) except replacing the ([ 1 ,3 ,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 5-(tert-butoxycarbonylamino)-l,3,4-oxadiazole-2-carboxylic acid in accordance with the method described in PCX Publication WO 2010/144338, which is incorporated by reference in its entirety,
H NMR (400 MHz, CD3OD) δ 7.81 (d, 1 H), 7.32 (d, 1 H), 6.95 (dd, 1 H), 3.44 (s, 1H), 3.03 (s, 2H).
MS calcd for
Figure imgf000081_0002
318
MS (ESI, negative) found: (M -1): 317
Example 21 : (R)-2-hvdroxv-3-(3-(methylamino)-3-oxopropanamido)-3,4-dihvdro-2H- benzo[elil ,21oxaborinine-8-carboxyli.c acid (21)
[0268] Compound (21) was prepared following the same procedure described in example 7 (steps 1-7) except replacing the ([ 1 ,3 ,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 3 -(methy lamin o)-3 -oxopropan oic acid.
Figure imgf000081_0003
H NMR (400 MHz, CD3OD) δ 7.82 (d, 1 H), 7.30 (d, 1H), 6.96 (dd, 1H), 3.30, (m, 1H), 3.27 (s, 2 I f ), 2.96 (s, 2H), 2.63 (s, 3H).
MS calcd for (Ci3H15BN206): 306 MS (ESI, positive) found: (M+l): 307
MS (ESI, negative) found: (M-l): 305
Example 22: (R)-3-(2-(azetidin-3-vlthio)acetamido)-2-hvdroxv-3,4-dihydro-2H- benzoielil .21oxaborinine-8-carboxvlic acid (22)
[0269] Compound 22 was prepared following the same procedure described in example 7 (steps 1-7) except replacing the ([ 1 ,3 ,4]Thiadiazol-2-ylsulfanyl)-acetic acid in step 6 with 2-({ l-[(tert-butoxy)carbonyl]azetidin-3-yl}sulfanyl)acetic acid.
Figure imgf000082_0001
22
H NMR (400 MHz, CD3OD) δ 7.84 (d, 1H), 7.34 (d, 1 H), 7.00 (dd, 1 H), 4.84 (m, 2H), 3.69 - 3.84 (in, 3H), 3.31 - 3.50 (m, 2H), 3.30 (HI, IH), 3.01 (m, 2H).
MS calcd for (C14H17BN205S): 336
MS (ESI, positive) found: (M+l): 337
MS (ESI, negative) found: (M-l): 335
General Procedure for Prodrug Formation:
[0270] To a solution of Compound 13 (0.5 mmol) in DMF (5 niL) was added a chloro or bromo substituted prodiug moiety (1 mmol), followed by K2Ci¾ (0.75 mmol). The resulting mixture was stirred at 50 °C for 18 hours and then brought to room temperature. After the mixture was concentrated, the residue was purified by prep- H P I. C (Cig, acetonitrile and water as mobile phases, 0, 1% formic acid) to obtain the titled compound. The following compounds were synthesized following this procedure.
Example 23: ( Vpivaloyloxymethyl 2-hvd.roxy-3-(2-(methylthio)acetamido)-3 ,4-dihydro-2H- benzo[e1[l ,21oxaborinine-8-carboxylate (23)
Figure imgf000082_0002
1H-NMR(400 MHz, CD3OD) δ 7.55 (d, IH), 7.21 (d, IH), 6.82 (t, IH), 5.93 (m, 2H), 3.17 (s, 2H), 2.80 - 3.18 (HI, 3H), 1.70 (s, 3H), 1.29 (d, 6H). MS calcd for (CigH24BN07S) 409
MS (ESI, negative) found: (M -1): 408
Example 24: (R)-(isopropoxycarbonyloxy)methyl 2-hydroxv-3-(2-(methylthio)acetamido)-3,4- dihydro-2H-benzo[el [ 1 ,21oxaborinine-8-carboxylate ( 24)
Figure imgf000083_0001
24
1H-NMR(400 MHz, CD3OD) δ 10.04 (bs, IH), 7.59 (d, IH), 7.22 (d, IH), 6.82 (t, IH), 5.92 (m, 2H), 3.30 (m, IH), 3.17 (s, 2H), 3.1 1 (m, IH), 2.82 - 2.89 (m, 2H), 1.69 (s, 3H), 1.21 (s, 9H). MS calcd for (Ci7H22BNOgS) 41 1
MS (ESI, negative) found: (M -1): 410
Example 25 : (RVbutyryloxymethyl 2-hydroxv-3-(2-(methylthio)acetamido)-3.4-dihvdro-2H- benzo[ein ,21oxaborinine-8-carboxylate (25)
Figure imgf000083_0002
25
1H-NMR(400 MHz, CD3OD) δ 10.05 (bs, IH), 7.57 (d, IH), 7.21 (d, IH), 6.81 (t, IH), 5.93 (m, 2H), 3.18 (s, 2H), 3.11 (m, IH), 2.75 - 2.95 (in, 2H), 2.37 (t, 2H), 1.62 - 1.70 (m, 5H), 0.90 (t, M l ).
MS calcd for (C17H22BNO7S) 395
MS (ESI, negative) found: (M -1): 394
Example 26: ( )-(2-ethylbutanoyloxy)methyl 2-hvdroxv-3-(2-(methvlt.hio)acet.amido)-3,4-
Figure imgf000084_0001
1H-NMR(400 MHz, CD3OD) δ 7.57 (d, 1H), 7.21 (d, 1H), 6.82 (t, 1H), 5.96 (s, 2H), 3.17 (s, 2H), 3.12 (s, 1H), 2.75 - 2.95 (m, 2H), 2.27 (m, 1H), 1.69 (s, 3H), 1.48 - 1.70 (m, 4H), 0.90 (t, 6H).
MS calcd for (Ci9H2fBN07S) 423
MS (ESI, negative) found: (M -1): 422
Example 27: (3R)- 1 -(ethoxvcarbonvloxv)ethyl 2-hvdroxv-3-(2-(methylthio)acetamido)-3,4- dihydro-2H-benzo[el [ 1 ,21oxaborinine-8-carboxylate ( 27)
Figure imgf000084_0002
27
1H-NMR(400 MHz, CD3OD) δ 10.03 (bs, 1H), 7.56 (d, 1H), 7.20 (d, 1H), 6.92, (m, 1H), 6.81 (t, 1H), 4.20 (q, 2H), 3.18 (s, 2H), 3.10 (s, 1H), 2.75 - 2.90 (m, 2H), 1.70 (s, 3H), 1.58 (d, 3H), 1.28 (t, 3H).
MS calcd for (Ci7H22BNOgS) 41 1
MS (ESI, negative) found: (M -1): 410
Example 28: Potentiation of Aztreonam
[0271] The potency and spectrum of β-lactamase inhibitors (BLIs) was determined by assessing their aztreonam potentiation activity in a dose titration potentiation assay using strains of various bacteria that are resistant to aztreonam due to expression of various β- lactamases. Aztreonam is a monobactam antibiotic and is hydrolyzed by the majority of beta- lactamases that belong to class A or C (but not class B or D), The potentiation effect was observed as the ability of BLI compounds to inhibit growth in the presence of sub-inhibitory concentration of aztreonam, MICs of test strains varied from 64 μg/mL to > 128 μg/mL, Aztreonam was present in the test medium at 4 μg/mL, Compounds were tested at concentrations up to 40 μg/mL. In this assay potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 4 μg/mL of aztreonam (MPC@4). Table 1 summarizes the BLI potency of aztreonam potentiation (MPC@4) for various strains overexpressing class A (ESBL and KPC), and class C beta- lactamases. Aztreonam MIC for each strain is also shown. The results were compared to comparative compounds A and B:
Figure imgf000085_0001
Compound A Compound B
TABLE t. Activity of BLIs to potentiate aztreonam against strains expressing class A and class C enzymes.
Figure imgf000086_0001
Example 29: Potentiation of Tigemonam
[§272] Selected β-lactamase inhibitors were also tested for their ability to potentiate the monobactam tigemonam. The potentiation effect is observed as the ability of BLI compounds to inhibit growth in the presence of sub-inhibitory concentration of tigemonam, MICs of test strains varied from 16 μg/mL to > 64 μg/lϊιL, Tigemonam was present in the test medium at 4 μg/mL, Compounds were tested at concentrations up to 40 μg/mL, In this assay potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 4 μg/mL of aztreonam (MPC@4). Table 2 summarizes the BLI potency of tigemonani potentiation (MPC@4) for various strains overexpressing class A (ESBL) and class C beta-lactamases. Tigemonani MIC for each strain is also shown. The results wrere compared to comparative compounds A and B:
Figure imgf000087_0001
Compound A Compound B
TABLE 2. Activity of BLIs to potentiate tigemonani against strains expressing class A and class C enzymes.
Figure imgf000087_0002
Example 30: Potentiation of Biapenem
[§273] β-lactamase inhibitors were also tested for their ability to potentiate the carbapenem biapenem against strains producing class A ( PC) and class D (OXA-48) carbapenemases. The potentiation effect is observed as the ability of BLI compounds to inhibit growth in the presence of a sub- inhibitory concentration of biapenem, Biapenem MIC of test strains were 16-32 μg/mL, Biapenem was present in the test medium at 1 μg/mL, Compounds were tested at concentrations up to 40 μg/mL, In this assay potency of compounds was reported as the minimum concentration of BLI required to inhibit growth of bacteria in the presence of 1 μg/mL of biapenem (MPC@i). Table 3 summarizes the BLI potency of biapenem potentiation (MPC@i) for two strains overexpressing class A (KPC) and class D (OXA-48) carbapenemases. Biapenem MIC for each strain is also shown. The results were compared to comparative compounds A and B:
Figure imgf000088_0001
Compound A Compound B TABLE 3. Activity of
BLIs to potentiate biapenem against strains expressing class A (KPC) or class D (OXA-48) carbapenemases.
Figure imgf000088_0002
Figure imgf000089_0001
Example 31 : Inhibitory Activity
[§274] i values of inhibition of purified class A, C and D enzymes were determined spectrophotometrically using nitrocefm as reporter substrate. Purified enzymes were mixed with various concentrations of inhibitors in reaction buffer and incubated for 10 min at room temperature. Nitrocefm was added and substrate cleavage profiles were recorded at 490 nm every 10 sec for 10 min. The results of these experiments are presented in Table 5. These experiments confirmed that the described compounds are inhibitors with a broad-spectrum of activity towards various β-lactamases. The results were compared to comparative compounds A and B:
Figure imgf000089_0002
Compound A Compound B
TABLE 4 Activity of BLIs (Ki, uM) to inhibit cleavage of nitrocefm by purified class A, C
and D enzymes
Figure imgf000089_0003
5 Y X X z X X X
6 Y Y z z z z Z
7 X X Y z X X Y
9 Y Y Y z Y Y Y
10 Y X Y z Y Y Y
11 Y X Y z X X X
12 X X Y Y X Y X
13 X Y Y z Y Y X
14 X X Y z Y Y Y
15 X X Y z Y Y X
16 Y X z z Y Y X
17 Y Y z z Y Y Y
18 Y X Y z Y Y Y
19 Y X Y z Y ND Y
20 Y Y Y z Y NF Y
21 Y X Y z Y ND X
22 Y X Y z Y ND Y
X = Less than 0.001 μ.Μ
Y = 0.001 μΜ to 0.01 μΜ
Z = Greater than 0.01 μΜ
Example 32: MexAB-OprM Dependent Efflux of BLIs
[0275] Efflux of BLIs from Pseudomonas aeruginosa by the MexAB-OprM efflux pump was also evaluated. The plasmid expressing the gene encoding KPC-2 was introduced into two strains of P. aeruginosa, PAMl 032 and PAMl 154 that overexpressed or lacked MexAB- OprM, respectively. Due to expression of KPC-2 both strains became resistant to biapenem, Biapenem is not affected by efflux in P. aeruginosa and both strains had the same biapenem MIC of 32 μg/ml, Potency of BLIs to potentiate biapenem in these strains was determined. Potency was defined as the ability of BLI to decrease MIC of biapenem 64-fold, from 32 μg/ml to 0.5 μg/ml, or MPC64. The ratio of MPC64 values for each BLI in PAM1032/KPC-2 (efflux proficient) and PAMl 154/KPC-2 (efflux deficient) was determined to generate the Efflux Index (EI). The results were compared to comparative compound A:
Figure imgf000090_0001
Compound A [0276] Table 5 shows MPCe4 and Els values for selected BLIs.
TABLE 5 MexAB-OprM Dependent Efflux of BLIs from P. aeruginosa
Figure imgf000091_0001
Example 33: Inhibition of Serine Proteases
[0277] The effect of selected BLIs on the enzymatic activity of some common mammalian serine proteases was evaluated. Serine proteases used in the studies are shown in Table 6. TABLE 6. List of Serine Proteases Used to Evaluate Selectivity of BLIs.
Figure imgf000092_0002
[0278) 50 μΐ of the diluted enzyme was mixed with 50 μΐ of inhibitor at various concentrations and 50 μΐ of corresponding buffer (Table 7). Reaction mixtures were incubated for 10 min at 37 °C. Subsequently, 50 μΐ of corresponding substrate (Table 7) was added and absorbance or fluorescence was monitored for 30 min on SpectraMax M2 plate reader (Molecular Devices). 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) and leupeptin were used as positive controls. Rates of reaction were calculated and presented relative to "no treatment" control. IC50 values were calculated based on inhibitor concentration producing 50% of enzyme inhibition. IC50 values for selected BLIs are shown in Tables 8A and 8B. The results were compared to comparative compounds A and B:
Figure imgf000092_0001
Compound A Compound B
TABLE 7. Enzyme substrates and buffers used in the study
Figure imgf000093_0001
TABLE 8A. ICS© values (in μ.Μ) for serine proteases inhibition by selected BLIs
Figure imgf000094_0001
TABLE 8B. IC50 values (in μ.Μ) for serine proteases inhibition by selected BLIs
Figure imgf000094_0002
Example 34: Serum Stability of Prodrugs
[0279] Prodrug strategy is one of the ways to achieve or increase oral bioavailability of therapeutic drags. Compound 13 was used as template a for various ester prodrugs. After a prodrug molecule is absorbed into systemic circulation, the prodrug molecule can be hydrolyzed in the blood to release the active form. The hydrolysis of several prodrugs by rat and human serum were evaluated. [0280] For all stability experiments the test compounds are treated with rat or human serum in Eppendorf tubes. One example of the testing procedures includes: 992 μΐ of serum was prewarmed at 37 °C for 2 minutes and then 8 μΐ of a compound (at 5 mg/ml, 125x) was added to get a final concentration of 40 μg/ml and immediately mixed. Alternatively, serum stability can be tested at 1 mg/ml. The tube was placed back in a 37 degree water bath and 100 μΐ-samples were taken at designated times and transferred directly into Eppendorf tubes containing 400 μΐ of precipitant solution (a 4,00 μg/mL solution of a standard compound (2-((3R,6S)-3- benzamido-2-hydroxy- 1 ,2-oxaborinan-6-yl)acetic acid) - in 10% water, 45% methanol and 45% acetonitrile). After vortexing for 30 seconds, the tube was centrifuged in a microcentrifuge for 10 minutes at 15 rpm. Next, 100 μΐ of the supernatant was combined with 600 μΐ of water and injected on LC-MS using 0.1% formic acid in water for mobile phase A and 0, 1% formic acid in methanol for mobile phase B on an ACE 5 CI 8 2.1x100mm column with a 10 μΐ. injection. The flow rate and gradient are adjusted as needed to give the desired resolution and ran time. The pH of the mobile phase is adjusted if needed to improve the chromatography,
[§281] The time course of both the disappearance of a prodrug and the appearance of the active form of that prodrug is presented in Table 9a and Table 9b.
TABLE 9a. The Time-course of hydrol sis of prodrugs by human serum
Figure imgf000095_0001
TABLE 9b. The Time-course of h dr ysis of rodru s b rat serum
Figure imgf000095_0002
NDT signifies below the quantifiable limit for this assay.
Example 35: Formation of Salts/Complexes of Boron ic Acid Derivatives to Maintain the Monomelic Form [0282] The compounds described herein were observed to form oligomers (such as dimers and trimers) in aqueous solution. The effect of additives that would form a salt or complex with the boronic acid derivatives was evaluated in order to identify those that would strongly favor the monomeric form at an acceptable pH for IV infusion (pH 4-8), A base or complexing agent was added to a dispersion of Compound 13 in water at the given concentration (Table 10), and the formed mixture was sonicated to provide a homogeneous solution. The pH of the resulting homogeneous solution was measured with a pH meter and the purity was monitored by HPLC.
[0283] Several bases and complexing agents were screened to identify those that would afford the highest monomer content as salt/complex with a desired pH, Oligomers were observed with one equivalent base or complexing agent, Oligomerization was more pronounced at higher concentrations with some bases and complexing agents. Among all the bases screened, the meglumine complex gave the highest percentage of monomeric form at the desired pH, A high percentage of monomeric form was observed at concentrations up to 50 mg/iiiL while the pH remained close to 7.
[0284] The results of salt/complex formation are shown in Table 10, When the concentration of Compound 13 was at 10 mg/m 1 and the pH of the solution is at 7.1, about 97.3% of the Compound 13 in the solution was in a monomeric form. When the concentration of Compound 13 was at 50 mg/m 1 and the pH of the solution is at 7.2, about 96,7% of the Compound 13 in the solution was in a monomeric form.
TABLE 10. List of Salt/Complexes of Compound 13 and their Solution pit and % Purity of Monomer.
Figure imgf000096_0001
Example 36. Intravenous Pharmacokinetics of Compounds [0285] Rats (11= 3 per compound) were administered by a single infusion. IV doses were infused over 0,5 hours via an indwelling femoral vein cannula. Plasma (~ 0,3 111L) samples were collected from each rat at designated time points up to 24 hours. Blood samples were centrifuged within 5 min of collection at 12000 g for 5 min to obtain plasma. The plasma samples were stored at -80°C until analyzed. Data were analyzed using WinNonlin.
TABLE 11. Intravenous Pharmacokinetics of select compounds
Figure imgf000097_0001
Example 37: Oral Pharmacokinetics of Pro-Drugs of Compound 13
[0286] Rats (11= 3 per compound) were administered a single oral dose. Oral doses were administered as a bolus. Plasma (~ 0.3 111L) samples were collected from each rat at designated time points up to 24 hours. Blood samples were centrifuged within 5 min of collection at 12000 g for 5 min to obtain plasma. The plasma samples were stored at -80°C until analyzed. Data were analyzed using WinNonlin,
TABLE 12. Bioavailability of Pro-Drugs of Compound 13
Figure imgf000097_0002

Claims

WHAT IS CLAIMED IS:
1. A compound having the structure of Formula (I) or Formula (1, 1):
Figure imgf000098_0001
or pharmaceutically acceptable salts thereof, wherein:
G is selected from the group consisting of -H, -N R R\ -CH2N3, -C(0)NR1R2, - CH2C(0)NR1R2, -CH2S(0)2NR1R2, -CH2-Y-Z, -CH2-Y-X, and -HIV:
Y is selected from a group consisting of -S-, -S(O)-, -S(0)2-, -0-, and -NR.1-;
R is selected from a group consisting of -H, -Ci-galkyl, -CR1R2OC(0)Ci-9alkyl,
CR1R2OC(0)OCi-9a
Figure imgf000098_0002
R1 and R are each independently selected from the group consisting of -H and - Ci-4alkyl;
R3 is -Ci-4alkyl;
R4 is present 1 to 3 times and each R4 is independently selected from the group consisting of -H, -Ci-4alkyl, -OH, -0-Ci-4alkyl, -S-Ci-4alkyl, halogen, and -CF3>
Z is selected from the group consisting of aryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen; heteroaryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen; and heterocycle optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen;
X is selected from the group consisting of
Figure imgf000098_0003
-CH2R5, -CH(R5)2, and -C(R5)3; and
R5 is selected from the group consisting of a halogen, cyano, and azido.
2, The compound of claim 1 having the structure of Formula (I):
Figure imgf000098_0004
or pharmaceutically acceptable salts thereof
3. The compound of claim 1 or 2, wherein:
each R4 is independently selected from the group consisting of -H, -Ci-4alkyl, - OH, -0-Ci-4alkyl, and halogen; and
Z is selected from the group consisting of aryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen and heteroaryl optionally substituted with Ci-4alkyl, amino, hydroxy, or halogen,
4, The compound of claim 1 or 2, having the structure of Formula (la) or Formula
Figure imgf000099_0001
or pharmaceutically acceptable salt thereof
5. The compound of any one of claims 1-4, wherein R is H,
6. The compound of any one of claims 1-4, wherein R is -CR1R2OC(0)Ci-9alkyl or
-CR1R2OC(0)OCi-9alkyl
7. The compound of claim 6, where R is -CR1R2OC(0)Ci-jalkyl or -CR1R2OC(0)OCi-5alkyl
8. The compound claim 6 or 7, wherein R in R is H and R in R is H or -CH3.
9. The compound of any one of claims 1-8, wherein R4 is selected from H, F, CI, -i l l ,,
Figure imgf000099_0002
10. The compound of any one of claims 1-9, wherein G is H,
1 1. The compound of any one of claims 1-9, wherein G is -M k
12. The compound of any one of claims 1-9, wherein G is -C(0)NR1R2 and R and R in G are each independently selected from -H and Ci-4alkyl.
13. The compound of claim 12, wherein R in G is -CH3 and R in G is -CJ¾,
14. The compound of any one of claims 1-9, wherein G is -CH2C(0)NR1R2 and R and R in G are each independently selected from -H and Ci-4alkyl.
15. The compound of claim 14, wherein R in G is -CH3 and R in G is H or -CH3,
16. The compound of claims 1-9, wherein:
G is -CH2_Y-Z;
Y is -S-; and Z is selected from the group consisting of imidazole, N-methylimidazole, aminoimidazole, triazole, N-methyltriazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, azitidine and piperdine.
17. The compound of claim 16, wherein Z is N-methyltetrazole.
18. The compound of claim 16, wherein Z is thiadiazole.
19. The compound of claim 16, wherein Z is aminothiadiazole.
20. The compound of claim 16, wherein Z is azitidine.
21. The compound of claims 1 -9, wherein G is -CH2-Y-X and Y is -S-.
22. The compound of claim 21 , wherein X is -CH3,
23. The compound of claim 21 , wherein X is -CH2CN.
24. The compound of claim 21 , wherein X is -CH2N3.
25. The compound of claim 21 , wherein X is -CH2F.
26. The compound of claim 21 , wherein X is -CHFo.
27. The compound of claim 21 , wherein X is -CF3.
28. The compound of claims 1 -9, wherein G is -SCH3,
29. The compound of claim 1 , having the structure selected from the group consisting
Figure imgf000100_0001
thereof. 30, The compound of claim 1 , having the structure selected from the group consisting
, or pharmaceutically acceptable salts
Figure imgf000101_0001
31. The compound of claim 1 , having the structure selected from the group consisting of
Figure imgf000101_0002
H
Figure imgf000101_0003
, or pharmaceutically acceptable salts thereof.
32, A compound having the structure of formula II or Formula II, 1 :
Figure imgf000101_0004
(II) ( H I )
or pharmaceutically acceptable salts thereof, wherein: elected from the group consisting of
Figure imgf000101_0005
Figure imgf000101_0006
Figure imgf000102_0001
The compound of Claim 32 having the structure of Formula (II)
Figure imgf000102_0002
(II)
or pharmaceutically acceptable salts thereof, wherein:
The compound of claim 32 or 33, wherein G is selected from the group consisting of
Figure imgf000102_0003
35. The compound of claim 32, having the structure of Formula Ila to Formula Ila. l
Figure imgf000102_0004
or pharmaceutically acceptable salts thereof.
36. The compound of any one of claims 32 to 35, having the structure selected from the group consisting of:
Figure imgf000102_0005
or pharmaceutically acceptable salts thereof.
37. The compound of any one of claims 32 to 35, having the structure selected from the group consisting of:
Figure imgf000103_0001
and or pharmaceutically acceptable salts thereof.
38, The compound of any one of claims 32 to 35, having the structure of
Figure imgf000103_0002
01- pharmaceutically acceptable salts thereof.
39. The compound of any one of claims 32 to 35, wherein G is selected from the group
consisting
Figure imgf000103_0003
40, A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 -39 and a pharmaceutically acceptable excipient,
41 , The pharmaceutical composition of claim 40, wherein the pharmaceutically acceptable excipient is a a monosaccharide or monosaccharide derivative.
42, The pharmaceutical composition of claim 41 , wherein the monosaccharide or monosaccharide derivative is meglumine.
43, The pharmaceutical composition of any one of claims 40 to 42, further comprising an additional medicament,
44, The composition of claim 43, wherein the additional medicament is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent,
45, The composition of claim 44, wherein the additional medicament is a β-lactam antibacterial agent,
46, The composition of claim 45, wherein the β-lactam antibacterial agent is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talaiiipicillin), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), SulbeiiiciUin, Benzylpenicillin (G), Clometocillin, Benzathine, benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin, (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (Dicloxacillin, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone,
Cefazafliir, Cefradine, Cefroxadiiie, Ceftezole, Cefaclor, Cefamaiidole, Cefmiiiox, Cefoiiicid, Ceforaiiide, Cefotiam, Cefprozil, Cefbuperazoiie, Cefuroxime, Cefuzoiiam, Cefoxitin, Cefotetaii, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmeiioxime, Cefodizime, Cefoperazoiie, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibiiten, Ceftiolene, Ceftizoxime, Flomoxef, Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, C'XA- 101 , R.WJ-54428, MC-04,546, ME 1036, Ceftiofur, Cefquinome, Cefovecin, R.WJ-442831 , RWJ-333441 , or R.WJ-333442.
47. The composition of claim 45, wherein the β-lactam antibacterial agent is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Paiiipenem,
48. The composition of claim 45, wherein the β-lactam antibacterial agent is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.
49. The composition of claim 45, wherein the β-lactam antibacterial agent is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof.
50. The composition of claim 49, wherein the penicillin is benzathine penicillin, beiizylpeiiicilliii, pheiioxymethylpeiiicilliii, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacillin, talapicillin, aspoxicillin, cloxacillin, nafcillin, pivampicillin, or a combination thereo
51. The composition of claim 49, wherein the cephalosporin is cephalothin, cephaloridin, cefaclor, cefadroxil, cefamaiidole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetril, cefotiam, cefotaxime, cefsulodin, cefoperazoiie, ceftizoxime, cefinenoxime, cefmetazole, cephaloglycin, cefoiiicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpiramide, cefbuperazoiie, cefozopran, cefepim, cefoselis, cefluprenam, cefuzoiiam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil, cefditoren pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, latamoxef, or a combination thereof.
52. The composition of claim 49, wherein the cephalosporin is an anti-MRSA cephalosporin.
53. The composition of claim 49, wherein the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
54. The composition of claim 49, wherein the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, panipenem, or a combination thereof.
55. The composition of claim 49, wherein the carbapenem is an anti-MRSA carbapenem,
56. The composition of claim 49, wherein the anti-MRSA carbapenem is PZ601 or ME 1036.
57. The composition of claim 49, wherein the monobactam is aztreonam, carumonam, BAL30072, or a combination thereof.
58. A method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof, a compound according to any one of claims 1 -39.
59. The method of claim 58, further comprising administering to the subject an additional medicament,
60. The method of claim 58 or 59, wherein the additional medicament is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent,
61. The method of claim 60, wherein the additional medicament is a β-lactam antibacterial agent,
62. The method of claim 61 , wherein the β-lactam antibacterial agent is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicilliii), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicilliii (G), Clometocillin, Benzathine, benzylpenicilliii, Procaine benzylpenicilliii, Azidocilliii, Penaiiiecilliii, Phenoxymethylpenicilli.il, (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticilliii, Cloxacillin (Dicloxacilliii, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, Razupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef,Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101 , RWJ- 54428, MC-04,546, ME 1036, Ceftiofur, Cefquinome, Cefovecin, R.WJ-442831, R.WJ-333441, or RWJ-333442.
63. The method of claim 61, wherein the β-lactam antibacterial agent is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Paiiipenem,
64. The method of claim 61, wherein the β-lactam antibacterial agent is selected from Aztreonam, Tigemonam, BAL30072, SYN 2416, or Carumonam.
65. The method of claim 61 , wherein the β-lactam antibacterial agent is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof.
66. The method of claim 65, wherein the penicillin is benzathine penicillin, benzylpenicillin, phenoxymethylpemcillin, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacillin, talapicillin, aspoxicillin, cloxacillin, nafcillin, pivampicillin, or a combination thereof.
67. The method of claim 65, wherein the cephalosporin is cephalothin, cephaloridin, cefaclor, cefadroxil, cefamaiidole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetril, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefiiienoxime, cefiiietazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpiramide, cefbuperazoiie, cefozopran, cefepim, cefoselis, cefluprenam, cefuzonam, cefpimizole, cefclidiii, cefixime, ceftibuteii, cefdiiiir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapeiie pivoxil, cefditoreii pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, latamoxef, or a combination thereof.
68. The method of claim 65, wherein the cephalosporin is an anti-MRSA cephalosporin,
69. The method of claim 65, wherein the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
70. The method of claim 65, wherein the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, paiiipenem, or a combination thereof.
71. The method of claim 65, wherein the carbapenem is an anti-MRSA carbapenem,
72. The method of claim 65, wherein the anti-MRSA carbapenem is PZ601 or ME 1036.
73. The method of claim 65, wherein the monobactam is aztreonam, carumonam, BAL30072, or a combination thereof.
74. The method of any one of claims 58 to 73, wherein the subject is a mammal,
75. The method of claim 74, wherein the mammal is a human,
76. The method of any one of claims 58 to 75, wherein the infection comprises a bacteria selected from Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Burkholderia cepacia, Aeromonas hydrophilia, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Bordetella pertussis, Bordetella para pertussis, Bordetella bronchiseptica, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Borrelia burgdorferi, Kingella, Gardnerella vaginalis, Bacteroides distasonis, Bacteroides 3452A homology group, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellular e, Mycobacterium leprae, Corynebacterium diphiheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.
77. The method of any one of claims 58 to 75, wherein the infection comprises a bacteria selected from Pseudomonas aeruginosa, Pseudomonas jluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella jlexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter caicoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainjluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, or Bacteroides splanchnicus.
78. A pharmaceutical composition, comprising:
a monosaccharide or monosaccharide derivative or monosaccharide derivative and
a compound of Formula III):
Figure imgf000107_0001
or pharmaceutically acceptable salts thereof, wherein:
A is selected from the group consisting of C5-1o carbocyclyl, Ce-ιο aryl, 5- 10 membered heteroaryl, and 5- 10 membered heterocyclyl;
Xa is -C(RgRh)-, -0-, -S-, -S(O)-, -S(0)2-, or -NR.1-;
Ra is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, -NR!R2, and
Figure imgf000108_0001
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2, -S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster;
Rb is selected from the group consisting of -H, halogen, optionally substituted -Q-6 alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, -NR!R2, and
Figure imgf000108_0002
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2, -S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster, and
Rc is selected from the group consisting of -OH, optionally substituted - O-Ci-6 alkyl
Figure imgf000108_0003
or Rb and Rc together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1- 3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen(N);
Rd is selected from the group consisting of hydrogen, -OH, optionally substituted -O-G-e alkyl
Figure imgf000108_0004
or
when Rb and Rc do not together form a 5-8 membered boron ester ring, then optionally Rc and Rd together with intervening atoms form a 5- 15 membered boron ester or amide ring, optionally comprising additional 1-3 heteroatoms selected from O, S, and N;
Re is independently selected from the group consisting of hydrogen, optionally substituted Ci-ealkyl, optionally substituted Cs^cycloalkyl, optionally substituted Ce-ioaryl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl, or Rd and Re together with the nitrogen to which they are attached form a 5-8 membered heterocyclic ring, optionally comprising additional 1-3 heteroatoms selected from O, S or N;
K is independently selected from the group consisting of -H, -OH, -C(0)G, -C(0)OG, -S(0)2G, -C(=NR1R2)G, -C(=NOR3)G, optionally substituted Ci-e alkyl, optionally substituted -O-Ci-ealkyl, optionally substituted C3-8 cycloalkyl, optionally substituted Ce-io aryl, optionally substituted 5- 10 membered heteroaiyl, and optionally substituted 3- 10 membered heterocyclyl;
Rs and R : are each independently selected from the group consisting of - H, Ci-6 alkyl, -OH, -OCi-ealkyl, -SCi-ealkyl, Cs-iocycloalkyl, C2-1oalkenyl, C2- loalkynyl, -NR1C(0)R5, -NR1S(0)2R3, -C(0)R5, -C(0)OR3-alkylaryl, optionally substituted Ce-ιο aryl, optionally substituted -O-Ce-ioaryl, -CN, optionally substituted 5-10 membered heteroaryi, optionally substituted -O-heteroaryl, optionally substituted 3-10 membered heterocyclyl, -S(0)(R3)R4, -S(0)2R3, K - O-COOR3, or Rg and Rh together with the carbon to which they are attached form a Cs-g cycloalkyl or a 4-8 membered heterocyclyl;
R is selected from the group consisting of -H, halogen, -Q^alkyl,
-CR5R6OC(0)Ci_9alkyl, -CR5R6OC(0)OCi_9alkyl, and
Figure imgf000109_0001
G is selected from the group consisting of hydrogen, N R R\ -CH2N3, - C(0)NR1R2, -CH2C(0)NR1R2, -CH2S(0)2NR1R2, -(CH2)n-Y-Z, -(CH2)n-Y-X, - 0-(CH2)B-C(0)NR1R2, -SR3, -CH2NR1C(0)R5, -C(=NOR3)-X, -C(=NOR3)-Z, - C(0)OR3, -C(0)-X, -C(0)-Z, -S(0)2R3, -C(0)NR1OR3, -NR^OR3), - NR1C(0)R3, -NR1C(0)NR2Rla, -NR1C(0)OR3, -NR1S(0)2R3, NR1S(0)2NR2Rla, -N R N R R -C(0)NR1NR2Rla, -S(0)2NR1NR2Rla, - C(=NR1)R5, -C(=NR1)NR2Rla, -NR1CR3(=NR2), and -NR1C(=NR2)NRlaR2a, optionally substituted C MO alkyl, optionally substituted C2-ioalkenyl, optionally substituted C2-ioalkynyl, optionally substituted C3-7 carbocyclyl, optionally substituted 5- 10 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5- 10 membered heteroaryi;
X is hydrogen or optionally substituted
Figure imgf000109_0002
Y is selected from a group consisting of -S-, -S(O)-, -S(0)2-, -CH2-, -0-, - O-CH2-, -C(O)-, and -NR.1-;
Z is selected from optionally substituted C3-8 cycloalkyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Ce-ιο aryl, optionally substituted 5- 10 membered heteroaryi;
each R1, R2, Rla and R2a are independently selected from the group consisting of -H, optionally substituted -Ci-ioalkyl, optionally substituted C2-ioalkenyl, optionally substituted C2-ioalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioatyl, and optionally substituted 5-10 membered heteroaryl;
R3 is hydrogen, optionally substituted Ci-ioalkyl, -optionally substituted Ci-ioalkyl-COOH, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioatyl, and optionally substituted 5-10 membered heteroaryl;
each R5 and R6 are independently selected from the group consisting of - H, -OH, -optionally substituted alkoxyl, optionally substituted -Ci-ioalkyl, optionally substituted C2-1oalkenyl, optionally substituted C2-1oalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5- 10 membered heteroaryl; R4 is present 1 to 5 times and each R4 is independently selected from the group consisitng of -H, -OH, halogen, -CF3, Ci-Ce alkenyl, Ci-Ce alkynyl, Ci-Ce heteroalkyl, C3-C7 carbocyclyl, 5- 10 membered heterocyclyl, aryl, 5- 10 membered heteroaryl, cyano, Ci-Ce alkoxy(Ci-C6)alkyl, aryloxy, sulfhydryl (mercapto), and -CH2)n,-Y'-(CH2)p.M';
m and p are independently 0 to 3;
Y' is selected from the group consisting of -S-, -S(O)-, -S(0)2-, -0-, CR5R6-, and -NR.1-;
M' is selected from the group consisting of -C(0)NR.1R2; -C(0)NR1OR3; -NR.1C(0)R5; -NR1C(0)NR.2Rla; -NR1C(0)OR3; -NR1S(0)2R3; NR1S(0)2NR2Rla; -C(=NR.1)R5; -C(=NR.1)NR2Rla; -NR1CR5(=NR.2); - NR.1C(=NR2)NRlaR2a; C alkyl optionally substituted with 0-2 substitueiits selected from the group consisting, -OR3, -N R R\ halogen, -C(0)NR1R2, and - NR.1C(0)R.5; C3-10 cycloalkyl optionally substituted with 0-2 substitueiits selected from the group consisting of CM alkyl, -OR3, -NR R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; Ce-io aryl optionally substituted with 0-2 substitueiits selected from the group consisting of C1 -4 alkyl, -OR3, -NR R\ halogen, -C(0)NR.1R2, and -NR1C(0)R5; 5 to 1.0 membered heteroaryl optionally substituted with 0-2 substitueiits selected from the group consisting of C M alkyl, -OR3, -NR R\ halogen, -C(0)NR1R2, and -NR1C(0)R.5; and 4 to 1.0 membered heterocyclyl optionally substituted with 0-2 substitueiits selected from the group consisting of Ci-4 alkyl, -OR1, -NR R\ halogen, -C(0)NR1R2, and -NR1C(0)R5; and
each 11 is independently 0-3.
79. The composition of claim 78, wherein A is selected from the group consisting of phenyl, biphenyl, naphthalenyl, phenanthrenyl, aiithraceiiyl, tetraliiiyl, fluoreiiyl, indenyl, indaiiyl, pyridyl, pyrrolyl, oxazolyl, indolyl and thienyl.
80. The composition of claim 78 or 79, wherein the compound of formula (III) has the structure of Formula (Ilia):
Figure imgf000111_0001
(Ilia)
or pharmaceutically acceptable salts thereof, wherein J, L, and M are independently selected from the group consisting of CR4 and N.
81. The composition of any one of claims 78 to 80, wherein Rb is-OH or optionally substituted -OCi-ealkyl,
82. The composition of any one of claims 78 to 81 , wherein Rc is -OH or optionally substituted -OCi-ealkyl,
83. The composition of any one of claims 78 to 82, wherein Rc is -OH and R is -OH,
84. The composition of any one of claims 78 to 80, wherein Rb and Rc together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1-3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen(N).
85. The composition of claim 84, wherein the compound of formula (III) has the structure of Formula (Illb):
Figure imgf000111_0002
(nib)
or pharmaceutically acceptable salts thereof, wherein J, L, and M are independently selected from the group consisting of CR4 and N.
86. The composition of claim 85, wherein the compound of formula (III) has the structure of Formula (IIIc): O
G -C
I
H
(IIIc)
or pharmaceutically acceptable salts thereof.
87. The composition of any one of claims 78 to 86, wherein K ' is C(0)OR and R is -0(CH2)nOC(0)-Ci_9 alkyl.
88. The composition of claim 87, wherein R is -0CH20C(0)-C(CH3)3, -OCH2OC(0)- CH(CH3)2, or -0CH20C(0)-(CH2)nCH3.
89. The composition of any one of claims 78 to 86, wherein Ra is C(0)OH.
90. The composition of any one of claims 78 to 82 and 84 to 89, wherein Rd is selected from hydrogen, -OH, halogen, -COOR, optionally substituted -O-Q-6 alkyl, -NR!R2, and - N(OR3)R!.
91. The composition of any one of claims 78 to 82 and 84 to 90, wherein R is -OH or optionally substituted -O-Q-6 alkyl.
92. The composition of claim 91 , wherein Rd is -OH,
93. The composition of any one of claims 78 to 92, wherein Re is independently selected from the group consisting of hydrogen, optionally substituted Ci-ealkyl, optionally substituted C3-7cycloalkyl, optionally substituted Ce-ioaryl, optionally substituted 5-10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl.
94. The composition of any one of claims 78 to 93, wherein Rf is independently selected from the group consisting of -C(0)G, -C(0)OG, and -S(0)2G.
95. The composition of any one of claims 78 to 94, wherein Rf is independently selected from-C(0)G or -C(0)OG.
96. The
consisting of
Figure imgf000112_0001
Figure imgf000112_0002
97. The composition of any one of claims 78 to 95, wherein G is -NH2.
98. The composition of any one of claims 78 to 95, wherein G is
Figure imgf000112_0003
-I l l-
99. The composition of any one of claims 78 to 95, wherein G is -C(0)NR1R2 and R and R in G are each independently selected from -H and Ci-4alkyl.
100. The composition of any one of claims 78 to 95, wherein G is -CH2C(0)NR1R2 and R and R in G are each independently selected from -H and Ci-4alkyl.
101. The composition of any one of claims 78 to 95, wherein
G is -0-(CH2)n-C(0)NR1R2;
n in G is 0-3; and
R1 and R2 in G are each independently selected from -H and Ci-4alkyl.
102. The composition of claim 101 , wherein G is -0-CH2-C(0)NH2.
103. The composition of any one of claims 78 to 95, wherein
G is - (CH2)n_Y-Z;
n in G is 0-3,
Y is -S-; and
Z is selected from the group consisting of imidazole, N-methylimidazole, aiiiinoimidazole, triazole, N-methyl triazole, aminotriazole, tetrazole, N-methyltetrazole, aminotetrazole, thiazole, aminothiazole, thiadiazole, aminothiadiazole, oxazole, oxadiazole, pyridine, pyridaziiie, pyrimidiiie, pyraziiie, azetidine and piperdine, each optionally substituted with one or more
Figure imgf000113_0001
hydroxy, or halogen.
104. The composition of claim 103, wherein n in G is 0,
105. The composition of claim 103, wherein n in G is 1.
106. The composition of claim 103, wherein Z is thiadiazole optionally substituted with one or more Ci-4alkyl, N R R\ hydroxy, or halogen.
107. The composition of claim 103, wherein Z is aminothiadiazole optionally substituted with one or more Ci-4alkyl, N R R\ hydroxy, or halogen.
108. The composition of claim 103, wherein Z is azitidine optionally substituted with one or more Ci-4alkyl, N R R\ hydroxy, or halogen.
109. The composition of any one of claims 78 to 95, wherein
G is -(CH2)n-Y-X;
n in G is 0-3;
Y is -S-; and
X is hydrogen or optionally Ci-4alkyl.
1 10. The composition of claim 109, wherein n in G is 0,
1 11. The composition of claim 109, wherein n in G is 1.
1 12. The composition of claim 109, wherein X is -CH3.
1 13. The composition of claim 109, wherein X is -CI¾CN.
1 14. The composition of claim 109, wherein X is -CH2N3.
1 15. The composition of claim 109, wherein X is -CH2F.
1 16. The composition of claim 109, wherein X is -CHF2.
1 17. The composition of claim 109, wherein X is -CF3.
1 18. The composition of any one of Clams 78 to 95, wherein
G is -(CH2)n_Y-Z;
n in G is 0-3,
Y is -CH2-, -0-, -0-C¾-, -C(O)-; and
Z is selected from the group consisting of phenyl, napthal, indole, pyrrolidine, thiophene, cyclopropyl, or cycloliexyl, each optionally substituted with one or more Ci- 4alkyl, N R R\ hydroxy, or halogen.
1 19. The composition of claim 1 18, wherein n in G is 1.
120. The composition of claim 1 18, wherein n in G is 2,
s selected from
Figure imgf000114_0001
The composition of any one of claims 78 to 95, wherein
G is -(CH2)n-Y-X;
n in G is 0-3;
Figure imgf000114_0002
X is Ci-4alkyl optionally substituted with one or more halogen, cyano, or azido.
123. The composition of claim 122, wherein n in G is 0 and Y is -0-,
124. The composition of claim 122, wherein n in G is 1.
125. The composition of claim 122, wherein n in G is 2,
126. The composition of claim 122, wherein X is optionally substituted Ci-4alkyl.
127. The composition of claim 78, wherein the compound of formula (III) has the structure selected from the group consisting of
Figure imgf000114_0003
Figure imgf000115_0001
Figure imgf000115_0002
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
-119-
Figure imgf000121_0001
pharmaceutically acceptable salts thereof.
128. The composition of claim 78, wherein the compound of formula (III) has the structure selected from the group consisting of
Figure imgf000121_0002
Figure imgf000122_0001
Figure imgf000122_0002
-121-
Figure imgf000123_0001
Figure imgf000123_0002
-122-
Figure imgf000124_0001
or pharmaceutically acceptable salts thereof.
129. The composition of any one of claims 78 to 128, wherein the monosaccharide or monosaccharide derivative is meglumine.
130. The composition of any one of claims 78 to 128, wherein the pH of the composition is in the range of about 5 to about 9.
131. The composition of any one of claims 78 to 128, wherein the pH of the composition is in the range of about 6 to about 8.
132. The composition of any one of claims 78 to 128, wherein the pH of the composition is in the range of about 6 to about 7.5.
133. The composition of any one of claims 78 to 128, wherein the pH of the composition is in the range of about 7.1 to about 7.3.
134. The composition of any one of claims 78 to 128, wherein the pH of the composition is about 7.2,
135. The composition of any one of claims 78 to 134, further comprising an additional pharmaceutically acceptable carrier or excipient,
136. The composition of any one of claims 78 to 135, further comprising one or more additional medicament,
137. The composition of claim 136, the additional medicament is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent,
138. The composition of claim 137, wherein the additional medicament is a β-lactam antibacterial agent,
139. The composition of claim 138, wherein the β-lactam antibacterial agent is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicilliii), Epicillin, Carbenicillin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Benzylpenicillin (G), Clometocillin, Benzathine, benzylpenicillin, Procaine benzylpenicillin, Azidocillin, Penamecillin, Phenoxymethylpenicillin, (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (Dicloxacillin, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, azupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradiiie, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefmiiiox, Cefonicid, Ceforani.de, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef,Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101 , R.WJ- 54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, R.WJ-333441, or RWJ-333442.
140. The composition of claim 138, wherein the β-lactam antibacterial agent is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem,
141. The composition of claim 138, wherein the β-lactam antibacterial agent is selected from Aztreonam, Tigemonam, BAL30072, SY K 2416, or Carumonam.
142. The composition of claim 138, wherein the β-lactam antibacterial agent is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof, wherein the penicillin is benzathine penicillin, benzylpenicillin, phenoxymethylpenicillin, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacillin, talapicillin, aspoxicillin, cloxacillin, nafcillin, pivampicillin, or a combination thereof.
143. The composition of claim 142, wherein the cephalosporin is cephalothin, cephaloridin, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetril, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefinenoxime, cefinetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpiramide, cefbuperazone, cefozopran, cefepim, cefoselis, cefJuprenam, cefuzonam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil, cefditoren pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, latamoxef, or a combination thereof.
144. The composition of claim 142, wherein the cephalosporin is an anti-MRSA cephalosporin.
145. The composition of claim 144, wherein the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
146. The composition of claim 142, wherein the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, panipenem, or a combination thereof.
147. The composition of claim 146, wherein the carbapenem is an anti-MRSA carbapenem,
148. The composition of claim 147, wherein the anti-MRSA carbapenem is PZ601 or ME 1036.
149. The composition of claim 142, wherein the monobactam is aztreonam, carumonam, BAL30072, or a combination thereof.
150. A method of treating or preventing a bacterial infection, comprising administering to a subject in need thereof, a composition according to any one of claims 78 - 149.
151. The method of claim 150, further comprising administering to the subject an additional medicament,
152. The method of claim 150 or 151 , wherein the additional medicament is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an anti-allergic agent,
153. The method of claim 152, wherein the additional medicament is a β-lactam antibacterial agent,
154. The method of claim 1 3, wherein the β-lactam antibacterial agent is selected from Amoxicillin, Ampicillin (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin), Epicillin, CarbeniciUin (Carindacillin), Ticarcillin, Temocillin, Azlocillin, Piperacillin, Mezlocillin, Mecillinam (Pivmecillinam), Sulbenicillin, Beiizylpenicillin (G), Clometocillin, Benzathine, beiizylpenicillin, Procaine beiizylpenicillin, Azidocillin, Penaniecillin, Phenoxymethylpenicillin, (V), Propicillin, Benzathine phenoxymethylpenicillin, Pheneticillin, Cloxacillin (Dicloxacillin, Flucloxacillin), Oxacillin, Meticillin, Nafcillin, Faropenem, Tomopenem, azupenem, Cefazolin, Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole, Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforani.de, Cefotiam, Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cefoxitin, Cefotetan, Cefmetazole, Loracarbef, Cefixime, Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefbimizole, Cefpiraiiiide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene, Ceftizoxime, Flomoxef,Latamoxef, Cefepime, Cefozopran, Cefpirome, Cefquinome, Ceftobiprole, Ceftaroline, CXA-101 , RWJ- 54428, MC-04,546, ME1036, Ceftiofur, Cefquinome, Cefovecin, RWJ-442831, R.WJ-333441, or RWJ-333442.
1.55. The method of claim 153, wherein the β-lactam antibacterial agent is selected from Ceftazidime, Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, or Panipenem,
156. The method of claim 153, wherein the β-lactam antibacterial agent is selected from Aztreonam, Tigemonam, BAL30072, SY K 241.6, or Carumonam,
157. The method of claim 153, wherein the β-lactam antibacterial agent is a penicillin, cephalosporin, carbapenem, monobactam, bridged monobactam, or combination thereof.
158. The method of claim 157, wherein the penicillin is benzathine penicillin, benzylpenicillin, phenoxymethylpenicillin, procaine, penicillin, oxacillin, methicillin, dicloxacillin, flucloxacillin, temocillin, amoxicillin, ampicillin, co-amoxiclav, azlocillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, apalcillin, hetacillin, bacampicillin, sulbenicillin, mecicilam, pevmecillinam, ciclacillin, talapicillin, aspoxicillin, cloxacillin, nafcillin, pivampicillin, or a combination thereof.
159. The method of claim 157, wherein the cephalosporin is cephalothin, cephaloridin, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetril, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefinenoxime, cefinetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceftriaxone, cefpiramide, cefbuperazone, cefozopran, cefepim, cefoselis, cefluprenam, cefuzonam, cefpimizole, cefclidiii, cefixime, ceftibuteii, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil, cefditoreii pivoxil, cefiiroxime, cefuroxime axetil, loracarbacef, latamoxef, or a combination thereof.
160. The method of claim 157, wherein the cephalosporin is an anti-MRSA cephalosporin.
161. The method of claim 160, wherein the anti-MRSA cephalosporin is cefiobiprole, cefiaroline, or a combination thereof.
162. The method of claim 157, wherein the carbapenem is imipenem, meropenem, ertapenem, faropenem, doripenem, biapenem, panipenem, or a combination thereof.
163. The method of claim 157, wherein the carbapenem is an anti-MRSA carbapenem,
164. The method of claim 163, wherein the anti-MRSA carbapenem is PZ601 or ME 1036.
165. The method of claim 157, wherein the monobactam is aztreonam, carumonam, BAL30072, or a combination thereof.
166. The method of any one of claims 150 to 165, wherein the subject is a mammal,
167. The method of claim 166, wherein the mammal is a human,
168. The method of any one of claims 150 to 167, wherein the infection comprises a bacteria selected from Pseudomonas acidovorans, Pseudomonas alcaUgenes, Pseudomonas putida, Burkholderia cepacia, Aeromonas hydrophilia, Francisella tularensis, Morganella morganii, Proteus mirahilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetohacter haumannii, Bordetella pertussis, Bordetella para pertussis, Bordetella bronchiseptica, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Borrelia burgdorferi, Kingella, Gardnerella vaginalis, Bacteroides distasonis, Bacteroides 3452A homology group, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellular e, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophytics, Staphylococcus intermedins, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.
169. The method of any one of claims 150 to 167, wherein the infection comprises a bacteria selected from Pseudomonas aeruginosa, Pseudomonas jluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enieritidis, Shigella dysenieriae, Shigella jlexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter caicoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainjluenzae, Haemophilus haemolyticus, Haemophilus parahaemofyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemofyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, or Bacteroides splanchnicus.
170, A chemical complex, comprising a complex between a monosaccharide or monosaccharide derivative and a com ound having the structure of formula (III):
Figure imgf000129_0001
(III)
or pharmaceutically acceptable salts thereof, wherein:
A is selected from the group consisting of C5-1o carbocyclyl, Ce-io aryl, 5- 10 membered heteroaryl, and 5-10 membered heterocyclyl;
Xa is -C(RgRh)-, -0-, -S-. -S(O)-, -S(0)2-, or -NR.1-;
R ' is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R
Figure imgf000130_0001
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2,
-S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster;
Rb is selected from the group consisting of -H, halogen, optionally substituted -C alkyl, -OH, -C(0)OR, optionally substituted -O-Ci-e alkyl, N R
Figure imgf000130_0002
optionally substituted -S-C1-6 alkyl, -C(0)NR1R2, -S(0)2NR1R2, -CN, optionally substituted -S(0)-C1-6 alkyl, optionally substituted -S(0)2-Ci-6 alkyl, and a carboxylic acid isoster, and
Rc is selected from the group consisting of -OH, optionally substituted - O-Ci-6 alkyl -NR'R2, and
Figure imgf000130_0003
or Rb and Rc together with intervening atoms form a 5-8 membered boron ester ring, optionally comprising additional 1- 3 heteroatoms selected from Oxygen (O), Sulfur(S) or Nitrogen(N);
Rd is selected from the group consisting of hydrogen, -OH, optionally substituted -O-G-e alkyl
Figure imgf000130_0004
or
when Rb and Rc do not together form a 5-8 membered boron ester ring, then optionally Rc and Rd together with intervening atoms form a 5- 15 membered boron ester or amide ring, optionally comprising additional 1-3 heteroatoms selected from O, S, and N;
Re is independently selected from the group consisting of hydrogen, optionally substituted G-ealkyl, optionally substituted C3-7cycloalkyl, optionally substituted Ce-ioatyl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl, or Rd and Re together with the nitrogen to which they are attached form a 5-8 membered heterocyclic ring, optionally comprising additional 1-3 heteroatoms selected from O, S or N;
R is independently selected from the group consisting of -H, -OH, -C(0)G, -C(0)OG, -S(0)2G, -C(=NR1R2)G, -C(=NOR3)G, optionally substituted Q-6 alkyl, optionally substituted -O-Ci-ealkyl, optionally substituted C3-8 cycloalkyl, optionally substituted Ce-ιο aryl, optionally substituted 5- 10 membered heteroaryl, and optionally substituted 3- 10 membered heterocyclyl;
Rs and Rh are each independently selected from the group consisitng of - H, Ci-6 alkyl, -OH, -OCi-ealkyl, -SCi-ealkyl, Cs-iocycloalkyl, C2-ioalkenyl, C2- loalkynyl, -NR1C(0)R5, - R' SCO^R3, -C(0)R5, -C(0)OR3-alkylaryl, optionally substituted Ce-ιο aryl, optionally substituted -O-Ce-ioaryl, -CN, optionally substituted 5-10 membered heteroaryl, optionally substituted -0-heteroaryl, optionally substituted 3 0 membered heterocyclyl, -S(0)(R3)R4' -S(0)2R3, R -
O-COOR3, or Rg and Rh together with the carbon to which they are attached form a C3-8 cycloalkyl or a 4-8 membered heterocyclyl;
R is selected from the group consisting of -H, halogen, -Q^alkyl,
-CR5R6OC(0)Ci_9alkyl, -CR5R6OC(0)OCi_9alkyl, and
Figure imgf000131_0001
G is selected from the group consisting of hydrogen, N R R\ -CH2N3, - C(0)NR1R2, -CH2C(0)NR1R2, -CH2S(0)2NR1R2, -(CH2)n-Y-Z, -(CH2)n-Y-X, - 0-(CH2)n-C(0)NR1R2, SR \ -CH2NR1C(0)R5, -C(=NOR3)-X, -C(=NOR3)-Z, - C(0)OR3, -C(0)-X, -C(0)-Z, -S(0)2R3, -C(0)NR1OR3, -NR^OR3), -NR1C(0)R3, -NR1C(0)NR2Rla, -NR1C(0)OR3, -NR1S(0)2R3, -NR1S(0)2NR2Rla, - N R N R R ; , -C(0)NR1NR2Rla, -S(0)2NR1NR2Rla, -C(=NR1)R5, C(=NR1)NR2Rla, -NR1CR3(=NR2), and -NR1C(=NR2)NRlaR2a, optionally substituted C MO alkyl, optionally substituted C2-ioalkenyl, optionally substituted C2-ioalkynyl, optionally substituted C3-7 carbocyclyl, optionally substituted 5- 10 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
X is hydrogen or optionally substituted
Figure imgf000131_0002
Y is selected from a group consisting of -S-, -S(O)-, -S(0)2-, -CH2-, -0-, - 0-CH2-, -C(O)-, and -NR.1-;
Z is selected from optionally substituted C3-8 cycloalkyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Ce-ιο aryl, optionally substituted 5- 10 membered heteroaryl;
each R1, R2, Rla and R2a are independently selected from the group consisting of -H, optionally substituted -Ci-ioalkyl, optionally substituted C2-ioalkenyl, optionally substituted C2_ioalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl;
R3 is hydrogen, optionally substituted Ci-ioalkyl, -optionally substituted Ci-ioalkyl-COOH, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioaryl, and optionally substituted 5-10 membered heteroaryl; each R5 and R6 are independently selected from the group consisting of - H, -OH, -optionally substituted alkoxyl, optionally substituted -Ci-ioalkyl, optionally substituted C2-1oalkenyl, optionally substituted C2-1oalkynyl, optionally substituted C3-7 cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted Ce-ioatyl, and optionally substituted 5-10 membered heteroaryl;
R4 is present 1 to 5 times and each R4 is independently selected from the group consisitng of -H, -OH, halogen, -CF3, Q-Ce alkenyl, Ci-Ce alkynyl, Ci-Ce heteroalkyl, C3-C7 carbocyclyl, 5-10 membered heterocyclyl, aryl, 5-10 membered heteroaryl, cyano, Ci-Ce alkoxy(Ci-C6)alkyl, aryloxy, sulfhydryl (mercapto), and -(CH2)M-Y' -(CH2)PM' ;
m and p are independently 0 to 3;
Y' is selected from the group consisting of -S-, -S(O)-, -S(0)2-, -0-, CR5R6-, and -NR.1-;
M' is selected from the group consisting of -C(0)NR.1R2; -C(0)NR1OR3; -NR.1C(0)R5; -NR1C(0)NR.2Rla; -NR.1C(0)OR3; -NR.1S(0)2R3; NR.1S(0)2NR2Rla; -C(=NR.1)R5; -C(=NR.1)NR.2Rla; -NR.1CR5(=NR.2); - NR.1C(=NR.2)NR.laR.2a; CM alkyl optionally substituted with 0-2 substitueiits selected from the group consisting, -OR3, -N R R\ halogen, -C(0)NR1R2, and - NR.1C(0)R5; C3-10 cycloalkyl optionally substituted with 0-2 substitueiits selected from the group consisting of CM alkyl, -OR3, -N R R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; Cs-10 aryl optionally substituted with 0-2 substitueiits selected from the group consisting of C alkyl, -OR3, -NR R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; 5 to 10 membered heteroaryl optionally substituted with 0-2 substitueiits selected from the group consisting of CM alkyl, -OR3, -N R R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R.5; and 4 to 1.0 membered heterocyclyl optionally substituted with 0-2 substitueiits selected from the group consisting of CM alkyl, -OR1, -NR R\ halogen, -C(0)NR.1R2, and -NR.1C(0)R5; and
each 11 is independently 0-3.
171. The chemical complex of claim 1.70, wherein the monosaccharide or monosaccharide derivative is meglumine.
PCT/US2014/010106 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof WO2014107535A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201480003981.3A CN104994844A (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof
MX2015008628A MX2015008628A (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof.
AU2014204045A AU2014204045B2 (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof
CA2894891A CA2894891A1 (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof
KR1020157021053A KR20150103269A (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof
BR112015016001A BR112015016001A2 (en) 2013-01-04 2014-01-02 compounds, pharmaceutical compositions and their uses and method for treating or preventing bacterial infection
JP2015551761A JP2016509594A (en) 2013-01-04 2014-01-02 Boronic acid derivatives and their therapeutic use
EP14735173.8A EP2941246A4 (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof
EA201591003A EA201591003A1 (en) 2013-01-04 2014-01-02 DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749210P 2013-01-04 2013-01-04
US61/749,210 2013-01-04
US201361780828P 2013-03-13 2013-03-13
US61/780,828 2013-03-13

Publications (1)

Publication Number Publication Date
WO2014107535A1 true WO2014107535A1 (en) 2014-07-10

Family

ID=51061421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/010106 WO2014107535A1 (en) 2013-01-04 2014-01-02 Boronic acid derivatives and therapeutic uses thereof

Country Status (12)

Country Link
US (1) US9642869B2 (en)
EP (1) EP2941246A4 (en)
JP (1) JP2016509594A (en)
KR (1) KR20150103269A (en)
CN (1) CN104994844A (en)
AU (1) AU2014204045B2 (en)
BR (1) BR112015016001A2 (en)
CA (1) CA2894891A1 (en)
EA (1) EA201591003A1 (en)
MX (1) MX2015008628A (en)
TW (1) TW201431866A (en)
WO (1) WO2014107535A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912169B2 (en) 2012-12-07 2014-12-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015179308A1 (en) * 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016165019A1 (en) * 2015-04-14 2016-10-20 B-Organic Films Corp. Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9637504B2 (en) 2014-06-11 2017-05-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9694025B2 (en) 2010-08-10 2017-07-04 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN108472284A (en) * 2015-09-11 2018-08-31 维纳拓尔斯制药公司 Beta-lactamase inhibitor
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US10464952B2 (en) 2015-12-10 2019-11-05 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10618918B2 (en) 2015-03-17 2020-04-14 Qpex Biopharma, Inc. Substituted boronic acids as antimicrobials
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR20210005910A (en) 2018-04-27 2021-01-15 다이니뽄 스미토모 세이야쿠 가부시키가이샤 Oxo-substituted compounds
EP3630782A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN113150022A (en) * 2021-04-23 2021-07-23 四川大学 3-substituted five-membered cyclic borate derivative, and pharmaceutical composition and pharmaceutical application thereof
US11091505B2 (en) 2017-03-06 2021-08-17 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US11352373B2 (en) * 2017-02-01 2022-06-07 Melinta Subsidiary Corp. Apparatus and continuous flow process for production of boronic acid derivative
KR20220088736A (en) 2019-10-25 2022-06-28 스미토모 파마 가부시키가이샤 Novel substituted condensed cyclic compound
EP3886798A4 (en) * 2018-11-29 2022-08-03 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013074615A1 (en) 2011-11-14 2013-05-23 Yale University Compositions and methods for modulating coagulation
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104981239B (en) 2013-01-04 2019-01-04 莱姆派克斯制药公司 Boronic acid derivatives and its therapeutical uses
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105801610B (en) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 New-type wide-spectrum beta-lactamase inhibitor
WO2017190043A1 (en) * 2016-04-29 2017-11-02 University Of Kansas Cephalosporin-type compounds

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005297A1 (en) 1986-03-03 1987-09-11 The University Of Chicago Cephalosporin derivatives
WO2004058679A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2009046098A1 (en) 2007-10-03 2009-04-09 Smithkline Beecham Corporation Novel cyclic boronate inhibitors of hcv replication
WO2009064414A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2009117540A1 (en) 2008-03-19 2009-09-24 Bristol-Myers Squibb Company Bridged heterocycles as hiv integrase inhibitors
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2010130708A1 (en) 2009-05-12 2010-11-18 Novartis International Pharmaceutical Ltd. Beta-lactamase inhibitors
WO2010144338A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
WO2013092979A1 (en) * 2011-12-22 2013-06-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
FR2574070B1 (en) 1984-11-30 1987-02-27 Stam CATALYST FOR TAKING LAUNCHED ANHYDRITE MORTARS WITH IMPROVED RESISTANCE TO HIGH TEMPERATURE AND HUMIDITY STORAGE, AND USE OF SUCH A CATALYST
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
JP2002504122A (en) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー Beta-lactamase inhibitors and methods of use
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO2000035904A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
HUP0202787A3 (en) 1999-09-25 2003-12-29 Smithkline Beecham Plc Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
AU762935B2 (en) 1999-10-28 2003-07-10 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
DK1322648T3 (en) 2000-09-14 2005-10-31 Pantherix Ltd 3- (heteroarylacetamido) -2-oxo-azetidine-1-sulfonic acid derivatives as antibacterial agents
US6586615B1 (en) 2001-01-10 2003-07-01 Bristol-Myers Squibb Company α-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (en) 2001-04-17 2002-11-07 Jerini Ag Immobilization method and arrangement of connections produced therewith on a planar surface
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
JP2003229277A (en) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd Material for light emitting element, light emitting element and light emitting device using the same
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
WO2004039859A1 (en) 2002-10-30 2004-05-13 Sumitomo Chemical Company, Limited High-molecular compounds and polymerer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (en) 2003-03-25 2009-03-04 三井化学株式会社 Azadiol complex compound and optical recording medium using the compound
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
CA2541832C (en) 2003-10-10 2009-11-24 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
JP4713574B2 (en) 2005-02-22 2011-06-29 テバ ファーマシューティカル インダストリーズ リミティド Rosuvastatin free from rosuvastatin alkyl ether and salts thereof and method for producing them
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
RS52068B (en) 2005-12-07 2012-06-30 Basilea Pharmaceutica Ag. Useful monobactam antibiotics
EP1988779B1 (en) 2006-02-16 2015-06-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
MX2009009918A (en) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections.
DK2231667T3 (en) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase INHIBITORS
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110124634A1 (en) 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
JP2013500974A (en) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド Trisubstituted boron-containing molecules
CA2828114A1 (en) 2010-02-26 2011-09-01 Gary Igor DMITRIENKO Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
EP3666778B1 (en) 2010-08-10 2021-11-10 Melinta Therapeutics, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2568680T3 (en) 2010-10-26 2016-05-03 Mars, Incorporated Borates as arginase inhibitors
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
WO2013104897A1 (en) 2012-01-09 2013-07-18 University of Tromsø Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2928898B1 (en) * 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (en) 2013-01-04 2019-01-04 莱姆派克斯制药公司 Boronic acid derivatives and its therapeutical uses
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (en) * 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) * 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
FI3604316T3 (en) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Synthesis of boronate salts
BR112016026291A2 (en) 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
CN112755039A (en) 2015-04-24 2021-05-07 莱姆派克斯制药公司 Methods of treating bacterial infections

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005297A1 (en) 1986-03-03 1987-09-11 The University Of Chicago Cephalosporin derivatives
WO2004058679A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2009046098A1 (en) 2007-10-03 2009-04-09 Smithkline Beecham Corporation Novel cyclic boronate inhibitors of hcv replication
WO2009064414A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2009064413A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2009117540A1 (en) 2008-03-19 2009-09-24 Bristol-Myers Squibb Company Bridged heterocycles as hiv integrase inhibitors
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2010130708A1 (en) 2009-05-12 2010-11-18 Novartis International Pharmaceutical Ltd. Beta-lactamase inhibitors
WO2010144338A1 (en) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
WO2013092979A1 (en) * 2011-12-22 2013-06-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"Modern Pharmaceutics", 2002
"Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
"Remington's The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
ANSEL: "Introduction to Pharmaceutical Dosage Forms", 2004
BIOCHEMISTRY, vol. 39, 2000, pages 5312 - 21
BIOORG. MED.CHEM. LETT., vol. 9, 1999, pages 34 - 346
BOU, G. ET AL., J. ANTIMICROB. AGENTS CHEMOTHER., vol. 44, 2000, pages 1556
BOU, G.MARTINEZ-BELTRAN, J. ANTIMICROB. AGENTS CHEMOTHER, vol. 40, 2000, pages 428
CHEM. REV., vol. 110, 2010, pages 3600 - 3740
COUTTS, S. J. ET AL., TETRAHEDRON LETTERS, vol. 35, no. 29, 1994, pages 5109 - 5112
HETEROCYCLES, vol. 36, 1993, pages 2687
J ANTIMICROB AGENTS CHEMOTHER, vol. 50, 2006, pages 2280
J. AM. CHEM. SOC., vol. 112, 1990, pages 3964 - 969
J. AM. CHEM. SOC., vol. 128, 2006, pages 11036
J. AM. CHEM. SOC., vol. 130, 2008, pages 6910 - 6911
J. AM. CHEM. SOC., vol. 132, 2010, pages 11825 - 11827
J. AM. CHEM. SOC., vol. 133, 2011, pages 409 - 411
J. MED. CHEM., vol. 38, 1995, pages 3094 - 3105
J. MED. CHEM., vol. 54, 2011, pages 7375
J. ORG. CHEM., 2012
J. ORG. CHEM., vol. 75, 2010, pages 468 - 471
LIEBERMAN ET AL., PHARMACEUTICAL DOSAGE FORMS: TABLETS, 1989
MATTESON, D. S., ASYMMETRIC SYNTHESIS WITH BORONIC ESTERS. ACCOUNTS OF CHEMICAL RESEARCH, vol. 21, no. 8, 1988, pages 294 - 300
MATTESON, D. S., TETRAHEDRON, vol. 45, no. 7, 1989, pages 1859 - 1885
MONTEFOUR, K. ET AL., CRIT. CARE NURSE, vol. 28, 2008, pages 15
NEMA ET AL.: "Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions", PDA J PHARM SCI AND TECH, vol. 65, 2011, pages 287 - 332, XP009166667, doi:10.5731/pdajpst.2011.00634
ORG. LETT., vol. 14, 2012, pages 3237 - 3239
PEREZ, F. ET AL., EXPERT REV. ANTI INFECT. THER., vol. 6, 2008, pages 269
POWELL ET AL.: "Compendium of Excipients for Parenteral Formulations", PDA J PHARM SCI AND TECH, vol. 52, 1998, pages 238 - 311, XP009119027
See also references of EP2941246A4 *
TETRAHEDRON LETTERS, vol. 44, 2003, pages 233 - 235
TETRAHEDRON, vol. 61, 2005, pages 10827 - 10852
YOSHIKAZU ISHII ET AL., ANTIMICROB. AGENTS CHEMOTHER, July 2010 (2010-07-01)
YUEN, A. K. L.HUTTON, C. A., TETRAHEDRON LETTERS, vol. 46, no. 46, 2005, pages 7899 - 7903

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694025B2 (en) 2010-08-10 2017-07-04 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US11684629B2 (en) 2010-08-10 2023-06-27 Melinta Subsidiary Corp. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10183034B2 (en) 2010-08-10 2019-01-22 Rempex Pharmaceuticals, Inc. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10639318B2 (en) 2010-08-10 2020-05-05 Rempex Pharmaceuticals, Inc. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10004758B2 (en) 2010-08-10 2018-06-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and methods of making the same
US11090319B2 (en) 2010-08-10 2021-08-17 Melinta Subsidiary Corp. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10172874B2 (en) 2010-08-10 2019-01-08 Rempex Pharmaceuticals, Inc. Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
US10214547B2 (en) 2012-12-07 2019-02-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9828391B2 (en) 2012-12-07 2017-11-28 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8912169B2 (en) 2012-12-07 2014-12-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10669290B2 (en) 2012-12-07 2020-06-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10125152B2 (en) 2013-01-10 2018-11-13 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9771382B2 (en) 2013-01-10 2017-09-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9040504B2 (en) 2013-01-10 2015-05-26 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9376454B2 (en) 2013-01-10 2016-06-28 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US11414435B2 (en) 2013-01-10 2022-08-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10294248B2 (en) 2013-03-14 2019-05-21 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US10669292B2 (en) 2014-05-05 2020-06-02 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
CN106459096B (en) * 2014-05-19 2019-03-08 莱姆派克斯制药公司 Boronic acid derivatives and its therapeutical uses
WO2015179308A1 (en) * 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2017517508A (en) * 2014-05-19 2017-06-29 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
CN106459096A (en) * 2014-05-19 2017-02-22 莱姆派克斯制药公司 Boronic acid derivatives and therapeutic uses thereof
US9637504B2 (en) 2014-06-11 2017-05-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US11008346B2 (en) 2014-06-11 2021-05-18 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9926336B2 (en) 2014-06-11 2018-03-27 Venatorx Pharmaceuticals Beta-lactamase inhibitors
US10294247B2 (en) 2014-06-11 2019-05-21 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9802966B2 (en) 2014-06-11 2017-10-31 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9783555B2 (en) 2014-06-11 2017-10-10 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP2017518991A (en) * 2014-06-11 2017-07-13 ベナトルクス ファーマシューティカルズ，インク． Beta-lactamase inhibitor
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10618918B2 (en) 2015-03-17 2020-04-14 Qpex Biopharma, Inc. Substituted boronic acids as antimicrobials
US10344043B2 (en) 2015-04-14 2019-07-09 B-Organic Films Corp Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives
CN107709339B (en) * 2015-04-14 2020-12-29 B-有机电影公司 Antiviral and antibacterial preparations based on quaternary ammonium compounds complexed with boric acid and derivatives thereof
WO2016165019A1 (en) * 2015-04-14 2016-10-20 B-Organic Films Corp. Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives
CN107709339A (en) * 2015-04-14 2018-02-16 B-有机电影公司 Based on the antiviral and antibiotic preparation with boric acid and its quaternary ammonium compound of derivative complexing
US10899776B2 (en) 2015-04-14 2021-01-26 Canh Feed Solutions Corp. Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives
CN108472284A (en) * 2015-09-11 2018-08-31 维纳拓尔斯制药公司 Beta-lactamase inhibitor
US10399996B2 (en) * 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US11046716B2 (en) * 2015-09-11 2021-06-29 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10464952B2 (en) 2015-12-10 2019-11-05 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11999759B2 (en) 2016-06-30 2024-06-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10570159B2 (en) 2016-06-30 2020-02-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11180512B2 (en) 2016-06-30 2021-11-23 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11560392B2 (en) 2016-08-04 2023-01-24 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
US11352373B2 (en) * 2017-02-01 2022-06-07 Melinta Subsidiary Corp. Apparatus and continuous flow process for production of boronic acid derivative
US11820784B2 (en) 2017-03-06 2023-11-21 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US11091505B2 (en) 2017-03-06 2021-08-17 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630782A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11066425B1 (en) 2018-04-27 2021-07-20 Sumitomo Dainippon Pharma Co., Ltd. Oxo-substituted compound
KR20210005910A (en) 2018-04-27 2021-01-15 다이니뽄 스미토모 세이야쿠 가부시키가이샤 Oxo-substituted compounds
US11702431B2 (en) 2018-04-27 2023-07-18 Sumitomo Pharma Co., Ltd. Oxo-substituted compound
EP3886798A4 (en) * 2018-11-29 2022-08-03 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
KR20220088736A (en) 2019-10-25 2022-06-28 스미토모 파마 가부시키가이샤 Novel substituted condensed cyclic compound
CN113150022B (en) * 2021-04-23 2022-12-06 四川大学 3-substituted five-membered cyclic borate derivative, and pharmaceutical composition and pharmaceutical application thereof
CN113150022A (en) * 2021-04-23 2021-07-23 四川大学 3-substituted five-membered cyclic borate derivative, and pharmaceutical composition and pharmaceutical application thereof

Also Published As

Publication number Publication date
EA201591003A1 (en) 2015-12-30
AU2014204045B2 (en) 2018-10-18
EP2941246A4 (en) 2016-12-21
MX2015008628A (en) 2015-09-23
EP2941246A1 (en) 2015-11-11
US9642869B2 (en) 2017-05-09
JP2016509594A (en) 2016-03-31
BR112015016001A2 (en) 2017-07-11
CA2894891A1 (en) 2014-07-10
KR20150103269A (en) 2015-09-09
CN104994844A (en) 2015-10-21
US20140194385A1 (en) 2014-07-10
TW201431866A (en) 2014-08-16
AU2014204045A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
AU2014204045B2 (en) Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) Boronic acid derivatives and therapeutic uses thereof
US11999759B2 (en) Boronic acid derivatives and therapeutic uses thereof
EP3145936B1 (en) Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) Boronic acid derivatives and therapeutic uses thereof
US10618918B2 (en) Substituted boronic acids as antimicrobials
US9241947B2 (en) Boronic acid derivatives and therapeutic uses thereof
US10206937B2 (en) Boronic acid derivatives and therapeutic uses thereof
US9156858B2 (en) Boronic acid derivatives and therapeutic uses thereof
US12016868B2 (en) Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14735173

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2894891

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201591003

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/008628

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015551761

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014735173

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015016001

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014204045

Country of ref document: AU

Date of ref document: 20140102

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157021053

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015016001

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150701